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4Foreword  
By John-Peter Kools and Rick Lines
We are pleased to welcome you to the 2016 Global State 
of Harm Reduction.
This year marks two important milestones for us: the 
10th anniversary of the Global State project and the 
20th anniversary of the founding of the International 
Harm Reduction Association, now known as Harm 
Reduction International.
Since it began in 2006, the Global State has emerged 
as one of the key resources for those working on harm 
reduction issues around the world.  It stands alone as 
the only independent, civil-society led project monitoring 
global progress on harm reduction, and on important 
related developments in national and international law, 
policy and advocacy.
Although this report bears HRI’s name, behind the 
scenes it is the product of dozens of colleagues working 
on harm reduction in all regions of the world, who 
collaborate with us in collecting data, sharing case 
studies and providing critical peer-review to ensure 
our information is as accurate as we can make it. In 
particular we must acknowledge the work of Catherine 
Cook, the author of the first edition of the Global State 
who has overseen the project from its inception.
Reflecting back over the ten years of the Global State, 
there is no doubt that the harm reduction approach 
has continued to grow year after year in country after 
country.  Indeed, harm reduction is accepted (or 
tolerated) in more than half of the countries of the world 
where injecting drug use has been reported.  Despite 
the well documented gaps in access and quality in many 
parts of the world, it can be said that harm reduction is 
present in the majority of countries where injecting is 
present.  No longer can our critics suggest our shared 
philosophy and approach to addressing the harms of 
drug use and drug policy is a fringe position.
Over the last ten years we have also seen other 
important developments.  When we started this project 
in 2006, the focus of the report (and indeed much of the 
harm reduction sector) was on HIV prevention among 
people who inject opioids. Since that time we have seen 
the development of critical programmes addressing 
viral hepatitis, overdose prevention and harm reduction 
among people who use stimulants, developments that 
have become an increasingly important part of our 
report.  Over the last decade we have also seen major 
developments in organising and networking by people 
who use drugs, which has made a critical contribution to 
national, regional and global advocacy.
Despite this progress, we all know the many problems 
that remain.  Harm reduction programmes are too few, 
too vulnerable and too underfunded in most parts of the 
world.  International donor support for harm reduction 
is under sustained threat. The United Nations appears 
to be turning its back on the issue of injecting drug 
use. Despite the growth of support for harm reduction 
around the world, criminalisation and prison continues 
to be the dominant paradigm of drug control, fueling 
ill-health and human rights abuses around the world.  
People are continuing to die needlessly, because too 
many governments are addicted to prohibition.
Harm reduction saves lives. Promotes health, human 
rights and dignity. Saves money.  The harm reduction 
movement, and the movement of people who use drugs, 
are on the right side of the issue, and the right side 
of history. As we prepare for another milestone next 
year, our 25th international conference to be held in 
Montreal, we are reminded of the words of the late Jack 
Layton, Canadian political leader and long-time harm 
reduction supporter.  ‘My friends, love is better than 
anger. Hope is better than fear. Optimism is better than 
despair. So let us be loving, hopeful and optimistic. And 
we’ll change the world.’
Rick Lines 
Executive Director
John-Peter Kools 
Chair 
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Introduction
About the Global State of Harm 
Reduction 2016
In 2008, Harm Reduction International (HRI) released 
the Global State of Harm Reduction, a report that 
mapped responses to drug-related HIV and hepatitis 
C epidemics around the world for the first time.(1) The 
data gathered for the report provided a critical baseline 
against which progress could be measured in terms 
of the international, regional and national recognition 
of harm reduction in policy and practice. Since then, 
the biennial report has become a key publication for 
researchers, policymakers, civil society organisations 
and advocates, mapping harm reduction policy adoption 
and programme implementation globally. Since HRI 
first began reporting, the harm reduction response has 
increased globally with harm reduction programmes 
now operating at some level in more than half of the 
158 countries in the world where injecting drug use has 
been documented. Harm reduction is now the majority 
response in the international community. 
The Global State of Harm Reduction 2016 continues to 
map the response to drug-related HIV, viral hepatitis 
and tuberculosis. It also integrates updated information 
on harm reduction services into each regional chapter, 
including on needle and syringe programmes (NSPs) 
and opioid substitution therapy (OST) provision; harm 
reduction services in prisons; access to antiretroviral 
therapy (ART) for people who inject drugs; overdose 
responses; policy developments; civil society 
developments; and information relating to funding for 
harm reduction. With changing patterns in drug use, the 
2016 report also reflects the use of, and harm reduction 
response to, amphetamine type stimulants (ATS).
This report and other Global State of Harm Reduction 
resources can be found at www.hri.global 
 
Methodology
The information presented in the two sections of the 
report has been gathered using existing data sources. 
These include research papers and reports from 
multilateral agencies, international non-governmental 
organisations, civil society and harm reduction networks, 
organisations of people who use drugs, and expert and 
academic opinion from those working on HIV, drug use 
and harm reduction. Harm Reduction International has 
also enlisted support from regional harm reduction 
networks and researchers to gather qualitative 
information on key developments and to review 
population size estimates, prevalence data on HIV and 
viral hepatitis among people who inject drugs, and the 
extent of NSP and OST provision.
Quantitative data for the tables at the beginning of 
each chapter in Section 2 have been obtained from a 
variety of sources and are referenced in each regional 
update. These data reflect the most recent available 
estimates for each country at the time of the data 
collection exercise (March to October 2016). Where no 
source was available, the data were unpublished or their 
reliability were questioned by civil society organisations, 
researchers or other experts, we have sought expert 
opinion to identify additional sources and verify their 
reliability. 
Where information in the tables is outdated, we have 
provided footnotes with a year of estimate. Unless HRI 
has been able to identify more recent data, prevalence 
figures for viral hepatitis have been sourced from the 
review of reviews published by Nelson and colleagues in 
2011.(2) Data from Western Europe and some countries 
in Eurasia has been sourced from the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) 2016 Statistical Bulletin, unless otherwise 
stated in the text.(3-6) Footnotes and references are 
provided for all estimates reported, together with any 
discrepancies in the data.
Figures published through international reporting 
systems, such as those undertaken by the United 
Nations Office on Drugs and Crime (UNODC), the World 
Health Organization and the Joint United Nations 
Programme on HIV/AIDS (UNAIDS) may differ from those 
collated here due to the varying scopes of monitoring 
surveys, and reliability criteria and a focus on regions 
that may include different country classifications.
Regions have been largely identified using the coverage 
of regional harm reduction networks. Accordingly, this 
report examines Asia, Eurasia (Central and Eastern 
Europe and Central Asia), Western Europe, the 
Caribbean, Latin America, North America, Oceania, the 
Middle East and North Africa, and Sub-Saharan Africa. All 
regional updates have been peer reviewed by experts in 
the field (see: Acknowledgements).
6Data quality
Since the dissolution of the UN Reference Group on HIV 
and Injecting Drug Use, there have been no updates on 
their independent peer-reviewed global epidemiological 
or service coverage systematic reviews. For some 
countries, the estimates published by the UN Reference 
in 2008 and 2010 remain the most recent available and 
reliable estimates.(7, 8) More recent data, where reviewed 
to be reliable, has been included from various sources. 
For Western European countries and some countries in 
Eurasia, EMCDDA has continued to be a crucial source of 
reliable data for this edition of the Global State as in past 
editions. Other sources include global AIDS response 
progress reports submitted by governments to UNAIDS 
in 2014/2015/2016, data published by UNODC in the 
World Drug Report in 2016, bio-behavioural surveillance 
reports, systematic reviews and academic studies. 
We have sought input from harm reduction networks, 
researchers, academics and other experts to inform 
our reporting on the existence and coverage of harm 
reduction. Where no updates were available, data from 
The Global State of Harm Reduction 2014(9) has been 
included, with footnotes provided on dates of estimate 
where necessary.
Although population size estimates for people who 
inject drugs have become available at the national level 
for several countries since 2008 (for example, through 
UNAIDS global AIDS progress reports), a systematic 
calculation of global population size estimates has not 
been conducted in the context of this report. 
Our data on epidemiology and coverage represent the 
most recent, verifiable estimates available. However, a 
lack of uniformity in measures, data collection methods 
and definitions for the estimates provided make cross-
national and regional comparisons challenging. 
The significant gaps in the data are an important reminder 
of the need for a greatly improved monitoring and data 
reporting system on HIV and drug use around the world.  
 
Limitations
The report aims to provide a global snapshot of harm 
reduction policies and programmes, and as such it has 
several limitations. It does not provide an extensive evaluation 
of the quality of the services that are in place, although 
where possible it does highlight areas of regional concern. 
While The Global State of Harm Reduction 2016 aims to 
cover important areas for harm reduction, it focuses 
primarily on public health aspects of the response. The 
report does not document all the social and legal harms 
faced by people who use drugs, nor does it cover all the 
health harms related to substance use, including those 
related to alcohol and tobacco. 
 
Report structure
Section 1 provides a global overview of harm reduction 
policy and programming.
Section 2 contains nine regional updates: Asia, Eurasia 
(Central and Eastern Europe and central Asia), Western 
Europe, Caribbean, Latin America, North America, 
Oceania, Middle East and North Africa and Sub-Saharan 
Africa. These examine developments in harm reduction 
since 2014. 
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Global Update: Behind the 
numbers 
 
This report is the fifth in the biennial Global State of 
Harm Reduction series tracking developments in harm 
reduction worldwide. The ‘Global State’ has become a 
vital source for researchers and advocates since the 
first edition in 2008, when it provided the first global 
snapshot of harm reduction responses.
Injecting drug use is a global phenomenon, documented 
in at least 158 of the world’s countries and territories.(1) 
Using primarily government reported data, UN estimates 
for 2014 found that 11.7 million people injected drugs 
worldwide, with 14% living with HIV, 52% living with 
hepatitis C and 9% living with hepatitis B.(9)a The harm 
reduction response, while in place to some degree 
in a majority of the world’s countries, falls far short 
of reaching most people who inject drugs worldwide. 
In 2016, 90 countries implement needle and syringe 
programmes (NSPs) to some degree and 80 have at 
least one opioid substitution programme (OST) in place.
Perhaps the most striking statistic to emerge from this 
year’s Global State of Harm Reduction is that since 2014, 
there has been no increase in the number of countries 
implementing - the first time that this has happened 
since the inception of the Global State in 2008. Of 158 
countries and territories where injecting drug use has 
been reported, 68 still have no NSP in place, and 78 
have no provision of OST. 
Behind these numbers is a gap between the 
international commitments made over the last two years 
and the levels of financial and political leadership being 
shown by both national governments and international 
agencies. In 2015, as part of the Sustainable 
Development Goals (SDGs), the UN General Assembly 
agreed a global target to end AIDS by 2030.(2)  
This year, member states at both the UN General 
Assembly Special Session (UNGASS) on Drugs and 
the High Level Meeting on HIV and AIDS committed 
to “minimising the adverse public health and social 
consequences of drug abuse”, and endorsed harm 
reduction interventions including “medication 
assisted therapy”, “injecting equipment programmes”, 
“antiretroviral therapy” and “opioid receptor 
antagonists”.(3) Yet as this year’s Global State shows, 
in many countries coverage of NSP and OST remains 
substantially below the minimum levels recommended 
by international guidance(4) and is insufficient to prevent 
HIV and hepatitis C epidemics among people who inject 
drugs. There are also an alarming number of countries 
where coverage of NSP and OST has decreased.
Underpinning the data is a deepening funding crisis 
facing harm reduction. Even in Europe, the region 
traditionally most supportive of harm reduction, a drop 
in government funding has resulted in service closures. 
International donor funding for the HIV response is in 
decline, and this problem is increasingly pronounced in 
middle-income countries (MICs) where harm reduction 
is most needed.(5) The Global Fund for AIDS, tuberculosis 
(TB) and Malaria has warned MICs to “begin or build 
upon transition preparations during the 2017-2019 
period”, and has listed 24 countries that will become 
ineligible for GFATM support in the coming years.(6) With 
international financing disappearing, harm reduction 
advocates in MICs are uncertain about what will replace 
it. The assumption from international agencies appears 
to be that national governments will fill this vacuum 
and invest. In May 2016, UNAIDS released “global” 
harm reduction resource needs estimates which did 
not include high-income countries and assumed that 
all upper MICs would fund their own responses.(7) In 
doing so UNAIDS has left behind some three quarters 
of people who inject drugs globally,b covering countries 
such as the US, Russia, Greece, Hungary, Bulgaria, 
Thailand, China, Mauritius and Belarus, where harm 
reduction programmes are severely limited even after 
decades of local advocacy.
One of the greatest challenges behind the Global State 
of Harm Reduction at present is the global leadership 
gap. The 2011 Political Declaration on HIV included 
a historical target to halve HIV transmission among 
people who inject drugs by 2015,(8) but this was missed 
by more than 80%. The 2016 UNGASS on Drugs and 
High Level Meeting on HIV had the potential to deliver 
a wholesale shift in priorities, but instead we saw only 
modest advances in harm reduction language and no 
commitment to address the funding crisis or to redirect 
funding away from enforcement approaches. HRI’s ‘10 
by 20’ campaign calls on governments to redirect 10% 
of the estimated US$100 billion currently spent on drug 
control to harm reduction. Research by HRI and the 
Burnet Institute has shown that such a redirection has 
the potential to virtually end AIDS among people who 
inject drugs.(5) 
a Results of independent academic systematic reviews to update global data on injecting drug use, HIV, hepatitis B and C prevalence, along with harm reduction coverage 
 estimates are due for release in 2017.
b HRI unpublished calculations using national population size estimates from the Global State of Harm Reduction 2014 categorised by country-income status.
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Alongside the high level obstacles, a range of practical 
challenges are emerging or intensifying on the ground. 
This year’s Global State reports increased injection of 
amphetamine-type stimulants (ATS) in every region 
of the world. Although in some countries there are 
bespoke harm reduction services for people who use 
ATS, these are few and small-scale. Amidst the UNODC 
funding cuts, long anticipated guidance on HIV and 
stimulant use have again been stalled. There is an 
urgent need for these guidelines and for adapted harm 
reduction responses. 
Further measures are also needed to respond to the 
phenomenal increase in overdose and rates of drug 
related deaths that have been documented in countries 
such as the US, Canada and the UK.(9-13) These include 
scaled-up distribution of naloxone (an opioid antagonist) 
and the removal of restrictive policies that prevent 
people who use drugs and their peers and families from 
accessing this life-saving medication.
In relation to hepatitis C, important advances have 
recently occurred through the development of more 
effective medicines (known as direct-acting antivirals or 
DAAs) and through efforts to make affordable generic 
versions of these drugs available. Price remains a central 
barrier as drug companies have not offered generic 
drugs to many countries with a high burden of hepatitis 
C, while stigma and discrimination against people who 
use drugs further restricts access.
Moreover, the provision of harm reduction services in 
prison settings continues to be woefully inadequate. In 
2016, only 8 countries implement NSPs in at least one 
prison, with NSPs entirely unavailable to prisoners in 
seven out of the nine regions reviewed in the Global 
State report. OST is provided in prisons in 52 countries, 
representing a 21% increase since the Global State 
last reported, but quality and other barriers remain. 
Prisoners also continue to face a heightened risk of 
overdose. This is despite the fact that the provision of 
harm reduction in prisons is not a policy option but a 
legally binding human rights obligation that must be 
urgently prioritised – and resourced - by political leaders. 
Behind these numbers remains a landscape of political 
neglect where harm reduction advocates and people 
who use drugs are struggling to fill the gap governments 
are leaving behind. Civil society is relied upon to deliver 
services, gather data, advocate for funding and fight 
for the rights of people who use drugs. Underfunded 
and politically ignored, it is no wonder that the harm 
reduction response is facing stagnation and in some 
cases regression.
At the 2015 International Harm Reduction Conference, 
ahead of the UNGASS on drugs, the harm reduction 
sector called for a harm reduction decade with a 
new approach to drug use rooted in science, public 
health, human rights and dignity.  It truly is time for 
governments and international agencies to rethink the 
objectives of global drug policy and revisit the means 
by which they measure their success, to encompass 
coverage of services, reduction of harms, and lives 
saved. Diplomats, UN agencies and civil society 
organisations are already embarking on the process to 
develop the next Political Declaration on Drugs in 2019. 
If that process is to be worth even the time already 
invested, it must secure a new decade of drug policy 
with harm reduction as a guiding principle. 
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Country or 
territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents 
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational 
At least 
one drug 
consumption 
room
OST in at 
least one 
prison
NSP in at 
least one 
prison
ASIA
Afghanistan 3 3 3 7 7 7
Bangladesh 3 3 3 7 7 7
Cambodia 3 3 3 7 7 7
China 3 3 3 7 7 7
Hong Kong 3 7 3 7 7 7
India 3 3 3 7 3 7
Indonesia 3 3 3 7 3 7
Laos PDR 3 3 7 7 7 7
Macau 3 3 3 7 3 7
Malaysia 3 3 3 7 3 7
Maldives 3 7 3 7 7 7
Mongolia 3 3 7 7 7 7
Myanmar 3 3 3 7 7 7
Nepal 3 3 3 7 7 7
Pakistan 3 3 7 7 7 7
Philippines 3 3 7 7 7 7
Taiwan 3 3 3 7 7 7
Thailand 3 3 3 7 7 7
Vietnam 3 3 3 7 3 7
EURASIA
Albania 3 3 3 7 3 7
Armenia 3 3 3 7 3 3
Azerbaijan 7 3 3 7 7 7
Belarus 3 3 3 7 7 7
Bosnia & 
Herzegovina
3 3 3 7 3 7
Bulgaria 3 3 3 7 3 7
Croatia 3 3 3 7 3 7
Czech Republic 3 3 3 7 3 7
Estonia 3 3 3 7 3 7
Georgia 3 3 3 7 3 7
Hungary 3 3 3 7 7 7
Kazakhstan 3 3 3 7 7 7
Kosovo 3 3 3 7 7 7
Kyrgyzstan 3 3 3 7 3 3
Latvia 3 3 3 7 3 7
Lithuania 3 3 3 7 3 7
Macedonia 3 3 3 7 3 7
The Global Harm Reduction Response
Table 1.1.1:  Countries or territories employing a harm reduction approach in policy or practicec
C The countries and territories represented in the table are those for which data are available. Those for which no data are available are not listed.
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Country or 
territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents 
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational 
At least 
one drug 
consumption 
room
OST in at 
least one 
prison
NSP in at 
least one 
prison
EURASIA continued
Moldova 3 3 3 7 3 3
Montenegro 3 3 3 7 3 7
Poland 3 3 3 7 3 7
Romania 3 3 3 7 3 7
Russia 7 3 7 7 7 7
Serbia 3 3 3 7 3 7
Slovakia 3 3 3 7 7 7
Slovenia 3 3 3 7 3 7
Tajikistan 3 3 3 7 7 3
Turkmenistan 7 3 7 7 7 7
Ukraine 3 3 3 7 7 7
Uzbekistan 3 3 7 7 7 7
WESTERN EUROPE
Austria 3 3 3 7 3 7
Belgium 3 3 3 7 3 7
Cyprus 3 3 3 7 7 7
Denmark 3 3 3 3 3 7
Finland 3 3 3 7 3 7
France 3 3 3 3 3 7
Germany 3 3 3 3 3 3
Greece 3 3 3 7 3 7
Iceland nk 7 3 7 7 7
Ireland 3 3 3 7 3 7
Italy 3 3 3 7 3 7
Luxembourg 3 3 3 7 3 3
Malta 3 3 3 7 3 7
Monaco nk 3 nk nk 7 7
Netherlands 3 3 3 3 3 7
Norway 3 3 3 3 3 7
Portugal 3 3 3 7 3 7
Spain 3 3 3 3 3 3
Sweden 3 3 3 7 3 7
Switzerland 3 3 3 3 3 3
Turkey 3 7 3 7 3 7
United Kingdom 3 3 3 7 3 7
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Country or 
territory
Explicit supportive 
reference to 
harm reduction 
in national policy 
documents 
At least 
one needle 
and syringe 
programme 
operational
At least 
one opioid 
substitution 
programme 
operational 
At least 
one drug 
consumption 
room
OST in at 
least one 
prison
NSP in at 
least one 
prison
CARIBBEAN
Puerto Rico 7 3 3 7 3 7
Dominican 
Republic
7 3 7 7 7 7
Trinidad & Tobago 3 7 7 7 7 7
LATIN AMERICA
Argentina 3 3 7 7 7 7
Brazil 3 3 7 7 7 7
Colombia 3 3 3 7 7 7
Mexico 3 3 3 7 7 7
Paraguay 3 3 7 7 7 7
Uruguay 3 3 7 7 7 7
NORTH AMERICA
Canada 3 3 3 3 3 7
United States 3 3 3 7 3 7
OCEANIA
Australia 3 3 3 3 3 7
New Zealand 3 3 3 7 3 7
MIDDLE EAST AND NORTH AFRICA
Egypt 3 3 7 7 7 7
Iran 3 3 3 7 3 7
Israel 7 3 3 7 3 7
Jordan 7 3 7 7 7 7
Lebanon 7 3 3 7 3 7
Morocco 3 3 3 7 3 7
Palestine 7 3 7 7 7 7
Syria 3 7 7 7 7 7
Tunisia 3 3 7 7 3 7
SUB-SAHARAN AFRICA
Ghana 3 7 7 7 7 7
Kenya 3 3 3 7 7 7
Mauritius 3 3 3 7 3 7
Senegal 3 3 3 7 7 7
Seychelles 7 7 3 7 7 7
South Africa 3 3 3 7 7 7
Tanzania 3 3 3 7 7 7
Zanzibar 3 7 7 7 7 7
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Needle and syringe programmes (NSPs)
In 2016, 90 countries and territories implement NSPs to 
varying degrees. Models of provision include: fixed and 
specialist NSP sites, community-based outreach, pharmacy 
provision and vending machines. Since the last edition of 
the Global State was published in 2014, there has been no 
change in the number of countries implementing NSPs. 
This is the first time since the inception of the Global State 
in 2008 that there has been no increase to report in the 
number of countries adopting this life-saving intervention. 
The number of operational NSP sites and the coverage 
provided through existing services varies widely among 
countries and regions. According to available data, 
a total of 17 countries have scaled-up NSP services 
between 2014 and 2016. These include: Nepal, Taiwan, 
Belarus, Czech Republic, Georgia, Hungary, Latvia, 
Lithuania, Moldova, Poland, Romania, Ireland, Sweden, 
Egypt, Kenya, South Africa and the US. The greatest 
increase in NSP provision has been seen in Taiwan, 
where 1,254 NSP sites now operate.(14) However, it is 
important to note that while the data in the Global State 
2016 represent the most robust available estimates, 
these are not always recent, and improvements in data 
surveillance regarding service provision are needed.
In many low- and middle-income countries, NSP 
coverage continues to be insufficient to prevent HIV and 
hepatitis C epidemics among people who inject drugs. 
Worryingly, in 20 countries NSP provision has decreased 
since 2014, these include: Afghanistan, China, India, 
Malaysia, Thailand, Kyrgyzstan, Slovakia, Slovenia, Austria, 
Belgium, Finland, Germany, Greece, Luxembourg, 
Norway, Spain, Iran, Morocco, Mauritius and Tanzania. 
Even in countries with good levels of NSP coverage, 
important gaps continue to exist. Reaching migrant 
communities, especially undocumented migrants, 
is difficult and many services still do not allow the 
provision of needles for people under the age of 18, 
which is now an explicit recommendation within UN 
technical guidance.(15) Further reported issues hindering 
effective NSP provision are limited after-hours services, 
geographic access and stigma and discrimination 
experienced by people who inject drugs accessing harm 
reduction services in some settings.(16)
Of 158 countries and territories where injecting drug use 
has been reported, 68 still have no needle and syringe 
programmes in place.
Opioid substitution therapy (OST)
In 2016, 80 countries and territories implement OST. 
Although this figure is the same as reported in 2014, 
OST has been newly implemented in Monaco (including 
within prisons), Senegal and Kenya. In 2014, the Global 
State reported that OST was available in Burkina Faso 
which has since been disproved. Although the United 
Arab Emirates and Bahrain do provide OST, this service 
is available for detoxification purposes only and is 
therefore not categorised as a harm reduction response.
Methadone and buprenorphine are the most commonly 
used OST medications, but in some countries others 
are also provided, including slow-release morphine and 
codeine and heroin-assisted treatment.(17) The number 
of sites providing OST and the proportion of people that 
receive opioid substitution therapy remains substantially 
higher in most high-income countries. Similar to NSP, 
low-and middle-income countries often have the fewest 
number of OST sites.
Since 2014, 16 countries have scaled-up their provision 
of OST services, including: China, Indonesia, Malaysia, 
Myanmar, Nepal, Taiwan, Vietnam, Belarus, Estonia, 
Hungary, Kyrgyzstan, Latvia, Macedonia, Montenegro, 
Iran and Mauritius, with Iran increasing provision by 
1,708 sites. However, provision of OST has decreased in 
several countries in Eurasia, with fewer sites reported in 
Moldova, Romania, Serbia, Slovenia and Tajikistan. 
As previously reported in 2014, coverage of existing 
programmes in many countries remains substantially 
below minimum levels recommended by international 
guidance. Improvement in scale and quality are urgently 
needed to ensure that interventions achieve the 
greatest impact.(4) 
Of 158 countries and territories where injecting drug use 
is reported, 78 have no provision of opioid substitution 
therapy in place. 
1.1 GLOBAL OVERVIEW
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Hepatitis C treatment access for people who inject drugs 
Approximately 80 million people are living with hepatitis C worldwide, with an estimated two-thirds of cases found among 
people who inject drugs.(18) In 60-80% of cases, the hepatitis C infection becomes chronic and approximately 700,000 
people with chronic hepatitis C die untreated each year.(18) 
Prior to the development of direct-acting antivirals (DAAs), hepatitis C treatments based on interferon had cure rates 
of less than 50%. DAAs have transformed cure rates to 90% and are not only much more effective, but are a far less 
aggressive form of treatment.(18) One of the central barriers to DAAs access is price. In Brazil, a 28-day supply of one of 
the generic DAAs (sofosbuvir) is US$2,292. In Romania the same drug costs US$16,368,(18) and in Japan a 12 week course 
of sofosbuvir is US$37,729.(19) Gilead Sciences, which owns a 20-year patent on sofosbuvir (marketed as Sovaldi®), is able 
through the effective monopoly granted by the patent, to charge any price that it estimates a given market can bear.(19) 
Asia is one of the regions disproportionally affected by hepatitis C with approximately 70% of people who inject drugs 
in the region living with the virus.(20) In 2015, Gilead Sciences (one of a number of companies who produce hepatitis 
C medicines) issued voluntary licences to 11 Indian generic producers, allowing them to produce and market generic 
sofosbuvir to selected markets with a 7% royalty payment to Gilead.(21) The 101 countries chosen by the company that 
can benefit from this scheme include Afghanistan, Bangladesh, Bhutan, Cambodia, Indonesia, India, Malaysia, Mongolia, 
Myanmar, Nepal, Pakistan, Sri Lanka, and Vietnam.(22) Generic sofosbuvir can potentially be sold in these countries for 
as little as US$300 per month,(23) but countries need to register to create regulations for its use, and this is taking time 
in some settings. In 2015, Georgia launched a new hepatitis C elimination programme, with an exceptional donation of 
free Sovaldi,® which Gilead announced as an experiment to show the impact of access to the medicine in an entire small 
country. This initiative should extend coverage from 5,000 to 20,000 in the coming years and will include people who use/
inject drugs.(18)
In March 2016, the Australian government made directly-acting antiviral treatments for hepatitis C available free of 
charge without restriction relating to drug use or disease stage – only the second country in the world to do so.(24)  
The availability of these new treatments through the Pharmaceutical Benefits Scheme (PBS) has seen an estimated 
26,360 people initiating treatment between March to September 2016, compared with 7,296 in 2015.(25) 
Gilead and other companies have not offered the possibility of generic drugs to many middle-income countries, like 
China, with a high burden of hepatitis C.(26) In some countries, the high cost of the medicines becomes one more reason 
to justify inaction around a disease that threatens the lives of people who inject drugs.(26) Although progress has been 
made in some countries, there is still a great way to go to ensuring treatment services are accessible, including for people 
who inject drugs who are disproportionally affected by the virus.
Price, however, is not the only barrier to treatment access. Stigma and discrimination related to drug use, as well as 
widespread misconceptions among treatment specialists about a lack of adherence to treatment by people who use 
drugs, create further barriers, despite clinical trials showing that tailored services for people who inject drugs have high 
adherence and retention rates.(27, 28) In October 2016, a report by the World Health Organization (WHO) highlighted 
that special efforts must be made to ensure treatment services are accessible to people who inject drugs, through 
adopting enabling policies and guidelines and decentralising care. Involving people who inject drugs in the development, 
implementation and oversight of hepatitis C services is also essential.(18)
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Amphetamine-type stimulants (ATS)d
It has been estimated that between 13.9 million and 
54.8 million people use amphetamines worldwide,(29) 
with more than 60% of global ATS use thought to be 
concentrated in Southeast Asia.(30) The wide-ranging 
global figures reflect the current lack of accurate data 
on amphetamine use. Data collection methods often 
vary from country to country, and some countries do 
not collect or analyse data at all, meaning that data are 
extremely limited and obtaining an estimate of global 
use is challenging. However, according to reports from 
civil society, academics, NGOs and international agencies 
ATS use is increasing in countries in every region of the 
world. 
In Australia, for example, there has been a rise in 
methamphetamine use between 2010 and 2014, with 
methamphetamine reported as the last drug injected 
by one-third of respondents in the 2014 Australian 
Needle and Syringe Program Survey (ANSPS).(31) More 
than 200,000 people are reported to be using crystalline 
methamphetamine (commonly known as ‘ice’) in 
Australia, an increase of 100,000 since last reported 
in 2007.(32) Increased ATS injecting, and high levels 
of marginalisation have been common factors in a 
number of the recent HIV outbreaks in some countries 
in Western Europe.(33) Crystalline methamphetamine 
is reported to be increasing in availability, including 
in countries where methamphetamine use has 
not been commonly reported in the past, such as 
Germany. (34) The Czech Republic has seen an increase 
in methamphetamine use from an estimated 20,000 
people using methamphetamines in 2007, to over 
36,000 in 2014, with injecting being the primary route of 
admission.(35) 
Very few harm reduction interventions are tailored 
towards people who use ATS and there is an urgent 
need for adapted harm reduction responses given the 
increase in ATS injecting.(36)
Drug Consumption Rooms
In addition to other effective harm reduction approaches 
such as OST(37) and NSP(38) provision, ten countries 
around the world operate drug consumption rooms 
(DCRs), also known as supervised injecting facilities 
(SIFs), or Medically Supervised Injecting Centres (MSIC).
(39) All but two of these services are found in Western 
Europe – the exceptions being in Vancouver, Canada, 
and Australia. DCRs are professionally supervised 
healthcare facilities where people can consume drugs 
in safe conditions. DCRs aim to attract hard-to-reach 
populations who may usually use drugs in risky and 
unhygienic conditions. One of the primary goals is to 
reduce morbidity and mortality by providing a safe 
environment and by training people on safer drug use. 
DCRs initially evolved as a response to health and public 
order problems linked to open drug scenes and drug 
markets in cities where a network of harm reduction 
services already existed but where difficulties were 
encountered in responding to the needs of people who 
use drugs.(40) 
In 2016, there are 90 DCRs operating worldwide 
in Canada, Australia, Denmark, France, Germany, 
Luxembourg, Netherlands, Norway, Spain and 
Switzerland. In October 2016, a DCR was introduced 
in Paris, France, and an increase in DCR sites has been 
seen in the Netherlands and Canada since the Global 
State last reported. However, both Switzerland and Spain 
have reduced the number of sites by one. At the time of 
reporting, both Ireland and Scotland plan to introduce 
supervised injecting facilities during 2016/7.(41, 42) 
Overdose
In 2013, a systematic review found that overdose and 
AIDS related mortality were the leading causes of death 
for people who use drugs.(43) In its 2014 Consolidated 
Guidelines on HIV Prevention, Diagnosis, Treatment and 
Care for Key Populations, the World Health Organization 
recommends that people likely to witness a drug 
overdose (including people who inject drugs and their 
families and friends) should have access to naloxone 
and training on how to use it. Naloxone, a highly 
effective opioid antagonist, is still unavailable outside 
of hospitals in many countries around the world. More 
countries are now implementing peer-distribution of 
naloxone, but on a global scale this remains limited. 
North America continues to have the highest drug-
related mortality rate in the world, contributing to an 
estimated 25% of drug-related deaths globally.(9) In 
the United States, the rate of fatal drug overdose has 
increased by 137% since 2000, with more people dying 
from drug overdoses in 2014 than during any previous 
year on record, 61% of which were opioid-related.(9, 10) 
Across the border in Canada, drug overdose deaths 
have jumped 327% since 2008.(11) Overdose also 
continues to be a major cause of death among people 
who use drugs in Western Europe, with more than 6,000 
deaths among this population each year, many involving 
opioids.(44) And in the UK, there has been a 64% increase 
in drug-related deaths linked to heroin and morphine in 
the last two years, now the highest ever recorded in the 
country.(12, 13) 
d Although amphetamines are often grouped with ecstasy in the category amphetamine-type stimulants, this report limits its scope to amphetamine, methamphetamine,  
 cathinone and methcathinone.
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The reasons behind these rises in fatal overdose are 
unclear but a number of factors may be involved 
including: increased heroin availability and prevalence of 
its use, higher purity, the increased levels of morbidity 
linked to an ageing cohort of people who use opioids, 
as well as changing consumption patterns, including the 
use of highly potent synthetic opioids and medicines.(45)
Developments have taken place in North America in 
response to this epidemic. In the US, 37 states and the 
District of Columbia have now enacted some form of 
Good Samaritan laws to protect people from arrest 
or prosecution for drug possession when they call for 
help in the event of an overdose.(46) Additionally, as of 
May 2016, naloxone programmes for law enforcement 
had begun in at least one municipality in 35 states.(47) 
In Canada, the federal government removed naloxone 
from the prescription drug list in March 2016 to allow 
its emergency use, without a prescription, outside 
of hospital settings.(48, 49) In a further move to make 
naloxone more accessible, Canada’s health Minister 
officially authorised naloxone nasal spray for non-
prescription use in October 2016.(50)
Unlike hepatitis C treatment, it is restrictive policies and 
scheduling naloxone as a prescription-only drug in many 
countries, rather than price, that limit its availability. 
However, given the increasingly high overdose rates 
documented, it is urgent that naloxone distribution is 
scaled-up to meet need. 
Prisons
Despite some momentum around decriminalisation in 
the last years, the global response to drugs remains 
predominantly punitive.(51) As a result, around 1 in every 
5 prisoners worldwide are being held on drug-related 
charges.(9) UNAIDS estimates that 56-90% of people who 
inject drugs will be incarcerated at some stage.(52)  
Injecting drug use continues to be consistently 
documented in prisons around the world and the 
prevalence of HIV, HCV and TB remain substantially 
higher inside than outside of prisons.(53) A recent 
comprehensive review of the global disease burden in 
prisoners found that of the approximately 10.2 million 
people incarcerated at any given time, an estimated 
3.8% are living with HIV, 15.1% with HCV, and 2.8% with 
active TB.(53) Findings from this year’s Global State reveal 
that the provision of harm reduction services in prison 
settings continues to be inadequate and far behind that 
of the wider community. 
In 2016, only 8 countries implement NSPs in at least one 
prison – Armenia, Germany, Kyrgyzstan, Luxembourg, 
Moldova, Spain, Switzerland, and Tajikistan. Civil society 
report that since 2014, Iran has ceased to make 
NSPs available to prisoners, signalling the end of NSP 
provision in prison settings in the MENA region.(54) NSPs 
are entirely unavailable to prisoners in seven out of 
the nine regions reviewed in the Global State report. 
Important legal and policy developments in France and 
Nepal, however, could – with a little political courage – 
see the introduction of NSPs in prisons in both countries 
soon.
At present, some form of OST is provided in prisons 
in 52 countries, representing a 21% increase since 
the Global State last reported. Notably, in the past two 
years OST has been initiated in at least one prison in 
India, Lebanon, Macau, Morocco, and Vietnam, while 
the service has been expanded to two more prisons 
in both Greece and Moldova. Guidelines on OST in 
prisons have also been developed in Tajikistan, although 
actual implementation of the service is still under 
consideration. Despite this important progress, the 
quality of prison-based OST varies considerably and 
serious barriers, including stigma and discrimination, 
unnecessary restrictions and long waiting times 
persistently impede access to this essential service 
where it does exist.
Despite a continued lack of systematic monitoring on 
the availability, accessibility and quality of diagnostics, 
treatment and care for HIV, HCV and TB in the world’s 
prisons, existing data suggest that these also continue to 
fail to meet prisoners’ needs in most countries.(53)  
At the same time, the fact that prisoners face a 
heightened risk of overdose following their release 
remains a very serious, yet almost universally neglected, 
issue in practice.(55) In 2016, it appears that only England, 
Scotland, Wales, Estonia, Norway, Spain, some parts of 
Canada and the United States provide varying degrees 
of overdose prevention training and naloxone to 
prisoners on or prior to their release. 
Prison-based harm reduction continues to be extremely 
vulnerable to budget cuts, financial crises, and changes 
in political environments globally. Regional overviews 
paint a bleak picture: harm reduction in prisons is either 
absent or plagued by restrictions, inconsistency and 
uncertainty. The provision of good-quality and accessible 
harm reduction, both inside and outside of prisons, is 
not a policy option but a legally binding human rights 
obligation.(56) It must be urgently prioritised – and 
resourced - by political leaders and prison authorities, 
and national, regional and international prison 
monitoring mechanisms should systematically examine 
issues relating to harm reduction during their prison 
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visits.(57) At the same time, efforts to provide alternatives 
to prison for people who use drugs must be intensified.  
 
International policy developments
United Nations Developments 
 
The United Nations General Assembly Special Session 
on Drugs (UNGASS) took place in New York from 19– 
21 April, 2016.(58) This event was the first such Special 
Session since 1998. It was originally scheduled to 
take place in 2019, to coincide with the completion 
of the 2009 Political Declaration on drugs,(59) but the 
governments of Colombia, Mexico and Guatemala called 
for this meeting to be brought forward to reflect the 
urgent need for debate and review(60) – a proposal that 
was supported by 95 member states at the UN General 
Assembly.
Harm reduction civil society groups viewed the UNGASS 
on drugs as an important moment to make progress in 
securing international recognition of harm reduction, 
and to move beyond the diplomatically ambiguous 
language of “related support services” that was 
eventually agreed in the 2009 Political Declaration. 
Ahead of the UNGASS itself several UN agencies 
inputted submissions into the process which explicitly 
supported harm reduction including UNAIDS,(7) WHO,(61) 
UNDP,(62) the UN University(63) and the Office of the High 
Commissioner on Human Rights (OHCHR).(64) Other 
intergovernmental bodies such as the European Union 
and African Union also supported harm reduction 
through submissions to the process.(58) 
In February 2016, an Informal Interactive Stakeholder 
Consultation was held in New York to solicit views from 
civil society and UN agencies about what the UNGASS 
outcome document should include. HRI and other NGOs 
called for a strong endorsement of harm reduction 
and for member states to redirect funding from drug 
enforcement to harm reduction programmes, in line 
with our ‘10 by 20’ campaign.(65) 
Despite promises that the preparatory process for the 
UNGASS would be held in an inclusive and consultative 
manner,(58) the final outcome document was negotiated 
by member states during ‘informal meetings’ to which 
UN agencies and civil society had no access. The final 
outcome document(3) was adopted without plenary 
discussion on the first day of the UNGASS on Drugs 
meeting and was followed by member states’ statements 
and five thematic round tables.(66) 
The UNGASS outcome document secured a 
commitment from member states to ‘minimising 
the adverse public health and social consequences 
of drug abuse’(65) and invites national authorities to 
consider specific interventions including ‘medication 
assisted therapy’, ‘injecting equipment programmes’, 
‘antiretroviral therapy’ and ‘opioid receptor antagonists’ 
such as naloxone for the treatment of overdose. It also 
urges states to provide these interventions in prisons 
and other custodial settings. In addition, the UNGASS 
document welcomes the Sustainable Development 
Goals (SDGs) and commits (in line with SDG target 3.3) 
to end AIDS and tuberculosis by 2030 and to “combat” 
viral hepatitis and other communicable diseases among 
people who use and inject drugs.(3) 
The term ‘harm reduction’ itself is not mentioned in the 
UNGASS outcome document, despite this being agreed 
language at the UN General Assembly level. While the 
mention of harm reduction interventions and the call to 
provide these in prisons can be seen as a step forward, 
civil society groups remain disappointed that the term 
harm reduction was not included in the final document. 
46 member states did, however, endorse or mention 
the need for harm reduction during the thematic round 
tables or in their plenary statements.(67) The Czech 
Republic, Estonia, Latvia, Lithuania, Poland, Romania 
and Slovenia all made statements in explicit support 
of harm reduction.(68) The European Union’s common 
position, which included Macedonia, Serbia, Ukraine, 
Albania, Bosnia & Herzegovina, Moldova and Georgia, 
also stated that harm reduction, as a proven effective 
measure in preventing overdose and the transmission 
of blood borne diseases, should be further promoted 
and implemented.(68) In the Latin America region, Brazil, 
Costa Rica, Colombia and Uruguay all made statements 
in support of harm reduction, but several Asian nations 
failed to lend their support. Australia, a previous world 
leader in harm reduction, made no reference to harm 
reduction in their statement. Although still refusing 
to mention the words ‘harm reduction’ in national 
policy and international forums, the US government is 
beginning to adopt more of a public health approach 
to drugs and continues to endorse harm reduction 
interventions.(47) At the UNGASS it specifically urged 
Member States to scale-up their public health responses 
to drugs and to adopt evidence-based interventions 
such as OST and NSPs.(69)
The UNGASS document also includes the strongest 
human rights provision ever adopted in a UN drug 
control resolution,(70) with Paragraph 4(o) calling on 
member states to adopt “practical measures to uphold 
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the prohibition of arbitrary arrest and detention and 
of torture and other cruel, inhuman or degrading 
treatment or punishment and to eliminate impunity”. 
(3) It is the only human rights provision which urges 
states to bring drug enforcement activities in line with 
international human rights obligations without making 
any concession to national law.  
 
A High Level Meeting (HLM) on Ending AIDS also took 
place in 2016, from 8 – 10 June in New York. The 
preparatory process was led by Zambia and Switzerland. 
While some elements of civil society engagement 
were improved ahead of the HLM, such as a funded 
Civil Society Task Force (CSTF),(71) 22 organisations 
representing key population groups such as LGBT 
groups, sex workers and people who use drugs were 
excluded from the process by a group of member states 
including Russia, Cameroon and Tanzania.(72) 
While it has the usual caveats to national legislation, 
paragraph 43 of the Political Declaration(73) explicitly 
admonishes the lack of progress in expanding harm 
reduction services, mentions the need to remove 
restrictive laws and advocates a focus on women, young 
people and prisons. This is the first ever UN Political 
Declaration to advocate for the provision of harm 
reduction in prisons and other custodial settings.
Paragraph 62 (d) also includes a reference to “minimising 
the adverse public health and social consequences of 
drug abuse”, using the weaker UNGASS language.(73) 
It is HRI’s understanding that during the negotiations, 
conservative states would only accept one reference to 
harm reduction. 
Global leadership on harm reduction
As described above, the UNGASS on drugs and the 
HLM on Ending AIDS secured clear commitments to 
provide harm reduction services, largely thanks to a 
number of champion governments. While there were 
important references, there were also significant gaps. 
For instance, the 2011 Political Declaration on HIV 
included a specific target to reduce transmission of 
HIV among people who inject drugs (PWIDs) by 50% 
by 2015.(8) A new target to reduce HIV among people 
who inject drugs was not included in either of the 2016 
documents,(74) suggesting a decline in global political 
leadership on harm reduction over the last two years, 
particularly from UNAIDS. In his review of the 2011 
Political Declaration, the UN Secretary General reported 
that there had been “mixed progress” in halving new HIV 
infections among people who inject drugs,(2) when in reality 
the world has failed to meet this target by more than 80%. 
This is one of several recent examples where UN 
agencies, and in particular UNAIDS, have missed an 
opportunity to hold governments who refuse to support 
even basic harm reduction services accountable for 
their inaction. In May 2016, UNAIDS again did not put 
the burden on governments  to act when it released 
figures estimating that just US$1.5 billion was needed to 
deliver harm reduction globally.(7) This figure excluded 
high-income countries altogether and assumed that 
upper middle-income countries would cover their own 
resource needs. By approaching resource needs in this 
way, HRI calculates that UNAIDS has excluded some 
three-quarters of people who inject drugs globally, with 
those left out living in countries like the USA, Russia, 
Greece, Hungary, Bulgaria, Thailand, China, Mauritius 
and Belarus, where harm reduction programmes 
are often severely limited. With 22 other civil society 
organisations, HRI wrote to UNAIDS Executive Director 
Michel Sidibe to raise concerns about these estimates 
and to urge UNAIDS to recruit a new focal point on 
people who inject drugs following the previous post 
holder’s departure.(75) However, the figures have not 
been revised and the focal point role has been merged 
into a wider key populations role, significantly reducing 
the time and commitment that UNAIDS can dedicate to 
harm reduction. 
Over the period 2015-2017, UNAIDS will cut its UBRAF 
funding for the UNODC HIV team by 75%, further 
reducing UN capacity and leadership on the health 
and rights of people who use drugs. UNODC is already 
warning that a number of its national and regional 
programmes are at risk of closure, an outcome that 
would squander advances made with law enforcement 
agencies, prison authorities and other traditional 
opponents of harm reduction. UNODC also warns that 
it will now be impossible to deliver the targets set out in 
the UNAIDS fast track strategy. 
 
The global state of harm reduction 
funding
Funding for harm reduction remains critically low in 
many parts of the world. Overall, the international donor 
funding for the HIV response that has supported harm 
reduction in low- and middle-income countries is in 
decline. Donor contributions totalled US$8.2 billion in 
2015, dropping 7% from the previous year,(76) whilst 
increasing donor focus on least developed countries 
means that middle-income states can no longer rely on 
donors to support their national HIV programmes.(76)e 
 The Global Fund, which remains the largest funder 
a	 There	are	exceptions	to	this,	including	for	example	the	Dutch	Ministry	of	International	Affairs	(BUZA),	the	Elton	John	AIDS	Foundation,	Open	Society	Foundations,	and	 
 PEPFAR. 
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of harm reduction, has stated that ”all upper-middle 
income countries regardless of disease burden and 
all lower-middle income country components with 
low or moderate disease burden, should begin or 
build upon transition preparations during the 2017-
2019 period”,f and has produced a list of 24 countries 
that are projected to become ineligible in the coming 
years.(6) Echoing international donor trends, UNAIDS 
has emphasised within its Fast-Track strategy that 
governments of upper middle-income countries must 
fund their own HIV responses.(73) They also state that 
”special provisions may be needed where the draw-
down of donor funding might result in de-funding of 
essential programmes for key populations in upper-
middle-income countries”’(73) 
More positively, in June 2016, the United States 
President’s Emergency Plan for AIDS Relief (PEPFAR) 
launched a new US$100 million Key Populations 
Investment Fund to expand access to proven HIV 
prevention and treatment services for key populations 
in PEPFAR’s priority countries,(77) which include a number 
of states and regions in major need of harm reduction 
investment.  
While domestic investment in HIV programmes is 
increasing in some countries, few are prioritising 
HIV prevention for key populations.g Among those 
governments reporting to UNAIDS on HIV prevention 
expenditure, only 3.3% of total HIV prevention funds 
were directed towards programmes for people who 
inject drugs. Within this, international donor funding 
represented three-quarters of the investment, 
compared with one-quarter from governments.(76)  
There are significant challenges and risks for countries 
being required to transition from international to 
domestically supported harm reduction programmes. 
The Eurasian Harm Reduction Network, with support 
from APMG, have developed the Transition Readiness 
Assessment Tool(78)h to analyse a country’s readiness 
for, and the risks of, transition from donor funding 
to sustainable domestic financing of harm reduction 
programmes. The tool has been piloted so far in Albania, 
Bosnia and Herzegovina, Macedonia, Montenegro and 
Romania.(79) 
To fully understand the gaps and upcoming shortages 
in harm reduction funding, and to allocate limited 
resources most effectively, it is becoming increasingly 
important to map existing investment at national level. 
Civil society organisations are leading on these efforts in 
Europe, Asia and the Middle East and North Africa (see 
regional chapters for more details). Key harm reduction 
donors, including the Global Fund and PEPFAR, are 
also making efforts to increase transparency of their 
investments in programmes for key populations. PEPFAR 
recently announced that they will be making quarterly 
data publicly available via the PEPFAR dashboards, 
including information relating to their investment in 
programmes for people who inject drugs.(80)
The Global Fund
In the previous iteration of the Global State, concerns 
that the New Funding Model (NFM) would decrease the 
Global Fund’s support for harm reduction were raised. 
The Global Fund analysis of approved NFM funding is 
partially complete, showing that by May 2016, US$142 
million of approved NFM funding was allocated to 
programmes for people who inject drugs (see table 1).i  
As expected, the highest proportion of the US$142 
million was allocated to NSP and OST (22.1% and 13.8% 
respectively) with another substantial proportion for 
management costs (17.2%).(112)
f GFATM Eligibility criteria http://www.theglobalfund.org/en/fundingmodel/process/eligibility.
g Key populations are those both vulnerable and most-at-risk of HIV infection, including people who inject drugs.  
h The tool and user manual can be downloaded from the EHRN website http://www.harm-reduction.org/library/transition-readiness-assessment-tool-trat.
i This amount covers 58.32% of the total NFM allocation for HIV & TB/HIV which amounts to US$7,756,993,172. A total of 98 out of 150 Grants had been analysed at the time  
 of writing from 62 of 110 Countries that the Global Fund funds, as well as 2 out of 7 Multi-Country Grants.
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Further analysis on certain country allocations is 
necessary to ascertain the extent to they have resulted 
in harm reduction service provision. In Nigeria, for 
example, US$8 million disbursed for harm reduction 
in 2015 may have been redirected to more politically 
supported HIV programming.(81) Once the analysis is 
complete, it may show that the overall allocation of 
Global Fund funding for harm reduction under the 
NFM will be comparable to that of the previous Round 
Based Model. These totals will mask many differences in 
national allocations, however, especially the inclusion of 
harm reduction components in Band 1 countries, such 
as Myanmar. The extent to which funding has declined in 
Band 4 countries is not yet clear, but extreme concerns 
remain for those that have been reliant on Global Fund 
monies for harm reduction and wider HIV prevention 
– especially in Eastern Europe, Central Asia and the 
Middle East.(82) The Global Fund allocation methodology 
continues to disadvantage these countries and several 
are now experiencing the reduction or complete loss of 
harm reduction support without any planned transition 
to national funding. 
The recent replenishment saw donors pledge US$12.9 
million to the Global Fund. It is essential that efforts are 
made to ensure that this success benefits all aspects 
of the response to HIV, TB and malaria, leaving no-
one behind. The Global Fund should remain global 
and restrictions from its donors, such as the funding 
condition from the UK Government that 85% of money 
be spent on low and lower-middle income countries,(83) 
should be rejected or rebalanced elsewhere. It is 
paramount that checks are in place to ensure grants are 
awarded on the basis of technically sound proposals 
which include adequate funds for harm reduction where 
there is a need. In addition, the US$800 million set aside 
by the Global Fund Board for ‘catalytic investments’ must 
be made available to protect harm reduction services 
in countries where these will not be supported by 
governments. 
The ’10 by 20’ campaign
What is clear from the sections above is that harm 
reduction cannot rely on HIV-related funding from 
donors and governments – both because the available 
funding is shrinking but also because harm reduction 
is much broader than HIV prevention and treatment, 
including responses to TB and viral hepatitis, prevention 
of overdose, efforts to strengthen the capacity of 
people who use drugs, advocacy for human rights, and 
much more. In recognition of this, HRI launched the 
international ’10 by 20’ campaign in 2015, calling on 
governments around the world to redirect 10% of the 
estimated US$100 billion that they currently spend each 
year on drug enforcement to harm reduction. 
Recent research by HRI and the Burnet Institute used 
mathematical modelling to show some of the potential 
impacts of redirecting just 2.5% (US$2.5 billion). It found 
that these funds would support medium coverage of 
NSP, OST and ART for people who inject drugs and 
that by 2030, this would result in a 65% reduction in 
HIV-related deaths and a 78% reduction in new HIV 
infections among this key population. Increased to 
7.5% (US$7.5 billion), this investment would deliver high 
coverage of harm reduction services worldwide and 
would come close to ending AIDS among people who 
inject drugs by 2030. 
 Bandj Total funding for PWID (US$) Median % of country HIV allocation
Band 1 Bangladesh, Benin, Burkina Faso, Burundi, Cambo-
dia, Chad, Congo (DR), Kenya, Myanmar, Nigeria, Senegal, 
Sierra Leone, South Sudan, Tanzania, Vietnam, Zanzibar
61,326,494 4.2%
Band 2 Djibouti, Laos 63,947 0.3%
Band 3 Indonesia, Philippines, Russian Federation, 
Thailand, Ukraine
56,125,659 21.2%
Band 4 Armenia, Azerbaijan, Belarus, Bhutan, Iran, 
Mauritius, Moldova, Mongolia, Paraguay 
20,528,373 15.4%
Multi-country Eastern Europe (Belarus, Georgia, 
Kazakhstan, Moldova and Tajikistan) 
4,500,000 N/A
j	 The	Global	Fund	NFM	classifies	countries	into	bands	using	the	following	criteria	and	allocations:	Band	1	–	below	US$2,000	GNI,	above	disease	burden	threshold	with	
	 US$11.2	billion	between	2014-2016;	Band	2	–	below	US$2,000	GNI,	below	disease	burden	threshold	with	US$915	million	between	2014-2016;	Band	3	–	above	US$2,000	GNI,	
	 above	disease	burden	threshold	with	US$1.5	billion	between	2014-2016;	Band	4	–	above	US$2,000	GNI,	below	disease	burden	threshold	with	US$1.1	billion	between	
 2014-2016.
Table 1: Global Fund funding for programmes for people who inject drugs from 58% of approved 
NFM grants(112)
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Human rights and harm reduction
In 2008, the then Special Rapporteur on the right 
to health noted that that the UN human rights and 
drug policy regimes operated as though they existed 
in ‘parallel universes’.(84) Eight years later, human 
rights concerns are now slowly but steadily being 
mainstreamed into the global response to drugs, with 
several important developments occurring in the last 
two years. 
In September 2015, the UN Human Rights Council 
convened its first ever high-level thematic panel 
on drug control(85) during which the Office of the 
High Commissioner for Human Rights presented its 
authoritative ‘Study on the impact of the world drug 
problem on the enjoyment of human rights’.(64)  
The report concludes that “the right to health should 
be protected by ensuring people who use drugs have 
access to health-related information and treatment on a 
non-discriminatory basis”, and recommends that harm 
reduction programmes be available for people who use 
drugs, “especially those in prisons and other custodial 
settings.”(64) This report shows a growing attention to 
drug control by the High Commissioner’s office over 
the past several years, and lays the groundwork for 
continued engagement on these issues.
The UNGASS on drugs was another important step 
in bridging the historic divide between human rights 
and drug policy. During the session, ‘human rights’ 
was agreed as one of the cross-cutting themes, with a 
roundtable held on the issue.k Over the course of the 
UNGASS, over 60 Member States voiced their opposition 
to the practice of the death penalty for drugs.(86) Several 
of the UN Special Procedures, including the Special 
Rapporteurs on health and torture, also made powerful 
interventions into the process.(87) Their open letter 
reaffirmed that harm reduction is not merely a policy 
option for States, but rather “a legal obligation as part 
of State obligations to progressively realize the right to 
health and to guard against inhuman and degrading 
treatment.”(87) As noted above, the UNGASS outcome 
document includes an important provision calling on 
states to adopt measures to bring drug enforcement 
activities in line with human rights obligations.(70) 
The following month, ahead of a High-Level Meeting 
on Ending AIDS, the Special Rapporteur on the right to 
health and his two predecessors published a joint article 
in which they declared that ending AIDS by 2030 would 
not be possible without harm reduction. Recognising 
that people who inject drugs have been among those 
left furthest behind in the global response to HIV, they 
urged Member States to take action by committing 
to “fully funding harm reduction programmes” 
and “removing punitive frameworks that fuel mass 
incarceration, HIV epidemics and overdose.”(88)
Many UN treaty bodies have also continued to 
strengthen their positions on harm reduction in the 
last two years. The UN Human Rights Committee, for 
example, raised concerns with Russia in 2015 about 
its legal ban on OST, as well as its approach to the 
treatment of prisoners who use drugs, which it felt 
did not adequately protect them from torture and 
ill treatment.(89) In July 2016, the UN Committee on 
Economic, Social and Cultural Rights commended the 
introduction of harm reduction strategies in Sweden, but 
expressed concerns about prisoners’ restricted access 
to OST, the prevalence of HCV among PWID, and the 
increasing rate of fatal overdoses in the country.(90) 
Despite this attention, the fact remains that human 
rights violations linked to drug control and enforcement 
remain endemic in many parts of the world. One of the 
most glaring examples of this is the Philippines, where 
President Duterte’s campaign to eliminate drug use 
has led to the State-sanctioned extra-judicial killing of 
more than 2,500 people accused of being drug vendors 
or drug users by police and armed vigilante groups 
since July 2016.(91) This brutal approach has been widely 
condemned by the international community, including 
the UN Secretary-General,(92) the International Narcotics 
Control Board,(93) and civil society.(94) Most recently, the 
Committee on Economic, Social and Cultural Rights 
urged the state to “stop and prevent extrajudicial 
killings and any form of violence against drug users”, 
“adopt a right-to-health approach to drug use with 
harm reduction strategies, such as syringe exchange 
programs” and “increase the availability of treatment 
services that are evidence-based and respectful of the 
rights of drug users.”(95)  
 
Research and data collection
In the context of shrinking funding for HIV-related 
harm reduction in many parts of the globe, it is 
increasingly important that national governments 
allocate available resources to achieve optimal impact 
and the requirement to ‘know your epidemic’ remains 
crucial. Governments must have recent reliable national 
and local epidemiological data as well as a clear 
understanding of any limiting factors that may affect 
their investments. Civil society also must be equipped 
with this information in order to make informed advocacy 
calls for strategic investment in harm reduction. 
k Video available here: http://webtv.un.org/search/round-table-3-30th-special-session-on-world-drug-problem-general-assembly/4855659142001?term=round%20table%203.
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Since the last Global State report was published in 
2014, harm reduction advocates have continued to 
make strong calls for UN agencies to reinstate an 
independent academic research group to carry out 
systematic reviews relating to injecting drug use, HIV and 
viral hepatitis, as well as the coverage of existing harm 
reduction programmes. The last systematic reviews 
were published in 2008 and 2010 by the Independent 
Reference Group to the UN on HIV and Injecting Drug 
Use,(96, 97) but with no updates since then there has been 
a dangerous overreliance on government reported data 
submitted to UN data-gathering mechanisms such as 
the Global AIDS Response Progress Reporting (UNAIDS) 
and the Annual Reports Questionnaire (UNODC). The 
extent to which these data have been subject to peer 
review, critique or are made public with transparent data 
sources varies considerably. Since 2014, systems have 
been established to improve collaboration between UN 
agencies and civil society on these datasets, but these 
do not substitute the need for an independent academic 
process. The implementation of programmes reaching 
people who use drugs remains highly political in many 
parts of the world and as such, these data are often also 
political, so independent academic processes to collate 
the most accurate reflections are essential.
In 2016, a consortium of academic researchers led by 
the University of New South Wales, in collaboration 
with WHO, UNAIDS, the Global Fund, Open Society 
Foundations and UNODC began systematic reviews 
of injecting drug use prevalence, HIV, HBV and HCV 
prevalence among people who inject drugs, as well as 
HIV prevention and treatment coverage, which are due 
to be published in 2017. This crucial work will inform 
programme planning, monitoring and evaluation, help to 
calculate the most accurate resource needs estimates 
and ensure strategic funding allocations, and be widely 
used by harm reduction advocates around the world.  
 
Technical guidance 
 
In 2015 and 2016, new guidance has emerged with 
regard to key populations and specific groups of people 
who inject drugs, both from UN agencies and civil society 
8 In June 2016, the World Health Organisation 
launched an update of the 2013 Consolidated 
guidelines on the use of antiretroviral drugs 
for treating and preventing HIV infection: 
recommendations for a public health approach. 
These guidelines incorporated an exhaustive 
review of new evidence and consultations 
to develop new recommendations. 
Recommendations include  initiating all adults 
with a CD4 count of less than 350 cells/mm in 
ART, and a recommendation to roll out pre-
exposure prophylaxis or PrEP.(98)
8 The World Health Organisation launched an 
update of its 2014 consolidated guidelines on 
HIV prevention, diagnosis, treatment and care 
for key populations in July 2016. This update 
expands upon the previous version to include 
new international guidelines on treatment 
as well as recommendations related to PrEP, 
clearer guidance on the peer distribution 
of naloxone and the “decriminalisation of 
behaviours such as drug use/injecting”.(99)
8 In 2015, the World Health Organisation 
launched a tool to supplement the consolidated 
guidelines for HIV prevention, diagnosis, 
treatment and care for key populations. 
The tool “to set and monitor targets for HIV 
prevention, diagnosis, treatment and care for 
key populations” aims to provide guidance on 
monitoring and evaluating the implementation 
of the comprehensive package of interventions 
to address HIV among key populations, it 
recommends engaging NGOs, communities 
and service providers in the planning and 
assessment process of such programmes.(100)
8 In July 2016, UNODC launched a guide to 
address the needs of women who inject drugs. 
This guide aimed to support service providers 
to develop gender sensitive programmes and 
to set targets to expand coverage and access 
for women who inject drug.(101)
8 The needs of young people who inject drugs 
were prioritised through the development of a 
technical brief by WHO, UNFPA, UNHCR, NSWP, 
The World Bank, INPUD, UNDP, UNESCO, 
UNODC, MSMGF, UNAIDS, HIV Young Leaders 
Fund, ILO and UNICEF in September 2015.(102) In 
October 2015, HRI along with the International 
HIV/AIDS Alliance, Save the Children and 
YouthRise also launched Step by Step, a toolkit 
to help harm reduction service providers 
prepare for work with children and young 
people who inject drugs.(103) 
8 In January 2016, UNODC, in collaboration 
with INPUD and LEAHN, developed a set of 
guidelines to improve cooperation between law 
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enforcement officers and HIV service providers.
(104) These guidelines build upon the training 
manual launched by UNODC in 2014 for law 
enforcement officials on HIV service provision 
for people who inject drugs.(105) 
8 In February 2016, HRI launched ‘Monitoring 
HIV, HCV, TB and Harm Reduction in Prisons: 
A Human Rights-Based Tool to Prevent Ill 
Treatment’.(57) This Tool provides support to 
national, regional and international prison 
monitoring bodies to help ensure that 
violations of prisoners’ rights in the context of 
HIV, HCV, TB and harm reduction are prevented 
and awareness is raised around the need to 
urgently address this gap in health provision. 
Civil society action 
 
The period before the UNGASS on drugs and the HLM 
on HIV in 2016 saw a major surge in international 
activism by harm reduction organisations, as well as 
greater coordination between the harm reduction, drug 
user and drug policy reform communities. 
HRI convened and resourced an international Harm 
Reduction Working Group which, in 2014, agreed to use 
the UNGASS and the HLM to call for a new approach to 
drug use rooted in science, public health, human rights 
and dignity – for a harm reduction decade. This call was 
officially launched at the International Harm Reduction 
Conference in Kuala Lumpur in October, 2015, and since 
then it has been endorsed by over 1,100 individuals 
and organisations. During thematic roundtables at the 
2015 Commission on Narcotic Drugs meeting and as 
part of the Informal Interactive Stakeholder Consultation 
in 2016, a number of civil society representatives used 
their speaking slots and interventions to call for a harm 
reduction decade and for specific commitments to scaling 
up harm reduction and protecting human rights.(65, 106)  
 
These calls were also reflected in a significant increase 
in online activity around the UNGASS and the HLM, with 
civil society organisations using Twitter, Facebook, blogs 
and other online tools to ensure that their messages 
were clearly heard. In addition, over 200 organisations 
came together to form www.stoptheharm.org, an online 
platform campaigning for a new global drug policy 
system.
Harm Reduction networks continue to operate in every 
region of the world. Global networks which have a focus  
on harm reduction include YouthRISE, International 
Network of People who Use Drugs (INPUD), (107), 
International Doctors for Healthy Drug Policies (IDHDP), 
Law Enforcement and Public Health Network (LEPH), 
Women’s International Harm Reduction Network 
(WIHRN) and the International Drug Policy Consortium 
(IDPC). 
Regional harm reduction networks include the Eurasian 
Harm Reduction Network,(108) Correlation,(109) Middle East 
and North African Harm Reduction Network (MENAHRA), 
the Harm Reduction Coalition (USA) and Intercambios 
(Latin America). 
Since the Global State reported in 2014, there have been 
significant developments in the visibility and resourcing 
of networks of people who use drugs. The European 
Network of People who Use Drugs relaunched in 2013 
with a new governance structure and set of priorities.(110)  
Regional networks of people who use drugs also 
continue to operate in other parts of the world, with the 
continued growth of the Asian,(111) Eurasian (ENPUD), 
Middle East and North African (MENAPUD) and Latin 
America Networks of People who Use Drugs.(111) 
The International Network of People who Use Drugs 
has also continued to grow since 2014, and in 2015, 
launched its consensus statement on drug use under 
prohibition.(107) Based on a set of regional consultations 
the consensus statement outlines the harms faced by 
people who use drugs and a set of advocacy priorities to 
mitigate such harms.
Civil society action continues to be central to the harm 
reduction response around the world. Harm reduction 
workers comprise a diversity of individuals, groups and 
organisations, including peer workers, outreach workers, 
service providers and advocates, who work tirelessly, 
often in hostile environments, to reduce the harms 
associated with drug use and drug laws and policies and 
to promote the rights to life, health, humane treatment 
and non-discrimination for people who use drugs. It is 
due to the commitment and tenacity of these individuals 
and organisations that harm reduction services are 
available in some parts of the world at all. Their value 
as human rights defenders and as the designers of 
the harm reduction response must be recognised. 
Protections must be put in place so that no harm 
reduction worker experiences human rights abuses in 
the course of their work, as is routine in countries such 
as Thailand and Russia, and so that harm reduction 
services can be effectively delivered to those who 
require them.  
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342.1 ASIA
Country/territory 
with reported       
injecting drug use
People who inject 
drugs
HIV 
prevalence 
among 
people who 
inject drugs 
(%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among 
people who 
inject drugs 
(%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among 
people who 
inject drugs 
(%)
Harm reduction response
NSPa OSTb
Afghanistan 40,900
(1) (13,500–
80,000) 4.4
(2) 31.2(2) 6.6(2) 318(3) 31(3)
Bangladesh 21,800–23,800(4)c 1.1 (5.3 in Dhaka(5) ) 39.6
(6) 9.4(7) 388(6) 33(6) (M)
Bhutan nk nk nk nk 7 7
Brunei Darussalam nk nk nk nk 7 7
Cambodia 1,300 (1,200–2,800)(8) 24.8(8) nk nk 35(9) 31(9)
China 2,580,000(10)d 6(11) 67 (60.9–73.1)(7) 9.6 (3.8–15.4)(7) 3814(11) 3767(11) (B, M)
Hong Kong nk nk nk nk 7 320(12)
India 1,700,000(13) 9.9(13) 41(7)e 10.2 (2.7–17.8)(7) 3277(14) 3145(15) (M, B, 0)
Indonesia 74,326 (61,901–88,320)(16)f 36.4
(17) 63.5(18)g 2.9(7) 3194(17) 387(19) (B, M)
Japan nk nk 64.8 (55–74.5)(7) 3.2 (2–4.3)(7) 7 7
Korea (Republic of) nk nk 54(7) 4(7) 7 7
Lao PDR 1,317(20) 0.1(21) nk nk 34(22) 7
Macau 238(23) 1.3(24) 80.4(25) 10.7(25) 34(25) (P) 34(25) (B, M)
Malaysia 170,000(26) 16.3(26) 67.1(7) nk 3662(26) 3838(26) (B, M)
Maldives 793 (690–896)(27) 0(28) 0.7(29) 0.8(29) 7 31(30) (M)
Mongolia 570 nk nk nk 31(31)
Myanmar 83,000(32) 23.1(32) 79.2(7) 9.1(7) 340(33) (P) 335(32) (B, M)
Nepal 52,174(34) 6.3(35) 87.3 (80.5–94)(7) 5.8 (5.5–6)(7) 360(36) 315(36) (B, M)
Pakistan 104,804(37) 37.8(38) 93(38) 6.8 (6–7.5)(7) 334(39) 7(B)(38) 
Philippines 20,000 (17,000–23,000)(40) 41.6
(41) 70(7) nk 3h 7
Singapore nk 2(42) 42.5(7) 8.5(7) 7 7
Sri Lanka nk nk nk nk 7 7
Taiwan 60,000(43)i 17.7(43) 41(7) 16.7(7) 31,254(44) 3162(44) (B, M)
Thailand 71,000(40, 45) 21(40) 89.8(7) nk 314(46) 3147J (M)
Vietnam 271,000 (100,000–335,000)(47) 40
(47) 74.1(7)k 19.5(7) 3297(P) 3145(48) (M)
 
nk = not known
ASIA
Table 2.1.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Asia
a	 All	operational	needle	and	syringe	programme	(NSP)	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.	
(P) = pharmacy availability.
b Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
c Data from 2009, and only for men who inject drugs.
d Figure indicates the number of registered people who use drugs who have been recorded by the police. There are an estimated 10 million people who use drugs thought to 
exist in China.
e	 HCV	prevalence	rates	vary	greatly,	from	90%	in	Manipur	to	1%	in	Bihar;	no	national	figure	is	available.
f The Indonesian Ministry of Health is working on new population size estimates which have yet to be released at the time of writing.
g Based on sub-national data from three cities: Tangerang, Denpasar, Makassar.
h Needles and syringes are distributed regularly to people who inject drugs but only at a health facility, thus limiting coverage.
i Based on longitudinal data from two prison cohorts.
j Civil society and experts in the region suggest that this estimate is too high and may not represent the actual level of OST provision in Thailand. It may include clinics that 
require	periodic	detoxification	and	re-enrolment.
k Figure from 2003.
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Both NSP and OST available
OST only
NSP only
Neither available
Not known
Map 2.1.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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362.1 ASIA
Harm reduction in Asia
Overview
Asia is the region with the second highest number of 
people living with HIV in the world (approximately 5.1 
million). living with HIV in the world.(49) Of the estimated 
300,000 new HIV infections in the region in 2015, 96% 
were in just nine countries: China, India, Indonesia, 
Malaysia, Myanmar, Pakistan, Philippines, Thailand 
and Vietnam; and were concentrated within three 
key population groups: people who inject drugs, men 
who have sex with men (MSM) and (male, female and 
transgender) sex workers.(49) According to a 2011 report, 
between 12 and 21 million people use opiates across 
Asia, representing half of the total global population of 
opiate users.(50) An estimated four million people inject 
drugs, the highest concentration in any region.(40) A 
disproportionate number of new HIV infections in Asia 
are found among the population of people who inject 
drugs.(49) Table 2.1.1 also illustrates very high levels of 
hepatitis C prevalence among this population. These 
figures clearly demonstrate the vital need for increased 
harm reduction service provision in Asia.
Since The Global State of Harm Reduction 2014, revised 
population estimates for people who inject drugs have 
been proposed and approved in India (ten times the 
size of previous estimates), Afghanistan (double previous 
estimates), Myanmar (approximately 10% more) and 
Thailand (approximately 65% more). A situational 
analysis of drug use in Mongolia, which was conducted 
in 2015 as a precursor to the implementation of a rapid 
assessment and response programme, revealed up 
to 2,300 people who use drugs, and 570 people who 
inject drugs, mostly concentrated in the capital city of 
Ulaanbaatar.(51) While such revised estimates may lend 
support to the perception that the number of people 
who use and inject drugs is increasing, sometimes new 
figures can be the result of differences in the research 
methodologies used.
In 2015, based on Global State 2014, it was reported 
that the average HIV prevalence among people who 
inject drugs in Asia was 15.4%.(52) New data (see Table 
2.1.1) suggest that this figure has risen to 17%, with 
increases in prevalence reported in Myanmar, Pakistan 
and Vietnam. Overlaps between people who inject 
drugs and other key population groups, including sex 
workers and MSM, have also been reported in several 
countries in the region, and require increased attention 
in the form of data gathering and integrated service 
delivery.(40, 53) Four Asian countries have been prioritised 
by UN agencies and other development partners due 
to the continued rapid expansion of their national 
HIV epidemics: Bangladesh, Indonesia, Philippines 
and Sri Lanka.(54) Meanwhile, several countries in the 
region continue to produce evidence that supports 
the effectiveness and cost-effectiveness of harm 
reduction interventions in the context of HIV and HCV 
transmission.(55–57)
Although the need for harm reduction is increasingly 
accepted across the region, a largely punitive policy and 
legal environment continues to undermine access to life-
saving harm reduction programmes. Eleven countries in 
the region still operate compulsory detention centres,(54) 
incarcerating over 455,000 people who use drugs in 
2014.(40) Although UN agencies and member states 
increasingly advocate an end to the death penalty for 
drug offences,(58) some Asian states continue to execute 
people in high numbers, in violation of international 
law and contrary to the global trend towards death 
penalty abolition. China, Singapore, Malaysia, Indonesia 
and Vietnam are all considered ‘high application states’, 
prescribing the death penalty for drugs as common 
practice.(59) While the Philippines abolished the death 
penalty for all crimes in 2006, President Rodrigo Duterte 
promised to restore capital punishment following 
his election in 2016 and has instigated thousands of 
extrajudicial killings of alleged drug suspects by police 
and armed vigilante groups.(60, 61)
Amphetamine-type stimulants remain the dominant 
drugs of choice in Asia, with between 3.5 and 20.9 
million people using amphetamines.(50) HIV incidence 
rates are notably high among this group,(6) yet tailored 
harm reduction and HIV prevention services for people 
who use amphetamines are lacking within the region.
 
Compulsory drug detention 
and rehabilitation centres in 
Southeast Asia
Detention and coercive treatment of people who use 
drugs remain the dominant approaches in 11 countries 
in the region,(54) including Cambodia, China, Indonesia, 
Lao PDR, Malaysia, Myanmar, Philippines, Thailand and 
Vietnam.(62, 63) UN agencies released a statement in 2012 
calling for the closure of compulsory drug detention and  
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rehabilitation centres.(64) They also hosted formal regional 
inter-governmental consultations involving policy-makers 
from Asia, international experts and multilateral agencies 
in 2010, 2012 and 2015 to encourage governments to 
accelerate the transition towards voluntary community-
based treatment and support services.
The Third Regional Consultation on compulsory centres 
for drug users (CCDUs) was held in September 2015 in 
Manila, the Philippines. It generated a commitment to 
transition away from compulsory models and towards 
evidence-informed and community-based approaches 
to address drug dependence. An expert paper produced 
by leaders from the region outlines key elements and 
principles that are important for a successful transition 
to voluntary community-based treatment and support 
services. It also proposes a model for initiating an 
effective transition at national level, and highlights recent 
examples of good practice from Cambodia, China, 
Indonesia, Malaysia and Thailand.(62)
Harm Reduction International also documented six 
models in developing community-based alternatives to 
CCDUs from Cambodia, China, India, Indonesia, Malaysia 
and Vietnam. While these programmes naturally differ 
within and across countries, several common elements 
have been identified as critical to effective community-
based services that meet the needs of people who use 
drugs.(65)
The Malaysian government initiated the conversion of 
compulsory detention centres into Cure and Care (CNC) 
centres in 2010. These centres offer voluntary access to 
a comprehensive package of health and support services 
for people who use drugs, which has been identified as 
a good practice model.(62) In recent evaluations of CNC 
centres, clients expressed satisfaction with treatment 
outcomes and identified diminished withdrawal 
symptoms and fewer cravings for drugs as important 
personal successes.(66) Analyses of participant interviews 
identified four CNC services that contributed the 
most to these positive results: methadone treatment, 
psychological counselling, religious instruction and 
recreation. The open environment, with strong 
and trusting relationships among peers and staff, 
contributed to improved programme adherence. 
Participants felt that their access to healthcare greatly 
benefited their overall health. Another study, comparing 
CNC centres and CCDUs in Malaysia, found that 50% of 
clients coming out of CCDUs relapsed within 32 days 
of release compared with 429 days for those attending 
CNC centres.(66) 
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
A total of 17 countries implement NSPs across Asia, a 
figure that has remained stable since the publication 
of the Global State 2012. Service-delivery modalities 
remain varied across the region, but implementation 
is concentrated largely in the civil society sector. As 
reported in 2012(29) and 2014,(67) no NSP sites are 
operating in Bhutan, Brunei-Darussalam, Hong Kong, 
Japan, Republic of Korea, Maldives, Singapore or Sri 
Lanka.
Few countries have reported changes in the scale of 
NSP service delivery. However, important reductions 
have occurred since the Global State 2014 in Afghanistan 
(from 31 to 18 sites), in India (from 295 to 277 sites) 
and in Thailand (from 38 to 14 sites). In Thailand, the 
dramatic decrease was precipitated by the sudden 
termination of the partnership with local pharmacists 
due to reduced funding.(68) Only Taiwan has recorded 
an increased number of NSP service-delivery sites, from 
1,103 to 1,254.
Reports show that Bhutan may implement NSPs in the 
coming years through Global Fund support.(69) However, 
many countries in the region report dwindling support 
for harm reduction – both financially and politically – 
in the wake of the Global Fund’s new funding model 
allocation. The decrease in NSP sites in the countries 
highlighted above is a direct consequence.
The temporary closure of an NSP has been reported at 
a methadone maintenance clinic in Cambodia, due to 
stigma and discrimination aimed at personnel running 
the service.(70) NSPs in Bangladesh, Indonesia and 
Lao PDR have also been impacted by reduced donor 
support, though the scale of the reduction of these 
services has yet to be officially reported.
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 Country Needles distributed per person who injects drugs per year
Afghanistan 159
China 204
India 240
Indonesia 44
Malaysia 61
Myanmar 168
Pakistan 178
Philippines 0*
Thailand 14
Vietnam 62**
*  Data from the Philippines show that among the 11,042 clients reached, an average coverage of 16 needles and syringes per client per month was achieved over a 
	 five-month	period	before	the	service	was	closed.
**  NSP coverage in Vietnam has fallen from 180 in 2012,(29) to 98 in 2014,(67) to 62 in 2016.
Table 2.1.2: Overview of needle distribution per person who injects drugs per year(40)
A pilot peer-operated NSP was initiated in 2014 in 
Cebu, the Philippines, despite legal provisions making 
possession of needles and syringes a criminal offence. 
A temporary exemption negotiated with the Dangerous 
Drugs Board allowed the NSP to operate as a scientific 
study to assess effectiveness of such interventions 
among people who inject drugs.(71) Although the project 
ended in December 2015, arrangements are in place 
to sustain this programme with Global Fund support. 
However, needle and syringe distribution remains 
on hold as local stakeholders evaluate the unfolding 
political turmoil around the extrajudicial killings of 
people alleged to be in the drug trade, as encouraged by 
President Duterte.
In Vietnam, the introduction of low-dead-space 
syringes was piloted with success in three provinces. 
An assessment of the pilot determined that exposure 
to social marketing approaches led to increased sales 
of commodities as well as increases in reported use 
and consistent use of such commodities.(72) Securing 
sustainable funding for this intervention has been an 
important challenge; at the time of writing, the project 
will run until the end of 2016 with support from the 
private sector.
Opioid substitution therapy (OST)
Fifteen countries in the region provide OST to people 
who use opioids. The number of sites has remained 
relatively stable since the Global State 2014, with 
increases documented in Malaysia (from 811 to 838 
sites), Taiwan (from 90 to 162 sites) and Vietnam (from 
80 to 145 sites). In Vietnam, government representatives 
stated in June 2015 that methadone was being 
dispensed to over 27,278 people in 43 provinces and 
cities.(73) While this increase is welcome, OST service 
coverage in the country is still considered extremely 
low, meeting only 15% of need.(74) In Indonesia, OST 
sites providing methadone have increased marginally, 
from 85 sites in 2014(67) to 87 in 2015.(19) Although there 
has been an increase in provision, levels remain low 
according to UN guidelines.(75)
Official documents indicate that plans are being 
developed to initiate OST for people who inject drugs in 
Pakistan, with buprenorphine availability before 2020.
(76) In Bhutan, a pilot OST programme was planned for 
2015 with financial support from the Global Fund, but it 
has not yet begun.(69) According to the UNODC Country 
Office in Afghanistan, plans are in place to scale up 
OST provision to 320 sites within the community (in 
Kabul, Herat, Balkh, Nangarhar, Badakhshan, Kunuz, 
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Ghazni and Kandahar) and 180 sites in prisons over the 
course of 2016.(77) As of 2016, OST continues to remain 
unavailable in nine countries across the region.
Since the Chinese government first supported the 
piloting of eight OST clinics in five provinces in 2004,(7) 
the harm reduction programme in the country has 
expanded dramatically. There are currently 767 OST 
sites operating in 28 provinces, with 184,000 people 
receiving methadone maintenance therapy when 
UNAIDS last reported in 2015.(78) Between 2009 and 
2013 in Yunnan, 63 new OST sites were established, 
with coverage reported to be 22.6%, equating to mid-
level coverage according to UN targets.(75)I Although 
harm reduction service providers illustrate promising 
results, it is important to note that NGOs delivering 
services operate in a difficult policy environment. China 
continues to support severe, punitive policies on drugs, 
with estimates of at least 600 people being executed for 
drug-related offences in 2014.(59)
In Thailand, detoxification and long-term maintenance 
with methadone has been provided for free since 
2014, as it is included in the universal health insurance 
scheme as well as in the social security scheme.(79) 
Methadone treatment is currently available only in 
district-/province-level hospitals and at a few remote 
drug treatment centres, reaching no more than 10% of 
all people who require methadone in the country.(79) In 
order to increase access, O-zone, a Thai NGO aiming to 
improve the quality of life for people who use and inject 
drugs in Thailand, has been implementing a peer-led, 
community-based methadone delivery service in the 
mountain village of Santikhiri in Chiang Rai province, 
where peer outreach workers operate methadone 
delivery at a drop-in centre with supervision from Mae 
Chan Hospital.(79) Initiated in 2013, the initiative attracted 
media attention and support from government agencies 
and has been replicated in Huay Pung in Chiang Rai 
province.
Provision of vital harm reduction services is often 
hindered by legal and policy barriers that restrict or 
prohibit implementation and scale-up, and the limited 
financial commitment of governments and donors 
means there is still much work to be done to ensure an 
enabling environment.
Amphetamine-type stimulants (ATS)
It has been estimated that between 13.9 million and 
54.8 million people use amphetamines worldwide,(80) 
with more than 60% of global ATS use thought to be 
concentrated in Southeast Asia.(81) The ATS market 
continues to expand, particularly in Southeast Asia, 
China and Australia.(82) For example, 74% of people who 
use drugs in one treatment centre in Cambodia were 
receiving treatment for crystal methamphetamine use,(83) 
and 58% of people in a treatment centre in Lao PDR 
were receiving treatment for methamphetamine use.(84)
A 2011 study conducted in three major urban areas 
in Malaysia found a rapid increase of ATS use in not-
in-treatment opiate injectors after 1997, which was 
associated with an increased risk of HIV infection.(85) 
However, project data from Thailand indicate that 
patterns of drug use in Bangkok are changing, with 
approximately 50% of clients in the central region 
injecting ATS and pharmaceuticals in 2014, compared 
with 70% who were injecting heroin in 2009 in the same 
region.(86) Anecdotal evidence from Japan also suggests 
that up to 50% of ATS users may be injecting.(87) 
In a 2016 study among 103 women who use drugs in 
Malaysia, ATS were the most commonly used drugs 
(45.6%).(88)
Very few interventions address ATS use in the region. 
The civil society organisation Health and Harm Reduction 
Tokyo has a 24/7 hotline in place to provide information 
to people who use and inject ATS drugs.(87) The Asia 
Pacific Coalition on Male Sexual Health (APCOM) is 
developing information, education and communication 
materials on chemsex for MSM in Thailand. It is worth 
noting that in the past two years an increasing number 
of harm reduction civil society organisations across the 
region have been calling for expanded HIV prevention 
interventions along with other harm reduction measures 
tailored to meet the needs of people who use but do 
not yet inject drugs. In light of the increasing trend of 
ATS use, Harm Reduction International produced an 
updated report in 2015 noting the ways in which harm 
reduction programmes can respond effectively to the 
harms associated with amphetamine use.(89)
Viral hepatitis
Asia is disproportionately affected by viral hepatitis: 67% 
of the world’s people living with hepatitis C (HCV) are 
found in this region.(90) Viral hepatitis has caused more 
than one million deaths in Asia, approximately 20% of 
which are related to chronic HCV.(91) HCV prevalence 
rates among people who inject drugs are over 80% in 
Nepal, Thailand and Pakistan; above 70% in Myanmar 
and Vietnam; and over 60% in Indonesia, China, Japan 
and Malaysia.(7) Where treatment is said to be available, 
it is often inaccessible for people who inject drugs.
 
i According to the 2012 revised WHO, UNODC and UNAIDS target-setting guide, less than 100 syringes distributed per person who injects drugs per year is considered low   
     coverage (100 to 200 is medium coverage and more than 200 is high coverage).
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Significant advances have been made in improving 
the efficacy of HCV treatment over the last few years. 
The introduction of direct-acting antiviral (DAA) based 
treatment regimens has shortened treatment times, 
reduced side effects and greatly increased the likelihood 
of virus elimination. The extremely high prices set 
by pharmaceutical company Gilead meant that such 
treatments remained out of reach of the majority 
of people who use drugs. However, a combination 
of factors have favoured generic production and a 
consequent drop in prices for DAAs in many countries 
in Asia. Specifically, Gilead issued voluntary licences to 
11 Indian generic producers, allowing them to produce 
and market generic sofosbuvir with a 7% royalty 
payment to Gilead.(92) These licences allow the export 
of generic sofosbuvir to 101 predefined countries, 
including Afghanistan, Bangladesh, Bhutan, Cambodia, 
Indonesia, India, Malaysia, Mongolia, Myanmar, Nepal, 
Pakistan, Sri Lanka, and Vietnam.(93) Generic sofosbuvir 
can be made available in the countries listed at a cost 
of approximately US$300 per month.(94) The licences 
exclude many large middle-income countries that are 
home to a significant proportion of people living with 
HCV in the region, including China and Thailand.(92)
While the availability of DAAs remains limited to 
some countries, generic companies are working to 
complete regulatory requirements for registration of 
the medicines prior to future marketing distribution.(95) 
The Thai government approved Gilead’s application to 
register sofosbuvir in Thailand in August 2015, but the 
Chinese government rejected one of Gilead’s patent 
requests for sofosbuvir in June 2015.(96) Malaysia plans 
to make treatment available to more than 1,000 people 
who inject drugs living with HCV in 2016, and more 
than 15,000 people by 2025.(97) In Manipur, India, the 
Community Network for Empowerment (CoNE), a local 
civil society network led by and delivering services to 
people who use drugs, established hepatitis B and C 
testing camps across nine districts over one month. 
The testing camps targeted people who use drugs and 
people living with HIV. This initiative won the innovative 
hepatitis testing contest initiated by the WHO at an 
award ceremony and symposium about hepatitis testing 
on 17 April 2015 during the International Liver Congress 
in Barcelona, Spain.(98) In Indonesia, PKNI (Persaudaraan 
Korban Napza Indonesia) is conducting a peer-driven 
study among 500 people who inject drugs to educate 
the community on HCV treatment access and literacy 
while assessing barriers to treatment uptake.(99)
 
 
Tuberculosis (TB)
Southeast Asia accounts for 38% of the global TB 
burden, with Bangladesh, India, Indonesia, Myanmar and 
Thailand among the highest TB-burden countries in the 
world.(100) Data on TB for people who inject drugs are 
sparse; however, individual studies indicate that there is 
a higher prevalence of TB among this population.(101, 102)
Although all eleven Member States of the United 
Nations within Southeast Asia have national TB control 
programmes, and TB mortality has decreased in the 
region by more than 50% since 1990,(100) the continuing 
high rates in some countries must be more robustly 
addressed. TB and HIV control programmes are 
improving,(100) but joined-up programmes need to be 
strengthened in countries with a high TB burden. In 
Bangladesh, for example, national TB/HIV operational 
guidelines were developed in 2009, and a national TB/
HIV committee has been put in place, yet, despite these 
policy improvements, limited numbers of NGOs provide 
HIV counselling, prevention and care for TB/HIV co-
infected individuals.(100)
The primary barriers to TB testing and treatment 
for people who inject drugs in Asia are a lack of 
integration into harm reduction programmes, stigma 
and discrimination against people who use drugs by 
service providers, a lack of awareness among criminal 
justice and healthcare providers, and limited testing and 
treatment opportunities at NSP and OST sites.(46, 97) Given 
the dearth of data on people who inject/use drugs and 
TB prevalence, it is clear that further research should be 
undertaken, and that greater integration of TB services 
into existing harm reduction initiatives is required.
Antiretroviral therapy (ART)
The Asia and Pacific region has the second highest 
number of people living with HIV in the world, estimated 
to be 5.1 million in 2015.(49) China, India, Indonesia, 
Malaysia, Myanmar, Pakistan, Philippines, Thailand 
and Vietnam account for around 96% of the 300,000 
new infections each year.(49) Although reports indicate 
a 5% decline in new HIV infection rates between 2010 
and 2015, testing rates remain suboptimal in many 
countries, with evidence suggesting that 1.9 million 
people living with HIV in Asia and the Pacific in 2015 did 
not know their status.(49)
While it is a fact that HIV in the region is concentrated 
among key populations, rates of HIV testing are extremely 
low among people who inject drugs. For example, fewer 
than one in three people who inject drugs in the region had 
tested for HIV in a 12-month period and knew their results.(49)
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UNAIDS reported in 2013 that of the total number 
of people living with HIV in Asia who are eligible for 
ART, only 18% accessed treatment.(103) ART coverage 
among people who inject drugs continues to remain 
low: just 5% in Malaysia,(104) only 2% in Thailand,(105) 6% 
in Indonesia(106)m and 4% in Vietnam.(106) There are very 
few ART sites in Afghanistan, and where they do exist, a 
lack of follow-up and a weak referral system hinder their 
success.(77) Similar to TB testing and treatment uptake, 
many barriers – including a lack of integration into harm 
reduction programmes such as NSPs and OST sites, fear 
of arrest and stigma and discrimination against people 
who use drugs by service providers – serve to further 
deter people who inject drugs into seeking either testing 
or treatment for HIV.(46, 77, 97)
Harm reduction in prisons
Over 3.89 million people are incarcerated in Asia,(107) 
and an additional 635,000 are being held in compulsory 
drug detention centres.(63) A large proportion of those 
in prison – for example, 20% in Japan,(108) 31% in 
Indonesia,(109) 50% in the Philippines(110) and 72% in 
Thailand(111) – are being held on drug-related charges. 
Across much of the region, incarceration rates have 
been on the rise since 2000, leading to overcrowding in 
many facilities. The increase has in large part been the 
result of repressive drug laws and policies implemented 
in pursuit of a ‘drug free’ Association of Southeast Asian 
Nations (ASEAN) by 2020.(112)
Injecting drug use continues to be common in the 
region’s prisons. A recent study in Indonesia, for 
example, found that more than half of a sample of 100 
prisoners had injected drugs while incarcerated.(113) 
Pakistan’s national anti-narcotics policy acknowledges 
that up to 40% of the prison population may be using 
drugs.(76) In the Maldives, more than two-thirds of 
incarcerated people who inject drugs have used drugs 
in prison, and almost one-third have injected while in 
prison.(114)
Data on HIV, HCV and TB prevalence in prison settings 
in Asia continue to be very scarce. In Malaysia, it has 
been reported that approximately 4.8% of sentenced 
prisoners are living with HIV.(112) Despite the known 
risks of HIV, HCV and TB transmission associated with 
injecting drug use and overcrowding in prison, few 
prisons offer comprehensive harm reduction services.
NSPs continue to remain unavailable to prisoners across 
the region. In 2015, however, government authorities 
in Nepal, in cooperation with national and international 
partners, developed standard operating procedures to 
scale up HIV prevention, treatment and care services 
in prison settings, which involved officially adopting the 
15 key interventions of the comprehensive package, 
including NSPs, OST and condoms.(115) In practice, at the 
time of reporting, prevention messages continue to be 
the only intervention available in prisons in Nepal.(116)
OST is available in only some prisons in India (Tihar 
prisons, the largest prison complex in South Asia),(117) 
Indonesia (11 prisons),(118) Macau,(119) Malaysia (18 
prisons)(26) and Vietnam (1 prison).(120) UNODC reports 
that a second prison-based OST programme will 
soon be launched in Vietnam (Ha Noi), and plans 
are reportedly in place to continue expanding the 
programme into other prisons.(120)
In Indonesia, prison-based OST and ART programmes 
are run by the Ministry of Health. Kerobokan prison in 
Bali, which has been used as a model, provides prisoners 
with condoms, OST, ART and bleach to sterilise injecting 
equipment (in the absence of sterile needles and 
syringes). It is important to note, however, that bleaching 
has proven ineffective at preventing HIV transmission.(121) 
Currently, up to 11 prisons in the country are providing 
OST to 248 prisoners, and an estimated 40 prisons are 
delivering ART to people living with HIV.(118)
Since Global State 2014, Cambodia’s Ministry of the 
Interior has publicly acknowledged the issue of drug 
use in prisons and reports indicate that there is some 
interest in piloting harm reduction interventions in these 
settings;(70) while in Myanmar, UNODC has reportedly 
voiced its support for initiating OST in prisons.
Where harm reduction and HIV treatment and care 
services are available in the region’s prisons, they can be 
difficult to access for various reasons (including stigma 
and discrimination) or not provided in accordance with 
international prison and human rights standards. A 
recent study on the factors affecting opioid dependence 
during incarceration in India, for example, found that 
74% of those surveyed chose to access OST while 
incarcerated. The majority of the remaining 26% did not 
access the service for fear of physical violence at the 
hands of other prisoners.(122) Similar barriers to access 
have been documented in Indonesia and Malaysia.(112)
In Malaysia, HIV testing continues to be mandatory upon 
entry to prison and those found to be living with the 
virus are segregated into special housing units. Not only 
is this a clear violation of international human rights law 
and minimum standards on the treatment of prisoners, 
but also it increases the risk of TB outbreaks and 
reinforces the stigmatisation of HIV in prison settings.(112)
m 2010 data.
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Due to the punitive environment that prevails in Asia, 
prisons remain one of the main sources of primary care 
for people who use drugs.(112) Given all of the above, 
harm reduction must urgently be prioritised in these 
settings and adequate resources allocated. That way, 
the region’s criminal justice systems can play a role in 
reaching global targets on HIV, HCV and TB.
Overdose
As in many other regions, data on the extent of drug-
related overdose prevention and management remain 
extremely limited across Asia. No country in the region 
collects and routinely monitors drug-related overdose 
deaths.
However, an opioid overdose prevention and 
management project – Servicing Communities with 
Opioid Overdose Prevention (SCOOP) – was integrated 
into the civil society response to HIV among people 
who inject drugs in Thailand in 2013 to address the 
growing needs of this community.(123) Civil society 
organisations facilitated access to naloxone across 
19 provinces over a two-year period. Important legal, 
policy and procurement barriers were addressed and, 
within 18 months of the project beginning, 1,575 vials 
of naloxone were distributed across implementation 
sites. At least 148 field workers and clients were trained 
to recognise an opioid overdose and to respond with 
emergency care and the injection of naloxone, with field 
workers successfully reversing 21 opioid overdoses 
using naloxone. Between January 2013 and June 2014, 
overdose prevention was discussed with each of the 
74,852 people entering the service, and the SCOOP 
project empowered and motivated both field workers 
and people who use drugs.(123) Overdose management is 
also part of the harm reduction package in Afghanistan, 
with naloxone distributed by outreach workers.(77)
Although China has no national programme for 
overdose prevention, AIDS Care China, with support 
from the European Commission-funded Asia Action 
project, started to operate naloxone peer-distribution 
programmes in Yunnan and Sichuan provinces. By 
the end of May 2014, 4,361 naloxone kits had been 
distributed by AIDS Care China to 1,900 people who 
inject drugs, and 119 people had been saved from fatal 
overdose.(10)
Policy developments for harm 
reduction
In late 2014 Thailand announced the establishment of 
an ASEAN Narcotics Cooperation Centre.(86) In 2015 the 
ASEAN Economic Community was officially established. 
That same year, ASEAN ratified the new ASEAN Post-
2015 Health Development Agenda, which maintains 
commitments to HIV through prioritisation of health-
related Millennium Development Goals (MDGs) as well 
as of prevention and control of communicable diseases. 
The ASEAN Task Force on AIDS is finalising a working 
paper on HIV prevention among people who inject drugs 
in order to generate better system-wide coherence 
within ASEAN’s various departments. A coalition of 12 
civil society organisations from Southeast Asia was 
formed in 2015 to advocate for improved support for 
harm reduction interventions in ASEAN countries.
In Afghanistan, new national harm reduction guidelines 
were approved by the Counter Narcotics High 
Commission in December 2014.(124) In parallel, a new 
national strategic plan on HIV was designed to improve 
results from investments in the response to HIV for the 
period 2016 to 2020.(124)
In Cambodia, a national strategic plan on harm 
reduction related to drug use was launched in March 
2016. However, following a request from the Cambodian 
police to amend drug laws, high-level government 
officials reported that current policies were too lenient, 
but any formal amendments would need careful 
consideration.(125)
In Malaysia, the Ministry of Health developed a new 
national strategic plan on ending AIDS for the period 
2016 to 2030. However, leadership changes in Malaysia’s 
national anti-drugs agency have weakened support 
for harm reduction and other effective approaches to 
address drug-related issues.(97)
In Myanmar, a workshop involving a broad range of 
stakeholders, including senior representatives of the 
government, parliamentarians, international health and 
legal experts, international and national NGOs, drug user 
networks, and development agencies, recommended an 
amendment to the drug law to include harm reduction.(126)
Thailand’s national harm reduction policy, formally 
approved in 2014, expired in October 2015. Despite this 
important setback, a national drug law reform process 
was initiated in 2015, which should conclude by the end 
of 2016 with formal recommendations for adjustments 
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for several drug-related statutes that could facilitate 
harm reduction service delivery in the future.
Several Asian nations were represented at the 2016 
UNGASS on the drugs. Unfortunately, few lent their 
support to harm reduction. Singapore’s intervention was 
notable as the nation’s representatives firmly opposed 
harm reduction.(127) China echoed Singapore’s statement, 
underlining that harm reduction is acceptable only if it 
is aimed at reducing drug use. Malaysia spoke on behalf 
of ASEAN countries, outlining positions similar to that 
taken by Singapore and reiterating the vision of a drug-
free region. Just Vietnam stated that harm reduction 
programmes are being implemented.(128)
Civil society and advocacy 
developments for harm reduction
Civil society organisations in Asia continue to play an 
important role in harm reduction, at both regional and 
national levels. The Asian Network of People who Use 
Drugs (ANPUD) is now well established. However, after 
several years of inactivity, the Asian Harm Reduction 
Network (AHRN) is no longer functioning. Similarly, the 
Regional Task Force on Injecting Drug Use and HIV/
AIDS in Asia and the Pacific, co-chaired by UNODC and 
UNAIDS, completed its operations in 2012.
National drug user networks are in place in Cambodia 
(Cambodian Network of People who Use Drugs – 
CNPUD), India (Indian Drug User Forum – IDUF), 
Indonesia (Persaudaraan Korban Napza Indonesia – 
PKNI), Myanmar (National Drug User Network Myanmar 
– NDNM), Thailand (Thai Drug User Network – TDN)(46)  
and Vietnam (Vietnam Network of People who Use 
Drugs – VNPUD). The Malaysian Network of People who 
Use Drugs (MANPUD) has been established(97) and the 
Malaysian Welfare Association of Recovering Drug Users 
(WARDU) is in the process of registering as an official 
network. Nepal also has several drug user networks, 
including one specifically for women; and a small group 
of people who use drugs established a network under 
the national People Living with HIV (PLHIV) network but 
this is yet to be officially recognised.
Although ANPUD has grown significantly since its 
inception, and the number of drug user networks 
continues to grow, albeit slowly, there remain important 
barriers – such as declining funding, repressive 
government regimes and stigma and discrimination – 
that hinder meaningful civil society engagement and 
overall coordination across the region. Regional sources 
of technical support on harm reduction include the 
Alliance Technical Hubs in Cambodia and India as well as 
the UNAIDS Technical Support Facility (TSF).
Across Asia, the ‘Support Don’t Punish’ campaignn has 
provided an opportunity for people who use drugs to 
have their voices heard and call for the end of their 
criminalisation and stigmatisation. The campaign’s 
‘global day of action’, which occurs on 26 June every year, 
has been an important tool to change the messaging 
around drugs and people who use drugs, with media 
outreach sometimes involving local/national celebrities 
(for example, the punk band Jeruji in June 2015 and rock 
band The Changcuters in June 2014 in Indonesia). The 
global day of action in Asia has also been an opportunity 
to bring NGOs together to discuss critical drug policy 
reform issues, and to open and build dialogue with 
government agencies, UN agencies, law enforcement 
officers, networks of people who use drugs, local civil 
society groups and harm reduction service providers.
On the first ‘Support Don’t Punish’ global day of action 
in Asia in 2013, 22 cities in five countries became 
involved in the campaign. In 2014, 33 cities in ten 
countries gathered under the ‘Support Don’t Punish’ 
banner – including representatives from Cambodia, 
India, Indonesia, Malaysia, Nepal, Philippines, Thailand 
and Vietnam. This number rose to 38 participating cities 
in the region in 2015, making Asia the region with the 
highest level of engagement in the campaign.
The NGO Bridge Hope and Health, together with Coact 
(an international peer-led support agency), with a 
small grant of US$15,000 from the Czech government 
and technical support funding from Open Society 
Foundations, delivered a two-day capacity-building event 
and trained an Afghan community team in overdose 
management and peer interventions for people who 
use drugs. The peer outreach team is in the process of 
documenting 16 active drug scenes identified around 
the Kabul area, and Coact is assisting in translating 
a community needs assessment into a formal needs 
assessment and outreach plan. The Bridge Hope and 
Health team received language training in Dari and 
English and support with social media to support their 
engagement with the international community. Due 
to the limited funding, only four months of operations 
for the staff team are covered and no harm reduction 
commodities such as NSP, OST or naloxone distribution 
are included. However, Bridge Hope and Health is 
mobilising resources and has launched a crowd-sourced 
fundraising campaign through social media to increase 
the harm reduction response in Afghanistan.
n See http://supportdontpunish.org/.
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The 24th International Harm Reduction Conference 
was held in Kuala Lumpur, Malaysia in October 2015. 
Malaysia’s leadership in introducing harm reduction 
measures ten years ago and the need to continue 
to scale up similar interventions globally featured 
prominently during the three-day conference. Over 
900 health workers, UN representatives, politicians, 
bureaucrats, researchers, medical professionals and 
community workers, representing over 70 countries, 
were in attendance at this biennial event. A civil society 
organisation coalition on the ASEAN drugs strategy 
was launched in the margins of the conference. This 
coalition, consisting of 12 civil society organisations from 
Southeast Asia, will seek to be a unifying voice and a 
platform for the engagement of harm reduction at the 
regional level.(97)
Funding developments for harm 
reduction
The funding landscape for harm reduction in Asia 
since Global State 2014 has been scarred by political 
constraints in terms of support for the approach, 
international donor withdrawal and transitions from 
donor funding to government funding for services.
Community Action on Harm Reduction (CAHR) – a 
project that aimed to expand harm reduction services 
to more than 180,000 people who inject drugs, their 
partners and children in China, India, Indonesia, Kenya 
and Malaysia – ended in 2014. The Asia Action on Harm 
Reduction project – funded by the European Union to 
empower civil society organisations and to increase the 
evidence and build political support for harm reduction 
among key policy-makers in Cambodia, China, India, 
Indonesia, Malaysia and Vietnam – ended in 2016.
The Australian government’s international assistance 
programme was revamped following cuts to foreign aid, 
with the result being that previous beneficiaries lost its 
support for harm reduction interventions across the 
region. For example, the HIV Cooperation Programme 
in Indonesia (HCPI) ended in December 2015, with no 
provisions to mend the funding gap.(129) Meanwhile, 
financial support for harm reduction from the World 
Bank, Open Society Foundations, UNODC and USAID has 
also decreased across the region.
Decisions on how to prioritise allocations under its 
new funding model have negatively impacted several 
Global Fund-supported programmes targeting people 
who inject drugs in Asia. However, the Global Fund 
approved a regional harm reduction advocacy grant 
covering seven countries in the region: Cambodia, India, 
Indonesia, Nepal, Philippines, Thailand and Vietnam. 
With a total budget of US$5 million over a three-year 
period, implementation is expected to begin in early 
2017.
Other sources of funding have been approved. A multi-
country grant awarded by the Dutch government to 
support HIV prevention among people who inject drugs 
also covers three countries in the region: Indonesia, 
Myanmar and Vietnam. PEPFAR has mobilised over 
US$20 million to support HIV prevention among key 
populations, including people who inject drugs. The 
United Nations Development Programme (UNDP) and 
the Global Fund have agreed a grant of US$8.7 million 
to scale up HIV prevention measures and treatment 
for people most at risk of contracting the virus in 
Afghanistan, including people who inject drugs and 
prisoners.(130)
By the end of 2011 the Malaysian government had 
invested approximately UIS$17.3 million of the national 
budget to support the implementation of harm 
reduction programmes through partnerships with 
civil society organisations.(65) For example, financial 
contributions for NSPs between 2006 and 2015 show 
that 69% of funds came from national donors (and 
31% from external sources).(131) A recent assessment of 
returns on investments and cost-effectiveness of harm 
reduction programming in Malaysia shows conclusively 
that priority harm reduction services such as the 
distribution of sterile injecting equipment and OST, 
even with the present moderately low coverage, are 
effective and cost-effective interventions for averting HIV 
infections.(132)
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Country/
territory with 
reported       
injecting drug 
use
People who inject 
drugs(1)
HIV 
prevalence 
among 
people who 
inject drugs 
(%)(2) 
Hepatitis C 
(anti-HCV) 
prevalence 
among 
people who 
inject drugs 
(%)(3)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among 
people who 
inject drugs 
(%)(4)
Harm reduction response
NSP(5, 6)a OST(7) b
Albania 4,000–6,000 0.5 28.8 11.5 32 36 (M)
Armenia 12,700(8) 6.3 nk nk 312 34 (M)
Azerbaijan 71,283(9) 9.5(9) 57.9(9) 7.4(9) 317 32 (M)
Belarus 75,000 25.1(10) 65.4(11) 6.9(11) 334(11) 319(11) (M)
Bosnia and 
Herzegovina 12,500 (9,500–15,500) 0.3 12–43.4
c 2–3 328 38 (B, M)
Bulgaria 19,000 10.6(12) 67.8 5.7 3100(13) 331 (B, M)
Croatia 10,000(14) 0.48 39.30 6.5 3102 (P) 3 (B, M)
Czech Republic 45,600(15) 0.2-0.3(15) 18.6 15.1 3105 (P) 3372(16) (B, M)
Estonia 13,801 (8,178–34,732) 50–60(17)d 75 21.3 336 38 (B, M)
Georgia 49,000(18) 2.2(19) 66(19) 7.2 318 318 (B, M)
Hungary 2,910-3,577(20) 0.0 24.1 0.5 346(11) 315(20) (B, M)
Kazakhstan 116,840(21) 7.9(22) 60.3(23) 7.9 3155	–	168 310(11) (M)
Kosovo 10,000-15,000(24) 0 26.6(25) 4.1(25) 3 33 (M)
Kyrgyzstan 25,500(26) 12.4–14.6 50 nk 340(27) 330(27)e (M)
Latvia 12,573 9.4(28) 74.2 1.6 319(29) 310(28) (B, M)
Lithuania 6,056(30) 3.2(31)-12.5(32) 57.1(32)  13.4(32) 314 319 (B, M)
Macedonia 15,000–20,000f 0.12(33) 64.5(33)  nk 316 (33) 316(33) (M, B)
Moldova 30,200(34) 7.9(16) 70.2–72.8(16) 3.4–14.2 328(11)g 319(11)h (M)
Montenegro nk 1.1(35)  53.6 nk 313 35(11) (M)
Poland 15,119 (10,444–19,794) 3(36) 44.3-72.4(36) 26.3-46.7(36) 334(36) 325 (B, M)
Romania 19,265 24.90i 79(37) 5 32(38) 3 8(39) (B,M)
Russia 1,815,000j 18–31(40) 72.5% (51.9–94.7)(41)  2.6-7.1
(42) 34(43) 7
Serbia 30,383 (12,682–48,083)(44) <5(45) 61(45) 68.95 (60.5 -77.4)(46)k 313
(45) 325(47) (B, M)
Slovakia 18,841 (13,732–34,343)l 0.3(48) 37.8 28.1 35(11) 3 7 (B, M) 
Slovenia 6,100 (5,580–6,750) 1.9 28.5 2 310(11) (P) 310(11) (B, M)
Tajikistan 25,000 (20,000–30,000) 13.5(49) 36.2 nk 351(11) 36(11) (M)
Turkmenistan nk nk  nk  nk 2(50) 7
Ukraine 310,000 21.9(51) 27.1m   4.5 31667 3169 (B, M)
Uzbekistan 80,000n 7.3(52) 21.8(52) nk 3235 7
 
nk = not known
EURASIA
Table 2.2.1: Epidemiology of HIV and viral hepatitis, and harm reduction response in Eurasia
a	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.	(P)	=	needles	and		
 syringes reported to be available for purchase from pharmacies or other outlets.
b (M) = methadone, (B) = buprenorphine, (O) = any other form (including morphine and codeine).
c	 Based	on	a	study	conducted	in	five	cities.	
d Based on a study conducted in two cities. 
e	 This	figure	is	inclusive	of	7	operating	in	prisons.
f Data from EMCDDA 2010 based on people who inject drugs in Skopje.
g There are an additional 16 sites operating in prisons.
h There are an additional 13 sites operating in prisons.
i	 Civil	society	believes	this	figure	to	be	higher.
j Figure from 2007.
k	 Based	on	findings	from	two	cities.
l Figure includes high-risk drug users. High-risk is considered to be recurrent drug use that causes negative consequences which may include health, psychological or social   
	 problems,	or	is	placing	the	person	at	a	high-risk	of	suffering	such	harms.
m Year of reporting: 2012 for both HCV and HBV, Global Fund Round 6 Programme monitoring, Alliance Ukraine.
n	 Year	of	estimate:	2006.	EMCDDA	Country	Profile:	http://www.emcdda.europa.eu/publications/country-overviews/uz#pdu.
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OST only
NSP only
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Map 2.2.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
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Harm reduction in Eurasia
Overview
Eurasia is one of the only regions of the world where 
HIV infection rates continue to rise at an alarming 
rate. This rise is most pronounced in the countries of 
Eastern Europe and Central Asia, where between 2010 
and 2015, UNAIDS reported a 57% increase in new HIV 
infections. (53) In 2015, over half of these new HIV cases 
were among people who inject drugs.(53) Over 20% of 
new HIV diagnoses in Romania and the Baltic states 
of Estonia, Latvia and Lithuania are among people 
who inject drugs and similar levels are almost reached 
in Bulgaria.(54) It is estimated that 3.1 million people 
who inject drugs live in countries in this region,(55) 1.8 
million of whom reside in Russia.(56) In 2015, it was in 
Russia that over 80% of the region’s new HIV infections 
occurred,(57) a situation attributed in large part to the 
absence of HIV prevention measures in place such as 
needle and syringe programmes (NSPs) and opioid 
substitution therapy (OST). Since the Global State last 
reported in 2014, HIV prevalence rates among people 
who inject drugs have increased in Belarus, Kazakhstan, 
Montenegro, and Ukraine. However, according to 
reports from Ukraine there has been a decrease in HIV 
prevalence among people who inject drugs observed 
in the last 7 years.(58) Although people who inject 
drugs account for up to 80% of people living with HIV 
infections in the region, it is reported that only a small 
minority (20%) are accessing anti-retroviral therapy 
(ART).(55) 
Harm reduction service provision is available to some 
extent in the vast majority of countries in the region. 
Needle and syringe programmes are available in all 29 
countries, but implementation levels vary widely. For 
example, only two NSP sites operate in Romania and 
four in Russia, none with the support of government, 
whereas 1,667 sites provide NSP in Ukraine (see Table 
2.2.1). OST provision also varies considerably, but is 
notably low in much of the region, with less than 10 
operational OST sites in many countries (see Table 
2.2.1). In the majority of countries, even those which 
have received support from the Global Fund to support 
service implementation and scale-up, harm reduction 
service provision falls far short of epidemiological need, 
and remains below the UN recommended levels.(59)
According to the most recent data from the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA), some countries in this region have witnessed 
a decline in opioid use, and an increase in amphetamine 
use. For example, in Hungary in 2014, only 2% of people 
who use drugs entering services used heroin as their 
primary drug, compared to 19% for stimulants other 
than cocaine.(20) Similar trends have also been observed 
in Poland, where 36% of people entering services 
reported stimulants as their primary drug, compared to 
5% reporting opioids during the same time period.(36) 
The Czech Republic has seen a marked increase in 
methamphetamine use from an estimated 20,000 
people using methamphetamines in 2007, to over 
36,000 in 2014, with injecting being the primary route 
of admission.(15) From a sample of 10,108 people who 
use drugs in the Czech Republic in 2014, 7,038 reported 
methamphetamine as their primary substance, known 
locally as ‘pervitin’.(15) These changing patterns of drug 
use highlight that harm reduction services must adapt 
and respond to need accordingly. In general, people 
injecting amphetamines will do so more frequently than 
those using opioids for example, so NSPs operating 
in areas where amphetamine use is increasing must 
ensure a greater volume of injecting equipment is made 
available to clients. 
Opioid use is not in decline across the whole region, 
however, with some countries witnessing an increase 
in opioid use (including synthetic opioids) among those 
entering drug services. For example, the majority of 
people entering drug dependence treatment in Estonia 
report using fentanyl,(56) the vast majority of people on 
the Register of Persons Treated for Psychoactive Drug 
Abuse in Croatia are treated for opioid use,(14) and 42% 
of people entering services in Romania report opioids as 
their primary drug.(60)
Overdose continues to be a major cause of death 
among people who inject drugs in countries within this 
region, as it was when the Global State last reported in 
2014. Where evidence is available, rates of overdose 
are high, with 21-24% of people who inject drugs in 
Central Asia reporting having experienced a non-fatal 
overdose in the past year.(61) The implementation of 
opioid overdose prevention strategies, such as naloxone 
distribution among people who use drugs, remains 
limited to pilot projects in a small number of countries 
in the region. Drug consumption rooms (DCRs) where 
people who use drugs are able to consume them with 
medical support or supervision, are another strategy to 
reduce drug-related deaths.(62) No country in this region 
has a DCR yet, but in 2015, in Ljubljana, Slovenia an NGO 
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obtained funding to prepare and operate a pilot drug 
consumption room to begin in 2016.(63) 
One of the most significant developments in the 
region in recent years is the departure of the Global 
Fund support for HIV work from countries such as 
Romania, Estonia, Serbia, Bosnia and Herzegovina, and 
Macedonia. This transition has resulted in a dramatic 
reduction in the number of NGOs delivering services, 
and in some countries has affected the spectrum 
and quality of harm reduction. For example, in Serbia 
following the end of the Global Fund, only one out 
of four NGOs providing NSPs continue to operate 
on a limited scale through trained outreach workers, 
with other NGOs providing needles via outreach on 
a volunteer basis until they could no longer provide 
the service.(64) Civil society state that there is a need 
for regulatory reform to ensure that NGOs are able to 
provide services through national funding mechanisms. 
This includes development of social contracting 
mechanisms, as well as licensing and accreditation 
of NGOs to make them eligible to apply for and 
receive government funding.(11) The role of NGOs and 
community-led service providers in HIV prevention is 
still not by many governments. At present, in much of 
Eurasia, national governments continue to be more 
inclined to direct funds towards antiretroviral therapy 
or rehabilitation services rather than harm reduction 
measures, despite the proven effectiveness of NSP and 
OST in reducing viral transmission among people who 
inject drugs.(65, 66)   
 
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
The number of sites providing NSP has increased in 
eight countries in the region since the Global State last 
reported in 2014. These are Belarus (33 to 34 sites), 
Georgia (14 to 18 sites), Hungary (29 to 46 sites), Latvia 
(18 to 19 sites), Lithuania (11 to 14 sites), Moldova (23 
to 28 sites), Poland (12 to 24 sites) and Tajikistan (43 
to 53 sites). Bulgaria, Kyrgyzstan, Romania, Slovakia 
and Slovenia have witnessed a decrease in NSPs, but 
the majority of countries (16) have seen no change 
in the number of NSP sites operating. The coverage 
of these programmes remains low across the region. 
In Macedonia in 2015, for example, the 16 NSP sites 
available in the country reached just 3,900 of the 
estimated 17,500 people who inject drugs.(33) Among 
Eastern European and Central Asian countries reporting 
to UNAIDS, only Kyrgyzstan claimed to implement NSP at 
coverage levels considered high by UN standards (over 
200 needles/syringes distributed per person who injects 
drugs per year).(57) It is important to note, however, that 
these data represent the most robust estimates, which 
are not necessarily recent. Despite the scaling-up of NSP 
services in some countries in the region, NSP coverage 
continues to remain insufficient to meet need and 
an urgent need for further investment in this service 
is essential, particularly in light of increasing trends 
towards methamphetamine injecting.(11)
Inadequate financial support from national government 
remains the primary constraint to sustainable NSP 
services. Many governments do not financially support 
the provision of this service, including Albania, Armenia, 
Azerbaijan, Belarus, Georgia, Kosovo, Kyrgyzstan, 
Macedonia, Tajikistan, Ukraine, and Uzbekistan.(11) In 
Armenia, the National AIDS Program 2011-2016, which 
was approved by the government, explicitly references 
NSP as a component of HIV prevention. However, the 
Ministry of Health has no explicit legal act on supplying 
NSPs and there are no government departments 
involved in supporting the service. It is , however, legal to 
provide NSP in Armenia.(11) 
Where government funding is not made available, 
countries often depend on international donor funding, 
which has been consistently decreasing in this region.(67) 
In light of the changing funding landscape, some 
governments provide partial funding for NSP provision, 
such as Bosnia and Herzegovina, Kazakhstan, Lithuania, 
Montenegro and Romania.(11) In others, such as Croatia, 
the Czech Republic, Estonia, Hungary, Poland, Slovenia 
and Slovakia, NSP is solely supported by government 
funds.(11) In countries such as the Czech Republic and 
Estonia, this financial support is coupled with political 
support for harm reduction and as such, funding to 
sustain these services is considered to be relatively stable. 
In others such as Hungary, government investment in 
NSP falls far short of what is required to support services 
to meet the needs of people who inject drugs.(68) 
In some countries where the Global Fund grants have 
reduced or come to an end, civil society report that NSP 
service provision has reduced in scope and/or scale as 
a result, for example in Albania, Macedonia, Romania, 
Serbia, Montenegro and Russia.o Inadequate funding 
remains a consistent constraint to accessible and high-
quality NSP provision in the region. Other barriers 
cited by civil society include repressive policy and legal 
environments, unequal coverage between urban and 
rural settings, a lack of legislative regulation of services, 
restrictive opening hours and poor quality injecting 
equipment.(11)  
o  Data relating to this reduction in service provision has only been updated in Romania. At the time of reporting no up-to-date site numbers were available for Albania, 
      Macedonia, Serbia or Russia, and the statement is based on civil society reports from the region.
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Opioid substitution therapy (OST)  
 
OST continues to be prohibited in Russia and 
Turkmenistan, despite its proven effectiveness as a first 
line of treatment for people who inject drugs(69) and the 
recommendation within UN guidelines to provide this 
as a key HIV prevention measure.(59) While 26 countries 
have some OST provision, coverage varies considerably 
and remains extremely low in some states.(11) OST is 
provided to less than 1% of people who inject drugs 
in Azerbaijan and Kazakhstan (0.2%),(57) 3% in Armenia, 
Moldova, Ukraine and Tajikistan,(11) approximately 
4.9% in Kyrgyzstan and 5.3% in Belarus.(57) One of the 
greatest barriers to effective service delivery of OST 
is the fact that many NGOs are simply prohibited to 
deliver it and that services are based within government 
premises.(11) Increases in OST provision have been 
seen in seven countries in the region since the Global 
State last reported in 2014. An increase has been 
observed in Belarus (14 to 19 sites), Hungary (12 to 15 
sites), Kyrgyzstan (20 to 30 sites), Latvia (4 to 10 sites), 
Macedonia (12 to 16 sites), and Montenegro (3 to 5 
sites), with the greatest increase in Poland, which has 
seen site provision increase from 3 to 25 sites. Moldova, 
Romania, Serbia, Slovenia, and Tajikistan have all 
witnessed a decrease in OST sites, but the vast majority 
of countries (14) where OST is available have seen no 
change in service provision. 
Unlike NSP, many governments fully fund OST 
provision, including Azerbaijan (although this service 
is only available in the city of Baku), Bulgaria, Croatia, 
Czech Republic, Estonia, Hungary, Latvia, Lithuania, 
Montenegro, Serbia, Slovakia and Slovenia.(11) In Hungary, 
Latvia and Lithuania, methadone prescription is financed 
by the government, and although buprenorphine can 
be prescribed, this must be financed by the individual.
(20, 28, 70) In Montenegro, buprenorphine was introduced 
in mid-2015, but it is still not used at national level, as 
doctors are afraid to prescribe it due to the absence of 
medical protocols.(11) In some countries OST is partially 
government funded, such as Georgia and Albania. In 
Albania, OST is financed partially through a Global Fund 
grant and partially from the Ministry of Finance. The 
NGO Aksion Plus initiated a small-scale buprenorphine 
project in Tirana, Albania, through financing from a 
special fund of laundered money seized from assets and 
illegal drug trafficking.(11) 
In Kazakhstan, methadone continues to be procured 
through a grant by the Global Fund whilst staff costs at 
sites are covered by the government.(23)  
 
Viral hepatitis
Hepatitis C prevalence rates among people who inject 
drugs are extremely high in many countries in Eurasia, 
reaching 50% or higher in 16 countries (Azerbaijan, 
Belarus, Bulgaria, Estonia, Georgia, Kazakhstan, 
Kyrgyzstan, Latvia, Lithuania, Macedonia, Moldova, 
Montenegro, Poland, Romania, Russia, and Serbia) from 
a total of 27 which provide data. Prevalence rates for 
hepatitis C are generally far higher than HIV rates for 
people who inject drugs across the region, although 
data limitations make it difficult to assess changes in 
the epidemic accurately. Hungary’s reported hepatitis 
C prevalence rate among people who inject drugs is 
24.1%, yet hepatitis C prevalence among people injecting 
stimulants during the same reporting year (2014) was far 
higher, at 74%.(20) 
In a number of countries, rapid screening for the 
hepatitis C virus cannot be carried out at community-
based harm reduction sites. Where such screening 
is available for people who inject drugs the test often 
depends on whether the person has state insurance 
or is able to cover the cost of testing themselves.(11) 
Exceptions to this can be seen in the Czech Republic, 
where hepatitis C testing and treatment is available 
to people who inject drugs in 39 clinics, including 
those in prisons.(15) Slovenia also provides hepatitis C 
treatment free of charge for all, although it is unclear 
how accessible this is for people who inject drugs.(63) In 
2015, Georgia launched a new hepatitis C elimination 
programme, with a donation of hepatitis C treatment 
from one of the largest healthcare providers. The new 
universal treatment plan should extend coverage from 
5,000 to 20,000 in the coming years and will include 
people who use/inject drugs.(71) In Lithuania, Moldova, 
and Romania, hepatitis C treatment is limited to holders 
of health insurance. In Russia, Tajikistan, Ukraine 
and Armenia, hepatitis C treatment is expected to be 
covered in full by the individual.(11) However, Ukraine has 
access for some treatment provision under a Global 
Fund grant.(58) The high cost of treatment, therefore, 
remains a key obstacle to access in most countries. 
Stigma and discrimination related to drug use, as well as 
widespread misconceptions among treatment specialists 
about a lack of adherence to treatment by people who 
use drugs, create further barriers. In Latvia, Montenegro, 
Serbia, and Albania, people who inject drugs are required 
to stop using drugs prior to receiving treatment.(11)
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Overdose 
 
Overdose continues to be a major cause of death 
among people who inject drugs in the region, with an 
estimated 100,000 people dying from an overdose-
related death in Russia alone each year.(72) In 2014, 
rates of overdose-related death reached 113 per 
million in Estonia.(56) In the Czech Republic, which has 
one of the strongest harm reduction responses in the 
region, overall mortality rates for people using OST 
were relatively low, ranging from 3.5 to 7.2 deaths per 
1,000 person years. In Bratislava, Slovakia, this rate was 
marginally higher at 7.3 deaths per 1,000 person years.(73) 
However, it is difficult to assess the true scale of 
overdose morbidity and mortality due to inconsistent 
reporting and differences in surveillance systems, which 
have led to systematic under-reporting of overdose-
related death. 
Naloxone, a highly effective opioid antagonist used 
to reverse the effects of opioid overdose, remains 
extremely limited in the region. In at least Kazakhstan, 
Latvia, Montenegro, Romania, Serbia, Slovenia and 
Uzbekistan, there are neither overdose prevention 
programmes in the form of education nor naloxone 
peer-distribution.(11) In Belarus, Bulgaria, and Russia, 
peer education programmes regarding overdose are 
provided, but naloxone is unavailable.(11) Naloxone 
became available via the three mobile NSP units in 
Lithuania in 2015, but the number of kits provided is 
not known.(70) In Estonia in 2013, the National Institute 
for Health Development launched a pilot take-home 
naloxone programme due to the high-rate of overdose-
related deaths in the country. People who use opioids 
and their families were taught to recognise the signs 
of an overdose and administer naloxone.(74) Between 
2013 and 2015, 1,630 naloxone kits were distributed. 
It is reported that overdose-related deaths reduced by 
over half, from 170 in 2012, to 84 in 2015.(68) In a recent 
Global AIDS Progress Report to UNAIDS, the Estonian 
government also report that naloxone became available 
within prisons in 2015.(75)
The vast majority of people who use opioids in the 
region have no access to life-saving naloxone.(11) Barriers 
to increasing access to naloxone include overregulation 
of both the management of naloxone by non-medical 
staff, including prohibitions against injection by non-
medical staff, and of the provision of naloxone by 
medical staff.(11) 
Tuberculosis (TB)
Multi-drug resistant TB rates are among the highest in 
the world in Eurasia.(76) Data on TB prevalence among 
people who inject drugs are sparse, and without these, 
it is difficult to assess the true scale of TB among people 
who inject drugs in the region. 
In all countries in the region, TB screening and 
treatment is available for the general population, 
which theoretically includes people who inject drugs. 
In Estonia, for example, it is reported that free TB 
screening is provided for people who inject drugs, 
people living with HIV, those living in shelters, prisoners 
and other groups considered to be at heightened 
risk of TB infection that may not be covered by health 
insurance.(74) However, throughout the region, TB testing 
and treatment services are not generally tailored to 
the needs of people who inject drugs, and are rarely 
linked to HIV or harm reduction services meaning many 
people are lost via the referral process to specialised 
TB facilities.(11) A study undertaken in Ukraine illustrated 
the improvement in healthcare quality indicators for 
people who inject drugs that can be achieved using an 
integrated service delivery model.(77) However, funding 
for such linked services is not only limited, but is rapidly 
depleting in the region due to the retreat of international 
donors such as the Global Fund.
In recent years, due to a change in the eligibility 
criteria for a number of countries, Global Fund grants 
supporting TB programmes have ended, and many 
governments are yet to allocate sufficient funding to 
address the significant gap in provision which has been 
left behind.(11) 
 
Antiretroviral therapy (ART)
In the majority of countries in the region there is a 
distinct lack of integration of HIV testing and treatment 
services within harm reduction programmes.(11) Where 
integration of these services does exist, it often 
depends on ad-hoc collaboration between harm 
reduction services and specialised medical facilities. 
This integration is driven by personal contacts and does 
not offer full or even coverage. In many countries this 
leads to late HIV diagnosis, low coverage of ART among 
people who inject drugs, and suboptimal adherence to 
treatment.(11) ART coverage remains extremely low in 
much of the region, with only 21% of people living with 
HIV accessing treatment in Eastern Europe and Central 
Asia.(53) This poor coverage is particularly pronounced 
among people who inject drugs. In Russia, for example, 
people who inject drugs make up 67% of the cumulative 
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HIV cases, and yet represent only 25% of those receiving 
ART.(78) In contrast, notable progress has been achieved 
in Ukraine, where increased government investment has 
resulted in a dramatic rise in people receiving ART from 
12,751 in 2010, to 43,790 people in 2013.(79) 
Disproportionately poor access to ART among people 
who inject drugs is further compounded by additional 
barriers in Armenia, Estonia, Lithuania and Tajikistan, 
where NGOs are prohibited from performing rapid 
testing for HIV and hepatitis C due to regulations that 
require them to hold a special medical license. To 
bypass this barrier, some NGOs collaborate with medical 
institutions to provide testing.(11) 
 
Harm reduction in prisons
Extremely punitive drug laws and policies across the 
region have given rise to some of the world’s highest 
incarceration rates. Of the 29 countries in Eurasia, 19 
still have incarceration rates that exceed the world 
average of 146 prisoners per 100,000 population, with 
10 exceeding 200: Turkmenistan (583), Russia (445), 
Belarus (306), Georgia (274), Lithuania (268), Latvia (239), 
Azerbaijan (236), Kazakhstan (234), Estonia (216), and 
Moldova (215).(80) People who inject drugs reportedly 
represent about one third of prisoners in the region, 
although they could make up between 50-80% of the 
prison population in some countries.(81) Similar to all 
other regions of the world, injecting drug use in prisons 
in Eurasia is common, with prevalence estimates ranging 
from 3% to 55%.(81) When all of these factors converge, 
the result is a much higher prevalence of HIV, HCV and 
TB in prisons than outside of prisons. For example, HIV 
prevalence in prisons exceeds 10% in Latvia (20.4%), 
Ukraine (19.4%), Estonia (14.1%), and Kyrgyzstan (10.3%), 
and remains significantly higher than in the broader 
community in Uzbekistan (4.7%), Lithuania (3.4%), 
Kazakhstan (3.9%), Azerbaijan (3.7%), Armenia (2.4%), 
Tajikistan (2.4%), Moldova (2.6%), and Georgia (0.9%).(81)
Despite this reality, harm reduction services remain 
scarce in the region’s prisons. Needle and syringe 
programmes are currently only provided in prisons in 
Armenia (all 11 prisons)(82), Kyrgyzstan (7 prisons),(27) 
Moldova (13 prisons on the ‘right bank’ and 3 prisons in 
the autonomous region of Transnistria)(34) and Tajikistan 
(1 prison).(83) In theory, NSPs are also available in 8 
prisons in Romania, but prisoners reportedly do not 
access them for fear of negative consequences(84) 
Despite their proven success, the few prison-based 
NSPs operating in the region face an uncertain future 
due to loss of funding from international donors.(81) 
Provision of OST in prisons is slightly more widespread, 
with the service currently available in at least one prison 
in 18 countries in the region. Quality and accessibility, 
however, vary considerably, both between and within 
countries. For example, in Bosnia and Herzegovina, 
prisoners can initiate OST at Orasje prison, but in 
Tuzla and Zenica prisons in Sarajevo, the service is 
only available to prisoners who were receiving it prior 
to incarceration.(85) In Albania,(86) Bulgaria,(11) Latvia,(87) 
Lithuania(70) Montenegro,(11) and Serbia,(11) OST cannot 
be initiated in prisons at all. Meanwhile, OST is only 
available for detoxification in some pre-trial detention 
facilities in Georgia.(81) A blanket prohibition on OST 
continues to be upheld in Russia, Turkmenistan and 
Uzbekistan, and the service is still unavailable in prisons 
in Azerbaijan, Hungary, Kazakhstan, Kosovo, Slovakia, 
Ukraine (although legislation from 2011 permits OST 
in prisons)(88) and Tajikistan. While guidelines on OST 
in prisons have been developed in Tajikistan, actual 
implementation of the service was last reported to be 
under consideration.(83) Positively, however, since the 
Global State last reported in 2014, OST was expanded to 
two more prisons in Moldova.(34) 
More countries must follow Moldova’s example and 
introduce, expand and/or remove any barriers to 
accessing NSPs and OST in their prisons as a matter 
of urgency. Not only is this a legally binding obligation 
under international human rights law, but it could also 
considerably reduce HIV transmission. Recent scientific 
modeling of the impact of incarceration and scale-up of 
OST in prisons on HIV transmission among people who 
inject drugs in Ukraine suggests that if prison-based OST 
were initiated in the country, 19.8% of HIV infections 
would be averted between 2015-2030, and community 
coverage of OST would increase by 8.3%.(81) 
Civil society reports that HIV treatment is available in 
prisons in all countries across the region, although 
the regulation, quality and coverage of this service 
varies considerably.(11) Azerbaijan and Kyrgyzstan are 
considered to provide high coverage of ART for people 
living with HIV who are diagnosed within prison,(89, 90) 
and Poland has reportedly increased ART coverage in 
the last 5 years, with all prisoners living with HIV now 
able to access the service.(91) In some countries, such 
as Tajikistan, ART coverage in prisons (43% in 2014) 
is substantially higher than it is outside of prisons.(83) 
Meanwhile, less than 4% of people living with HIV in 
Ukrainian prisons currently have access to ART,(92) while 
frequent lack of medication in Russian prisons that ART 
availability is sporadic.(11) In some prisons in Bosnia and 
Herzegovina, HIV treatment is not available.(85) 
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Importantly, where ART and other essential health 
services are available in prisons, barriers of all kinds 
continue to impede their access. For instance, in 
the Czech Republic, prisoners are required to pay a 
“regulatory fee” of CZK30 for every medical appointment 
and every prescription, which - as a rule - is not 
reimbursed by health insurance.(93) 
Information on hepatitis C testing, treatment and care 
in the region’s prisons is scarce, but civil society reports 
that it typically reflects the situation outside of prisons.(11) 
In Georgia, a recently launched internationally funded 
HCV elimination strategy has included prisoners, 
enabling them to access costly new direct-acting 
antiviral treatments.(94) At the same time, the European 
Committee for the Prevention of Torture recently 
reported that funding for peg-interferon treatment 
for HCV in relation to newly detected cases was being 
discontinued in Serbian prisons.(95) Across the border 
in Bosnia and Herzegovina, prisoners are reportedly 
being prescribed non-evidence-based treatments, such 
as artichoke tablets, which are believed by some health 
professionals to cure HCV.(85) 
Civil society reports that testing and treatment for 
TB is likely available in all prisons in the region.(11) In 
Georgia, all prisons are now covered by the national 
programme for the Prevention of Tuberculosis which 
has resulted in a 52% reduction in TB prevalence in the 
prison system since 2012.(96) Information on naloxone 
in prisons is limited, but news that Estonia introduced a 
take home naloxone programme from prisons in 2015, 
with prisoners who inject drugs now being trained in its 
use prior to release, is promising.(75) In terms of condom 
provision, civil society reports that in most countries’ 
prisons, condoms are either available to a limited extent 
in prisons where there are relevant NGO projects 
distributing them, or not available at all.(11)  
 
Policy developments for harm 
reduction
The majority of countries (26 of 29) have national 
HIV or drug policies that include explicit support for 
harm reduction.(50) However, most countries also 
have strongly punitive drug policies which emphasise 
criminalisation of drug use and possession. Within this 
policy environment, hostility towards harm reduction 
is common. National legislation on drugs in the former 
Soviet states includes tables that set thresholds for 
considering illicit drug seizures as ‘small’, ‘large’, and 
‘extremely large’, with associated criminal laws and 
prison terms. Thresholds for possession which lead to 
imprisonment are low, especially in comparison to the 
commonly disproportionate length of prison sentences 
for offenders.(11) At the time of reporting the only two 
countries which had decriminalised the possession 
and use of small quantities of drugs in the region were 
the Czech Republic and Armenia. In Armenia, use and 
possession of small amount of drugs for personal use is 
not a criminal offence. However, the administrative fine 
for possession is so high that many cannot afford to pay 
and instead are arrested for non-payment.(11) The low 
prevalence of HIV among people who inject drugs in the 
Czech Republic has been attributed to decriminalisation 
combined with sustained and scaled-up NSP and OST 
provision.(97)
Legislation in the vast majority of countries does not 
include options for providing non-criminal measures 
as an alternative to prison for drug use or possession. 
Moreover, in countries where such non-criminal options 
are available, these are often not utilised. For example, 
in Estonia, a lack of motivation by law enforcement and 
criminal justice institutions to use non-criminal options, 
along with an absence of implementation mechanisms, 
results in criminal sanctions remaining the norm.(11) Civil 
society report that fear of potential arrest and criminal 
penalties among people who use drugs significantly 
interferes with the utilisation and provision of NSP and 
OST services in the region, where data is often shared 
with the police.(11) 
In April 2016, during the United Nations General 
Assembly Special Session (UNGASS) on the drugs 
in New York, the Czech Republic, Estonia, Latvia, 
Lithuania, Poland, Romania and Slovenia all made 
statements in explicit support of harm reduction(98)
The European Union (EU)’s common position, which 
included Macedonia, Serbia, Ukraine, Albania, Bosnia 
& Herzegovina, Moldova and Georgia, also stated 
that harm reduction, as a proven effective measure in 
preventing overdose and the transmission of blood 
borne diseases, should be further promoted and 
implemented.(98) It is important to note, however, that 
the expressions of international support among these 
countries have not yet been matched by financial or 
political commitments. 
 
Civil society and advocacy 
developments for harm reduction
Civil society continue to play a crucial role in advocating 
for harm reduction in the region and internationally. 
In recent years, the changing funding landscape has 
increasingly required civil society to focus their advocacy 
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on the sustainability of harm reduction funding in the 
region. In 2014, the Eurasian Harm Reduction Network 
(EHRN) became the principal recipient for the first Global 
Fund regional HIV/AIDS grant in Eastern Europe and 
Central Asia (EECA) and created a regional research and 
advocacy programme, ‘Harm Reduction Works! – Fund 
it’. The goal of this programme is to strengthen advocacy 
by civil society, including people who use drugs, for 
sufficient, strategic and sustainable investments in harm 
reduction as HIV prevention in the region.(99) The project, 
which covers Belarus, Georgia, Kazakhstan, Moldova, 
Tajikistan and Lithuania, is due to end in March 2017, 
when the results of the programme will be published.
In 2015, EHRN and the Global Fund co-organised a 
technical consultation in Istanbul, Turkey, bringing 
together key stakeholdersp to shape an appropriate 
technical framework for the transition from Global Fund 
funding to national funding, and the sustainability of 
HIV and TB programmes in the region. Also in 2015, 
in Tbilisi, Georgia, the Regional High Level Dialogue on 
Successful Transition to Domestic Funding of HIV and 
TB Response in Eastern Europe and Central Asia ‘Road 
to Success’ meeting was held. 318 delegates from 31 
countries gathered, representing governments from 
Eastern Europe and Central Asia (EECA), civil society 
organisations, key populations and communities, 
international organisations and technical agencies with 
the goal of discussing commitments and principles of 
the successful transition process from donor to national 
funding. 
In early 2016, the Georgia Network of People Who Use 
Drugs (GeNPUD) established the Georgian National 
Drug Policy Platform (GNDP), creating a broad national 
drug policy platform.(11) The GNDP unites a broad range 
of over 30 organisations, which include community 
organisations and drug user activists, service delivery 
organisations, drug clinics and medical personnel, 
researchers and academics, human rights organisations 
and activists. Members agreed on three priority areas: 
1) drug policy reform 2) improving the availability and 
quality of services, and 3) reducing stigma and raising 
public awareness. It is the first time that representatives 
of different sectors were able to come together, agree 
on common goals and pool their efforts in petitioning 
governments to take action in the field of drug use and 
harm reduction initiatives.(11) 
There are some well-established networks of people 
who use drugs in the region, with the Eurasian Network 
of People Who use Drugs (ENPUD) at regional level, and 
country-based active drug user networks in Macedonia, 
Georgia, Azerbaijan, Kyrgyzstan, Montenegro and Romania.(11) 
Funding developments for harm 
reduction
Since the Global State last reported in 2014, there have 
been a number of civil society initiatives with a focus 
on advocacy for harm reduction funding in this region. 
EHRN’s ‘Harm Reduction Works! – Fund It’ project has 
examined funding levels and challenges for NSP and 
OST in Belarus, Georgia, Kazakhstan, Moldova, Tajikistan 
and Lithuania. A project report released in 2015 stated 
that harm reduction in the region remained heavily 
dependent on international donor support. It raised 
serious concerns regarding the lack of commitment of 
the Government of Georgia to fund NSPs, the minimal 
domestic contributions in Moldova and Tajikistan (15% 
and 2% respectively), the lack of domestic support for 
OST in Kazakhstan and at the limitations of domestic 
support in Lithuania which do not allow harm reduction 
services to meet the national need.(100) In Ukraine, the 
government recently committed to coverage of some 
methadone after the threat of a reduction in Global 
Fund support, and in the municipality of St Petersburg 
in Russia, the government are also expected to begin 
supporting needle and syringe programming. Both 
of these contributions, however, will be insufficient to 
match the reduction in Global Fund support, or to reach 
the desired coverage levels.(101) 
Research carried out by HRI within an EC-funded 
project ‘Harm Reduction Works!’q also examined the 
sustainability of harm reduction funding in European 
Union states within the Eurasia region. These are 
generally the countries with the more established harm 
reduction programmes in the Eurasia region with, for 
example, civil society reporting that funding for harm 
reduction in the Czech Republic and Estonia was 
considered to be relatively stable and secure. However, 
there were grave concerns raised about the potential 
for rapid increases in HIV infection among people who 
inject drugs in some countries due to poor funding or 
an imminent end to funding for harm reduction. For 
example, currently in Bulgaria, a Global Fund grant is 
ending without any indication that government will 
fund existing harm reduction services to continue 
operating. In Romania, there has been a decrease in 
the already limited harm reduction service provision 
in recent years as a result of funding cuts, with some, 
though insufficient, investment by the municipality of 
Bucharest.(101) Similarly, minimal domestic support for 
harm reduction in Hungary continues to limit the extent 
to which services can prevent epidemics from rapidly 
increasing among people injecting drugs. There remain 
p Including national government agencies, donor organisations, technical support providers, UN agencies, civil society organisations and communities.
q Jointly coordinated by EHRN and HRI running from 2014-2016.
57 GLOBAL STATE OF HARM REDUCTION 2016
many challenges in establishing existing spending 
on harm reduction, highlighting the need for greater 
transparency among governments and donors on their 
harm reduction investments and for this spending 
to be the systematically tracked. This information is 
urgently needed if the limited available funds are to be 
invested optimally and according to epidemiological 
need.r By far the biggest challenge to the sustainability 
of harm reduction in this region, however, remains the 
lack of political acceptance of harm reduction and the 
unwillingness of governments to invest what is required. 
Transition from Global Fund 
support to national funding for 
harm reduction
In most countries in Eurasia, harm reduction 
programmes have been introduced and financially 
supported by international donors, with national 
funding supporting all OST and NSP delivery in only a 
few EU Member States. In all other cases the Global 
Fund has been the single major funding source for 
these programmes. However, the Global Fund has 
been revisiting its priorities and funding policies and 
has been gradually withdrawing from many countries 
within Eurasia. Due to this, these countries have 
engaged in the process of transition from Global Fund 
funding to national funding for HIV and TB programmes. 
Experience accumulated in relation to sustainability of 
donor funded programmes, and the results of Global 
Fund withdrawal from Albania, Romania, Bulgaria, 
Estonia, Montenegro, Russia and Serbia, suggest 
that this will be a challenging process and that there 
are considerable risks to the sustainability of HIV 
programmes in the region. Since the Global State last 
reported, there has been a rise in HIV prevalence among 
people who inject drugs in Montenegro and a decrease 
in harm reduction services in Romania going from 7 
NSPs in 2014, to 3 in 2016, and from 13 OST sites in 
2014, to 8 in 2016. 
In the environment of ever-limited funding and an 
abundance of competing priorities for scarce public 
health resources, harm reduction interventions, still 
subjects of political and ideological controversy, seem 
to be most vulnerable. Furthermore, countries lack 
mechanisms to finance NGOs through government 
budgets. In Georgia, NSPs are projected to receive no 
domestic funding, however a transition plan is being 
finalised for government approval for the beginning of 
2017, which should include funding for NSPs.(102) 
 
In Tajikistan, just 1.6% of NSP costs will be received from 
government funding, with the government covering 
15% of costs in Moldova.(11) Starting from 2015, the 
Global Fund has reduced its financial support to Russia 
by approximately 30%, which immediately resulted 
in a dramatic decrease in the coverage of already 
limited harm reduction services. Support is set to end 
entirely by 2018. The total number of HIV prevention 
projects among key populations has decreased from 
62 to only 19, and annual coverage of harm reduction 
services decreased by over 60% from 66,351 in 2014, to 
25,390 in 2015.(103) It is likely that many other transition 
countries will not be able to sustain the existing harm 
reduction programmes at even a low level of coverage, 
let alone scale up to UN recommended standards.
r The report will be published in the coming months by HRI.
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Country/
territory 
with 
reported       
injecting 
drug use
People who inject drugs (1)
HIV 
prevalence 
among 
people who 
inject drugs 
(%)(2)
Hepatitis C 
(anti-HCV) 
prevalence 
among 
people who 
inject drugs 
(%)(3)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among 
people who 
inject drugs 
(%)(4)
Harm reduction response
NSP(6, 7)a OST (8) b DCR(5)
Andorra nk nk nk nk nk 7 7
Austria 11,000-15,000(9) 10.5 51.3 (33.9-74.1) 1-44.1(9) 337 3 (B, M, O) 7
Belgium 25,295 (17,638–35,699) 0.0–5.7 17.1–75.1c 0.1.9 396 3140 (B, H, M)
7
Cyprus 291 (216–427) 0–1.6 43.1 0.9 31 32 (B, O) 7
Denmark 12,754 (10,066–16,821)d 2.1 52.5 1.3e 3 3 (B, H, M) 5
Finland 15,611 (13,770–22,665)f 1.19g 74h nk 340 3 (B, M,O) 7
France 122,000i 6.2j 63.8k 0.8l 3583 3 (B, M,O) 1(10)
Germany 94,250 (56,000–169,500)(11) 1.6-9.m 62.6-73n 0.1-6.3o 3156 3 (B, H, M) 24
Greece 5,120 (4,209-6,303) 6.4-8.5 66.7-73.5 1.9-2.8 316 3 56(B, M,O) 7
Iceland nk nk 63p nk nk 3 (B, M) 7
Ireland 6,289 (4,694–7,884)(12)q 6r 41.5s 0.5t 3143 3 721(B, M,O) 7
Italy 326,000u 30.1 54 12.1(13) 3620 3 (B, M,O) 7
Luxembourg 1907 (1,524–2,301)v 4.5 80.7-90.7w nk 38 3 (B, M,O) 1
Malta 1,524-2,301 0 14.7 1.8(14) 37 3 (B, M) 7
Monaco nk nk nk nk 3nk 31(25) 7
Netherlands 2,390 (2,336–2,444)x 0 66.7y 0 3175 3 (B, H,M) 31
Norway 8,145 (6,948-9,842)z 2.4 62.1 0.9aa 333 3 (B, M) 1
Portugal 14,426 (12,732-16,101)bb 14.7 84.4 5.2 3 3 (B, M) 7
Spain 9,879 (7,971-11,786)cc 30.6dd nk nk 31578 3 (B, H,M) 12
Sweden 8,021ee 7.4ff 96.8gg nk 36 3110 (B, M) 7
Switzerland 31,653 (24,907–38,399) (12)hh nk nk nk 3 3 (B, H,M,O) 12
Turkey nk 0.2 42.8 4.2 7 3 (B) 7
UK 122,894 (117,370-131,869)(16) 1(16) 50(16)ii 0.2jj 31,523 3 (B, H,M,O) 7
 
 
nk = not known
WESTERN EUROPE
Table 2.3.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Western 
Europe
a	 Figure	is	based	on	total	number	of	fixed	sites	(including	specialist	agency	sites,	 
 vending machines, pharmacy-based services and prison-based services)   
 combined with total number of mobile sites (outreach workers and services  
 carried out by a van). Data is from 2014 unless otherwise stated.
b (M) = methadone, (B) = buprenorphone, (O) = any other form (including  
 morphine and codeine). Figures for the number of sites are often not available  
 in Western Europe due to a variety of service providers which include general  
 practitioners.
c Estimate is based on sub-national data 2014.
d Estimate based on Global State of Harm Reduction 2014 report. No new data  
 available.
e Year of estimate: 2007. See: reference 9.
f Year of estimate 2012.
g Estimate is based on sub-national data from 2014.
h Estimate is based on sub-national data from 2014.
i Year of estimate: 1999.
j Estimate is based on sub-national data from 2011/12.
k Estimate is based on sub-national data from 2011.
l Estimate is based on sub-national data from 2011.
m Figure is based on sub-national data from 2013/14.
n Estimate is based on sub-national data from 2013/14.
o Estimate is based on sub-national data from 2013/14.
p Year	of	estimate:	1990–1993.
q Year of estimate: 1996.
r Year of estimate: 2010.
s Year of estimate: 2010.
t Year of estimate: 2010.
u Year of estimate: 1996.
v Year of estimate: 2009.
w Year of estimate: 2005.
x Year of estimate: 2008.
y Year of estimate: 2014.
z Year of estimate: 2013.
aa Estimate is based on sub-national data from 2012.
bb Year of estimate: 2012.
cc Year of estimate: 2013.
dd Year of estimate: 2013.
ee Year of estimate: 2008-2011.
ff	 Estimate is based on sub-national data from 2012.
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Harm reduction in Western Europe
Overview
In much of Europe, HIV rates among people who inject 
drugs are reported to be stable or declining, with 1,236 
newly reported drug-injection related HIV diagnoses 
in the European Union in 2014, the lowest number 
reported in more than a decade.(17) A recent UNAIDS 
report estimates there to be between 719,000 to 
914,000 people who inject drugs in Western Europe, 
with HIV incidence among this population estimated 
to be 0.8%.(18) The low rates of HIV infection can be 
attributed to early scale-up of harm reduction measures 
in many countries.(19) Localised outbreaks of new 
HIV infections among people who inject drugs have 
been documented, however, in Ireland, Scotland, and 
Luxembourg in 2015.(17) In Ireland, data from 2014 
indicated that among the 359 people newly diagnosed 
with HIV, 25 were linked to unsafe injecting, a rise from 
previous years. (17) An epidemiological investigation has 
been launched to determine the reasons behind this 
increase.(17) 
Changes in drug use patterns, particularly increased 
amphetamine-type stimulant (ATS) injecting, and high 
levels of marginalisation have been common factors 
in a number of the recent HIV outbreaks in Western 
Europe.(17) Crystalline methamphetamine is reported 
to be increasing in availability, including in countries 
where methamphetamine use has not been commonly 
reported in the past. For example, according to the 
Federal Criminal Police Office in Germany, the number 
of first-time crystalline methamphetamine users 
increased by almost 7% in 2013.(20) The region has also 
seen a rise in the use of synthetic ATS substances such 
as mephedrone. Although first synthesised in 1929, 
mephedrone did not become widely available until 2007, 
and has now been placed under national legislative 
controls in a total of 31 countries.(21) Since mephedrone 
was scheduled under Article 2 of the Convention on 
Psychotropic Substances and made an illicit drug, the 
United Kingdom has been the only country in Europe 
to conduct repeat surveys on mephedrone use. 
According to the Crime Survey for England and Wales 
(CSEW) 2011/12, mephedrone had the highest annual 
prevalence rate of any ATS, ranking fourth among 
the general population, and third among those aged 
between 16-24.(20) There are currently relatively few harm 
reduction programmes for people who use ATS. In light 
of this, in 2015, Harm Reduction International produced 
a report synthesising available data and programme 
experience in this area, noting the ways in which harm 
reduction programmes can respond effectively to 
reduce the harms that can be associated with ATS use.(22)
Although Western Europe is home to many of the 
strongest national harm reduction programmes in the 
world, with the vast majority of countries offering needle 
and syringe programme (NSP) provision and half of all 
opioid users accessing opioid substitution therapies 
(OST),(23) there are still important gaps in service 
provision. For example, access to hepatitis C treatment 
for people who inject drugs remains consistently low 
and new direct-acting antivirals (DAAs) continue to 
be priced out of reach. A myriad of factors, including 
criminalisation, stigma and inadequate medical and 
social services contribute to disproportionally high 
mortality and morbidity among people who use drugs in 
Europe, and overdose continues to be a major cause of 
death. 
 
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs) 
 
In Western Europe, NSPs operate in 19 of the 23 
countries (please refer to Table 2.3.1), to greater 
or lesser degrees. In a few of the countries in the 
region, the annual number of syringes distributed per 
person who injects drugs per year approaches the UN 
recommended high coverage level of 200.(25, 26) Since 
the Global State last reported, the number of NSPs 
has declined in Austria, Belgium, Finland, Germany, 
Luxembourg, and Norway, with a large decrease in 
service provision seen in Portugal (from 1,270 to 590) 
and Spain (from 2,386 NSPs to 1,578).(27)
In Austria, syringes are available at 15 fixed sites, 
there are also 20 syringe vending machines located 
in five provinces, and five sites serviced by outreach 
workers. Syringe vending machines are also available 
in Luxembourg(28) and Germany, the latter having the 
highest number of syringe vending machines in the 
world (approximately 160 across nine of its 16 federal 
states).(29) Although Germany’s NSP service currently 
spans 180 cities, there is still a need for increased 
investment, particularly in light of the declining numbers 
of NSP sites.(30) In the majority of countries in the region, 
needles and syringes can be also be purchased without 
a medical prescription at most pharmacies, which play 
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a vital role in providing NSP services.(31) In the Flemish 
region of Belgium, annual evaluations of the needle and 
syringe programmes indicated that pharmacies play an 
important role, with almost two-thirds of people who 
inject drugs reporting purchasing needles through this 
medium as opposed to NSP sites.(32) Pharmacy provision 
often ensures that even where NSP sites do not cover 
a wide geographical area, sterile injecting equipment 
is still available to people. However, pharmacy staff are 
often not equipped with the expertise to provide harm 
reduction advice and will be unlikely to have had training 
in this area. 
NSP service delivery varies widely across Western 
Europe. In Belgium in 2014, approximately 926,000 
syringes were distributed through 51 specialised 
agencies and 14 sites serviced by outreach workers, 
coordinated by the Free Clinic in the Flemish community 
and by Modus Vivendi in the French community.(32) In 
Portugal, the National Commission for the Fight Against 
AIDS (Comissão Nacional de Luta Contra a SIDA), in 
cooperation with the National Association of Pharmacies 
(Associação Nacional de Farmácias), implements the 
national needle and syringe programme “Say No to 
a Second-Hand Syringe”, which was established over 
twenty years ago to prevent HIV transmission among 
people who inject drugs. The programme involves 
pharmacies, primary care health centres and NGOs, 
and includes several mobile units.(33) In 2012, a mobile 
medical care unit was launched in Luxembourg as 
an additional service to the five fixed sites and three 
vending machines, and facilitated the provision of 
primary medical care at low-threshold harm reduction 
centres.(28) It is reported that most of those registered 
as people who inject drugs in the countrykk were then 
able to obtain syringes from specialised agencies as 
well as pharmacies. Drug services in Luxembourg 
are decentralised and most commonly provided by 
state-accredited NGOs financed by the government. 
Many of the specialised agencies providing NSP have 
signed agreements with the Ministry of Health which 
guarantee their annual funding.(28) However, civil society 
organisations report that there have been problems 
with harm reduction funding for measures such as 
NSPs.(34)
Even in countries with relatively good levels of NSP 
coverage, important gaps exist. Reaching migrant 
communities, especially undocumented migrants, is 
difficult and many services still do not allow the provision 
of needles for people under the age of 18, which is 
now an explicit recommendation within UN technical 
guidance.(35) In Greece, an urgent priority to respond 
to the needs of the refugee population is reported to 
have affected mobile NSP provision. In 2015, 368,000 
syringes were distributed, a decrease from 2014 figures, 
even though a further two sites had been initiated. This 
decrease was attributed to a re-focusing of three out of 
four mobile sites to the needs of refugee.(36)  
Opioid substitution therapy (OST)
There were an estimated 644,000 people who use 
opioids receiving OST in Western Europe in 2014, 
equating to about half of all people using opioids in the 
region.(23) Coverage rates vary widely across the region, 
however, from low coverage in Cyrpus, for example, to 
high coverage in countries such as France and Portugal. 
Methadone remains the most commonly prescribed 
form of opioid substitute, received by 61% of those 
receiving OST.(23) OST in the region is prescribed from 
various sites, including healthcare centres, specialist 
treatment facilities, via general practitioners, and 
outreach services. Due to this dispersal of prescription 
sites, the actual numbers of OST sites in countries within 
the region are often difficult to determine. 
In some countries, national OST coverage may reach 
UN-recommended levels, while at the local level there 
may be some regions or some populations in those 
countries for whom coverage remains inadequate. In 
Germany for example, although OST is estimated to 
be received by 30-50% of people who inject drugs,(37) 
regulations for prescribing are reported to be overly 
bureaucratic, serving as a deterrent in attempting to 
access OST. In 2016, with pressure from prescribing 
doctors and NGOs, the barriers regarding access were 
considered by the Federal Ministry of Health in Berlin, 
and amendments have been made in order to attract a 
greater number of doctors as OST prescribers.(30) 
In Greece, the Greek Organisation Against Drugs 
(OKANA) is the only organisation which has legal 
permission to establish, operate and monitor OST. 
According to latest available estimates from 2014, a 
total of 10,266 people who use drugs received OST, 
with buprenorphine-based treatment being the most 
predominant substitute. In the Attica region of Athens, 
where the majority of opioid users are situated, 
waiting lists to initiate OST still average three years,(36) 
highlighting the inadequacy of harm reduction provision 
in this area, despite a large scaling-up process which 
started after the HIV outbreak in 2011. 
In Cyprus, OST was introduced in 2007 and is currently 
only available from two specialised drug treatment 
service units (one hospital and one private clinic). OST is 
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prescribed in the form of oxycodone, dihydrocodeine, 
buprenorphine, and methadone, but the latter is only 
used for detoxification purposes. In 2014, 178 people 
were receiving OST in Cyprus.(38) Similarly, Turkey 
introduced OST in 2009, with buprenorphine and 
naloxone licensed for use for both detoxification and 
substitution since 2010. Prior to 2014, OST was only 
prescribed by psychiatrists, but since 2014 all drug 
treatment centres licensed by the Ministry of Health 
have been able to implement OST provision.(39) 
Drug Consumption Room (DCRs)
Alongside other effective harm reduction approaches 
such as OST(40) and NSP(41) provision, several countries in 
the region operate drug consumption rooms (DCRs).(42) 
These are professionally supervised healthcare facilities 
where people can consume drugs in safe conditions. 
The first supervised drug consumption room was 
opened in Berne, Switzerland in June 1986.(5)  
In subsequent years further facilities were established in 
Germany, the Netherlands, Spain, Norway, Luxembourg, 
Denmark, Greece, and France.(5) Currently, there are 
87 DCRs operating across eight countries in Western 
Europe: Denmark, Germany, Luxembourg, Netherlands, 
Norway, Spain, Switzerland and France.(5) In 2014, the 
only DCR available in Greece was closed due to policy 
makers’ failure to adpot the necessary legislative 
amendments. Both Norway and Luxembourg are 
preparing to open a second DCR but these may not 
be in operation until 2018. In January 2016, France 
approved a six-year trial of drug consumption rooms, 
with facilities opened in Paris in October 2016.(5) 
Switzerland is also planning to open a further DCR in 
the near future,(43) and Ireland is planning to introduce 
supervised injecting facilities during 2016.(44) 
There is often political resistance to DCRs. For example 
in Bavaria, Germany, despite the high rates of drug-
related deaths, the regional government did not issue 
the required regulation for operating DCRs.(30)
Viral hepatitis
Although Western Europe has good harm reduction 
practices and programme provision when compared to 
the rest of the world, access to hepatitis C treatment for 
people who inject drugs is still low.(45, 46) With hepatitis 
C (HCV) antibody levels among national samples of 
people who inject drugs between 14-84% in 2012/13, 
five of the ten countries with national data reported HCV 
prevalence rates in excess of 50%.(17) In Western Europe, 
as in the rest of the world, there is a significant gap in 
data relating to HCV prevalence and access to testing 
and treatment for people who inject drugs. However, 
the limited available data suggest an increasing epidemic 
among people who inject drugs in the region. Among 
countries with national trend data for the period 2006-
2013 declining HCV prevalence among people who inject 
drugs was only reported in Norway, whilst six others 
countries observed an increase.(17)
Deaths from HCV related to end stage liver disease 
and liver cancer doubled during the last decade in the 
UK, with the majority of people who died being from 
marginalised and under-served groups in society such 
as people who inject drugs.(47) In England and Wales, 
50% of people who inject drugs are believed to have 
contracted HCV, with lower levels in Northern Ireland 
(23%) and higher levels in Scotland (57%).(47) In response 
to this, Scotland has in place a well-funded hepatitis 
C programme, which makes testing available in low-
threshold settings and provides treatment to people 
who inject drugs.(48) In France, 344 anonymous screening 
centres operate and screen for infectious diseases such 
as HIV and HCV, but as far as the Global State is aware, 
they do not offer treatment options for HCV.(49) 
One of the primary barriers in achieving HCV viral 
suppression is the cost of treatment. A revolution in 
treatment came about via the approval by the European 
Commission in January 2014 of direct-acting antivirals 
(DAAs). However, these new DAAs are expensive 
when compared to older medicines. In a survey of 21 
European Union countries, the European Monitoring 
Centre on Drugs and Drug Addiction (EMCDDA) found 
that the average cost of three months treatment was 
around €60,000, whereas treatment with HCV medicines 
from the previous generation of drugs cost between 
€17,000 - €26,000.(23) It is clear from Table 2.3.1 that the 
need for HCV treatment for people who inject drugs is 
considerable, and that addressing this gap is imperative. 
Tuberculosis (TB)
Findings of a report undertaken by the EMCDDA in 
2011 suggested that TB in Europe is predominantly 
concentrated among high-risk groups, such as migrant 
populations, homeless people, people who use drugs 
and people in prison.(50) People who are living with HIV 
and who inject drugs are two to six times more likely to 
develop TB than non-injectors, and commonly have co-
morbidities with hepatitis B and HCV infection. Despite 
these facts, data on TB prevalence and treatment access 
among people who inject drugs in Western Europe 
continues to be limited. Globally, TB-related deaths 
among people living with HIV have fallen by 32% since 
2004,(51) and in 2014, the percentage of identified HIV-
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positive tuberculosis patients who started or continued 
on antiretroviral therapy (ART) reached 77%.(51)
Antiretroviral therapy (ART)
As noted in the overview of this chapter, HIV prevalence 
rates among people who inject drugs are reported to be 
stable or declining.(17) In Belgium, for example, only 11 
people newly diagnosed with HIV reported injecting drug 
use as the probable mode of transmission in 2014.(52)  
In the UK, there were an estimated 2,160 people who 
inject drugs living with HIV in 2014, with approximately 
150 new HIV diagnoses believed to be as a result of 
sharing injecting equipment.(15) The Netherlands has also 
witnessed a decreasing trend in the annual number of 
new HIV diagnoses among people who inject drugs.(53)  
Similarly, Greece reported a 12.9% decrease in new 
HIV diagnoses among people who inject drugs in 
2014,(54) although recent reductions in funding for harm 
reduction have begun limiting the provision of HIV 
prevention interventions among this group. 
ART is available in principle in all countries in Western 
Europe, however, in a recent report by the European 
Centre for Disease Prevention and Control (ECDC) and 
the EMCDDA, Spain, Greece, Portugal and Sweden 
all reported people who inject drugs experiencing 
difficulties in accessing treatment, care and support. 
Spain also noted a reluctance by service providers to 
prescribe ART for people who inject drugs due to a lack 
of services to support adherence to treatment.(55)  
Late presentation (where people learn their HIV status 
at the point when their immune system is already 
significantly compromised) is often much more common 
among people who inject drugs,(55) and late diagnosis 
was reported in more than half of HIV cases acquired 
through injecting drug use in Austria (61%), Belgium 
(57%), Greece (75%), Ireland (56%), Italy (61%), Portugal 
(59%) and Spain (55%).(55)
Although the information available on the level of access 
to ART among people who inject drugs is only partial 
in Western Europe, data continues to suggest that 
improvements may be needed in social and adherence 
support for people who inject drugs to ensure ART is 
made more easily available.
Harm reduction in prisons
Since Portugal decriminalised drugs for personal 
possession in 2001, there has been a trend towards 
reducing the likelihood of imprisonment for minor 
offences related to use and personal possession of 
drugs in Western Europe.(23) Some countries such as 
Spain and Italy only apply non-criminal sanctions (e.g. a 
fine) for offences relating to drug use and possession,(23) 
while Ireland recently announced its intention to 
decriminalise substances including heroin, cocaine and 
cannabis in the near future.(56) Despite these positive 
developments, most western European countries still 
treat drug use and possession as a criminal offence. 
In fact, the majority of drug law violations in the region 
currently relate to use or possession for use, which 
has resulted in a very large proportion of the prison 
population comprising of people who use and inject 
drugs.(23)
Injecting drug use in prisons in the region is common. At 
last count, between 5% and 38% of prisoners in Europe 
had ever injected drugs,(57) and between 2% and 31% 
of prisoners in the European Union, depending on the 
country, reported having ever injected drugs while in 
prison.(58) At the same time, prevalence estimates for 
HIV (4.6%) and HCV (15.5%) in Western Europe remain 
considerably higher among the prison population than 
the broader community.(59) These figures highlight the 
need for quality harm reduction services in the region’s 
prisons. 
Availability of OST is improving, with all countries 
apart from Andorra, Cyprus, Iceland and Monaco now 
providing the service in some or all prisons. Since the 
Global State last reported in 2014, pilot OST programmes 
have been introduced in two prisons in Greece,(54) 
with indications that this service could be scaled up in 
the future.(60) OST coverage in prisons is considered 
high in Austria, France, Ireland, Spain, the UK and 
Luxembourg,(61, 62) however there remains considerable 
room for improvement in terms of accessibility and 
the quality of the service in many countries in the 
region. In Finland and Malta, for example, OST is mostly 
available to prisoners who were receiving it prior to 
incarceration,(63, 64) while in the UK, OST is available in all 
prisons and can be newly initiated, but accessibility is 
restricted due to time-limited prescribing.(65) In Portugal 
and Greece, long waiting times act as a serious barrier to 
access for many prisoners,(60, 66) while in Ireland, quality is 
said to vary by institution.(67) In Germany, access to, and 
quality of, OST in prisons varies by region.(30)  
In the German region of Bavaria, for example, OST is 
not available to prisoners at all. This was very recently 
the subject of a European Court of Human Rights case, 
where Germany was ultimately found to be in violation 
of the prohibition of cruel, inhuman and degrading 
treatment for denying the applicant access to OST while 
in detention.(68) 
Provision of prison-based NSPs continues to be 
inadequate in Western Europe, with the service only 
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available in Spain (22 prisons),(69)ll, Luxembourg (both 
prisons),(62) Germany (one female prison in Berlin)(30) 
and Switzerland (three prisons).(43) An important legal 
development in France, however, is reason to remain 
optimistic that this service will soon become more widely 
available in prison settings in the region. In December 
2015, the country enacted a new law (Loi Santé), which 
includes a specific section on compulsory compliance 
with the principle of equivalence specifically in relation 
to the provision of harm reduction in prison settings. 
The law provides that harm reduction services that are 
available in the broader community, including NSPs, 
must also be available in prison settings.(70)
Condom provision in Western European prisons 
varies by country and/or prison. In Spain, for example, 
condoms are available and easily accessible in all 72 
prisons, while in all Belgian and approximately 85% of 
Swiss prisons, condoms can be accessed discreetly 
through machines.(43, 61) Condoms are only available on 
request at medical services or the prison health service 
in Finland, Portugal, the Netherlands and France, while 
in Austria and Denmark, female condoms are only 
available in approximately half of the prisons detaining 
female prisoners.(61) In the UK and Germany, condoms 
are reportedly not available in all prisons,(30, 65) whereas 
in Italy and Cyprus, condoms are not available in prisons 
at all.(71, 72) 
Availability, accessibility and quality of diagnostics, 
treatment and care for HIV, HCV and TB in the region’s 
prisons also vary. For instance, HIV-related services 
are reportedly not available to female prisoners in 
Cyprus,(72) while ART is only available in 89% of Italy 
prisons.(71) In Switzerland, HCV testing and treatment 
are only available in 85% of prisons,(43) while in Finland 
and Ireland, HCV treatment is only provided to prisoners 
who use drugs if they are either stable on methadone or 
have achieved abstinence for a period of time.(61)  
This type of variable standard of care contravenes 
international human rights law and standards relating 
to the treatment of prisoners. Measures must urgently 
be taken to ensure that all prisoners have equal access 
the same quality of services available to the broader 
community. 
Since the Global State last reported in 2014, the UK 
has been implementing a programme across the 
country that aims to achieve a higher and more uniform 
standard of care in prisons. The universal ‘opt-out’ blood 
born virus (BBV) testing programme, which is expected 
to be fully implemented in all prisons in England by the 
end of 2016-17, offers prisoners the chance to be tested 
for infections near reception and at several time points 
thereafter by appropriately trained health care staff.  
A preliminary evaluation of the programme undertaken 
in 2015 revealed a near doubling of BBV testing only 6 
months after it was introduced.(73) 
Despite people who inject drugs being at particular risk 
of overdose following release from prison, take-home 
naloxone kits are still not widely available to prisoners 
either during their incarceration or following release 
in Western Europe. In Spain, for example, naloxone is 
reportedly only available to prisoners in Madrid.(61) As 
far as we are aware, naloxone is only available in some 
prisons in Norway, and all prisons in England, Wales and 
Scotland.61) Scotland’s National Naloxone Programme, 
which began in 2011 and supplies naloxone kits for 
home leave and/or on release to those identified as 
being ‘at risk’ while in prison, has been recognised as 
a model of good practice. A recent evaluation of the 
programme found that it was associated with a 36% 
reduction in the proportion of opioid-related deaths that 
occurred in the 4 weeks following release from prison.(74) 
 
“Improving Prison Conditions by 
Strengthening Infectious Disease 
Monitoring”, an HRI led project 
 
HRI’s two year, EU co-funded project, “Improving 
Prison Conditions by Strengthening Infectious Disease 
Monitoring” came to an end in September 2016. Led 
by HRI and implemented with partners in 7 European 
countries, this project aimed to improve prison 
conditions and reduce ill treatment of prisoners 
by strengthening HIV, HCV, TB and harm reduction 
monitoring in prisons.  
The project mapped HIV, HCV, TB and harm reduction 
in prisons and current monitoring practices on these 
issues in Catalonia (Spain), Greece, Ireland, Italy, Latvia, 
Poland, and Portugal. In each of these countries, rates 
of HIV, HCV and TB inside prisons were higher than 
rates in the general population, particularly in Latvia. 
While each country was found to provide a wide range 
of harm reduction services in the broader community, 
the majority failed to provide these same services, or 
the same quality of these services, in prison settings. 
Where harm reduction services had been available and 
easily accessible in prison settings for some time, such 
as in Catalonia, better health outcomes were observed, 
including significantly reduced rates of HIV and HCV 
incidence. A scarcity of systematic and  
ll	 Correct	numbers	are	always	difficult	to	pin	down.	In	2014,	the	Global State reported that NSPs were available in 38 prisons in Spain based on a UNODC document. This year, 
 we relied on the most recent Secretaria General de Instituciones Penitenciarias’ annual report (2014, published in 2015), which indicated that only 22 prisons provided the 
 service.   
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comprehensive monitoring of HIV, HCV, TB and harm 
reduction in prisons was observed at the national level 
in all countries surveyed. Overall, the provision of harm 
reduction in each of these countries’ prisons varied 
considerably, but certain key themes and lessons were 
distilled, including around features of an enabling 
environment for harm reduction, resource allocation, 
collection of data, and accessibility of services. 
The project also charted existing European and 
international public health and human rights standards 
relating to HIV, HCV, TB and harm reduction, as well 
as monitoring practice in relation to these issues. This 
research found that United Nations human rights 
bodies and the European Court of Human Rights are 
increasingly finding that issues relating to disease 
transmission in detention – including the denial of harm 
reduction services and the inadequate prevention, care 
or treatment – can contribute to, or even constitute 
conditions that meet the threshold of ill treatment. In 
spite of this, however, HIV, HCV, TB and harm reduction 
are not adequately monitored in the current European 
and International approach to the prevention of ill 
treatment in prison settings.
Finally, based on this research, a user-friendly, human 
rights-based tool was developed, in consultation with 
an Expert Committee, to generate better informed, 
more consistent, and sustained monitoring of HIV, HCV, 
TB and harm reduction in prisons by national, regional 
and international human rights-based monitoring 
mechanisms. 
For more information on the project, or to access all 
reports and the monitoring tool, please visit:  
https://www.hri.global/prison-project.
 
 
Overdose
Overdose continues to be a major cause of death 
among people who use drugs in Western Europe, with 
more than 6,000 deaths among this population each 
year, many involving opioids.(24) In 2012, the six highest 
national mortality rates associated with drug overdose 
in Europe were reported by countries located in the 
north (in descending order): Norway, Ireland, Sweden, 
Finland, Denmark and the UK.(24) The overdose mortality 
rate in Norway, for example, is comparable to or higher 
to the overdose mortality rates in the 1990s prior to the 
introduction of harm reduction measures.(24) In the UK, 
there has been a 64% increase in drug-related deaths 
linked to heroin and morphine from 2014-2016, the 
highest ever recorded in the country.(65, 75)  
The reasons behind these rises in fatal overdose are 
unclear but a number of factors may be involved 
including: increased heroin availability and prevalence of 
its use, higher purity, the increased levels of morbidity 
linked to an ageing cohort of drug users, as well as 
changing consumption patterns, including the use of 
highly potent synthetic opioids and medicines.(23)  
Overdose is predominantly reported among older opioid 
users (35-50) but increases in overdose deaths are 
also seen among the under-25s in some countries (for 
example, Sweden) warranting closer scrutiny.(23)  
Whilst heroin remains the most commonly used 
opioid, synthetic opioids are increasingly used and 
there has been a rise in the number of countries 
reporting synthetic opioids as the primary drug used 
by those entering treatment. Synthetic opioids used in 
substitution treatment (e.g. methadone, buprenorphine) 
are also regularly found in toxicology reports and these 
substances are associated with a substantial share of 
drug-related deaths in some countries (e.g. Ireland, 
France, Finland and the UK).(23)
In its 2014 Consolidated Guidelines on HIV Prevention, 
Diagnosis, Treatment and Care for Key Populations, the 
World Health Organization recommends that people 
likely to witness a drug overdose (including people 
who inject drugs and their families and friends) should 
have access to naloxone and training on how to use 
it. Naloxone, a highly effective opioid antagonist, often 
continues to be blocked by administrative barriers in 
the region, being available by prescription or medical 
personnel only, rather than for peer-distribution. 
However, Scotland is the first country in the region to 
have a nationwide take-home naloxone programme, 
initially piloted in 2007. The naloxone distribution system 
targets people who have been in contact with drugs 
services, including NSP and OST programmes.(76)  
Scotland now also distributes naloxone to people who 
inject drugs at the end of their prison sentence. The 
Scottish Government’s 2014 assessment of the first 
three years of this programme estimated that over 500 
overdose deaths had been averted, and 90% of people 
who participated said that the programme had helped 
them to better understand the causes of overdose.(77)  
In Italy, naloxone is available over the counter from 
pharmacies, and take-home naloxone is also distributed 
through drop-in centres and outreach programmes in 
the country.(78) 
In the spring of 2014, a trial project of nasal naloxone 
sponsored by the Norwegian Ministry of Health and 
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care Services was launched in Oslo and Bergen. Within 
this project, staff working in low-threshold services 
were trained and overdose response kits distributed 
to people who use drugs. The project is now being 
expanded to train police and security staff, staff at 
detoxification centres, emergency health centres 
and prisons.(79) In October 2015, legislative changes 
were introduced in the UK to increase the availability 
of naloxone, making this specific drug exempt from 
prescription-only medicine requirements when it is 
supplied by drug services commissioned by a local 
authority or the National Health Service.(16) Overdose 
prevention remains a relatively neglected issue in much 
of Western Europe and there is a need for continued 
advocacy for political and financial support for cost-
effective and proven overdose prevention measures 
such as take-home naloxone programmes(80) and drug 
consumption rooms. There is great potential for valuable 
lessons and experiences to be taken from Scotland and 
Italy in implementing take-home naloxone programmes 
to be shared with other countries in the region, and 
elsewhere. 
 
Policy developments for harm 
reduction
In comparison to some other regions, Western 
European HIV policy frameworks have specifically 
addressed and acknowledged harm reduction as a 
central component of the HIV response. At the regional 
level, harm reduction is noted in the European Union 
Action Plan on HIV/AIDS in the EU and Neighbouring 
Countries: 2014-2016,(81) which is harmonised with the 
WHO-led European Action Plan for HIV/AIDS 2012-
2015,(81) in which harm reduction is also covered. 
Attention to harm reduction in European drug policy 
frameworks is also improving. The EU Drugs Strategy 
(2013-2020)(82) and EU Drugs Action Plan (2013-2016) 
addresses harm reduction, human rights, civil society 
engagement and transparency more than in previous 
European Union drug policy documents. Advocacy and 
policy work by civil society had a positive impact on 
support for harm reduction in these processes.
As harm reduction services have become widespread in 
the region, increasing focus has been placed on service 
quality, culminating in the adoption of ‘Minimum quality 
standards in drug demand reduction in the European 
Union’ by the EU Council of Ministers in September 
2015. Sixteen standards for prevention, treatment, harm 
reduction and social reintegration set minimum quality 
benchmarks for interventions. These newly adopted 
standards represent a major development at the EU 
level, and serve to facilitate the sharing of best practice 
at a European level.(23) 
During several important international policy processes, 
the European Union championed harm reduction both 
regionally and through individual member state support. 
In April 2016, during the United Nations General 
Assembly Special Session (UNGASS) on the drugs in 
New York, Italy, Finland, Norway, Sweden, Germany, the 
Netherlands, Lichtenstein, Portugal, Greece, Austria, 
Cyprus, Malta and Belgium all made statements in 
explicit support of harm reduction.(83) The European 
Union’s common position also stated that harm 
reduction, as a proven effective measure in preventing 
overdose and the transmission of blood borne diseases, 
should be further promoted and implemented.(83) 
During the UNGASS roundtable on health and drugs, a 
Scottish National Party (SNP) Member of Parliament (MP) 
also made the case for increased investment in harm 
reduction. 
Following the UNGASS, in June 2016, a United Nations 
General Assembly High-Level Meeting (HLM) on Ending 
AIDS was held, and a new Political Declaration adopted 
by United Nations Member States, which charts a 
course to end AIDS as a public health threat by 2030. 
This meeting gave governments the opportunity to 
elaborate on how they intended to meet the target of 
ending AIDS by 2030. Greece, the UK, the Netherlands 
and Switzerland explicitly supported harm reduction in 
their national statements during the HLM. Several other 
countries including Denmark, Liechtenstein, Germany, 
Sweden, Norway, Finland, Luxembourg and the EU 
referred to the need to target interventions towards key 
populations, with several mentioning people who inject 
drugs specifically. (See the Global Overview section of 
this report for more analysis of the outcome for harm 
reduction within recent high level political processes).  
 
Civil society and advocacy 
developments for harm reduction
Civil society organisations continue to play a significant 
role in mobilising and advocating for harm reduction in 
Western Europe, both at national and regional levels. 
The European Civil Society Forum on Drugs, modelled 
after Europe’s Civil Society Forum on HIV, is a diverse 
group representing civil society organisations engaged 
in service provision and advocacy relating to the 
prevention of drug use, drug-related treatment, social 
support services and harm reduction. 
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The meaningful involvement of people who use drugs in 
policy development and service delivery is often aided by 
civil society harm reduction networks, and/or networks 
of people who use drugs. The European Network of 
People who Use Drugs (EuroNPUD) was founded in 
2011 within the framework of a European Commission-
supported project to form the European Harm 
Reduction Network.(84) The network was relaunched 
in 2013 during a side meeting at a peer workshop on 
HCV and drug use. EuroNPUD is now comprised of an 
Executive Committee with representation from across 
the European Region and has identified a number of 
key thematic areas for focus including NPS, HCV and 
overdose prevention.(85) 
The European Harm Reduction Network lost funding 
at a regional level in 2014, leaving  an important gap 
remaining for a strong and funded regional harm 
reduction network. However, a number of other 
networks continue to progress and have undertaken 
projects focusing on various aspects of harm reduction. 
The Correlation network(86) established the ‘Hep C 
and drug use initiative’ in 2013, the purpose of this 
platform is to reduce the burden of HCV among people 
who use drugs by promoting universal access to HCV 
prevention, treatment and care through collaborative 
activities including research, advocacy and civil society 
strengthening.(87) The ‘NPS in Europe’ is a multi-partner 
project aiming to increase knowledge and understanding 
of the risks associated with the use of new psychoactive 
substances and effective harm reduction responses. 
This project is undertaken by APDES (Portugal), CUNI 
(Czech Republic), Rainbow Group (Netherlands), Praxis 
(Greece), Carusel (Romania), Sananim (Czech Republic) 
and Monar (Poland).(88) 
At national level the existence of harm reduction 
networks varies across the region. There is no national 
harm reduction network in Switzerland, however, there 
are two regional networks on harm reduction in the 
German and the French parts of Switzerland.(43) In the UK 
there are a number of coalitions, including the National 
Needle Exchange Forum, UK Harm Reduction Alliance 
and the Harm Reduction Network. The Naloxone Action 
Group has also been recently formed to place pressure 
on local commissioners to pay for naloxone and for 
amendments to be made in prescribing regulations. This 
group includes civil society, activists and drug treatment 
providers.(65) Germany also has a national network on 
harm reduction, Akzept, with many smaller state level 
civil society organisations operating at the local level. 
Alongside this Germany also has JES, its national network 
of drug user rights groups , which is one of the oldest in 
the world.(30) National harm reduction networks are also 
in existence to some extent in Italy, Portugal and France.  
 
Funding: developments for harm 
reduction
This region contains some of the earliest adopters and 
long-term implementers of harm reduction and as 
such, Western European countries are among those 
globally that invest most heavily in harm reduction. 
However, there remains much variety in the levels and 
sustainability of harm reduction funding between and 
within countries. Limited political support for harm 
reduction still hinders investment in some countries and 
austerity measures brought in following the financial 
crisis continue to affect the sustainability of services in 
the region.
In 2015 and 2016, HRI and EHRN coordinated an EC 
funded project called ‘Harm Reduction Works!’ that 
aimed to fill a knowledge gap on harm reduction funding 
across EU member states and build the capacity of 
civil society to call for strategic investment into harm 
reduction.mm In many countries surveyed, civil society 
identified the need for greater transparency of harm 
reduction investment. Spending on key harm reduction 
interventions such as NSP and OST was challenging 
in all countries surveyed and gaps in knowledge 
remain. However, the research did indicate that several 
countries have seen harm reduction funding cuts 
in recent years, for example, as a result of national 
austerity measures. The resultant impact on service 
provision in Greece, for example, has been marked 
and there are concerns that the potential for another 
sharp increase in HIV among people who inject drugs 
is now apparent. In some countries it was reported 
that challenges to sustainable, adequate financing for 
harm reduction were faced at the local level, despite 
endorsement of the approach in national policies. Six 
out of twenty Italian regions currently have no harm 
reduction services in place, for example, while others 
with supportive local governments have well-functioning 
harm reduction services.(78) In the UK, this was also 
highlighted as an issue, with the expectation that some 
parts of England will see dramatic cuts to services in the 
near future.
Most countries in the region cover the majority of the 
harm reduction investment without external support. 
While some countries have received international 
donor support, for example from the Elton John AIDS 
Foundationnn and the European Commission,oo much of 
this support has decreased or stopped in recent years. 
mm		A	report	summarising	the	research	findings	is	due	to	be	published	in	the	coming	months.	
nn    Elton John AIDS Foundation (EJAF) for example, provided support to the roll-out of a nationwide pharmacy NSP programme since 2011.
oo   European Commission funds supported harm reduction scale up in Greece in 2011/2012, in response to the rapid increase in HIV infection among people who inject drugs, 
   but this funding has now stopped.
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There are concerns from civil society in many countries 
that the need for a well-funded harm reduction 
response is more pressing than ever, with drug use 
trends changing and NPS and stimulant use increasing. 
In order for harm reduction approaches in Western 
European countries to adapt to these new trends, 
adequate funds and political support is required. 
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Regional Overview
2.4  Caribbean
762.4 CARIBBEAN
Country/territory 
with reported       
injecting drug usea
People who inject 
drugs
HIV prevalence 
among people 
who inject 
drugs (%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among people 
who inject 
drugs (%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among people 
who inject 
drugs (%)
Harm reduction response
NSPb OSTC
Bahamas nk nk nk nk 7 7
Bermuda nk nk nk nk 7 7
Dominican Republic 200,000–350,000(1) 11(2) 3.4(1) 3.1(1) 31 7
Haiti nk nk nk nk 7 7
Jamaica nk nk nk nk 7 7
Puerto Rico 29,130(3)d 22.9(4) 89(5)e nk 36(6)f 38 (M, B, O)
Suriname nk nk nk nk 7 7
nk = not known
Caribbean
Table 2.4.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in the Caribbean
a In 2008 the United Nations Reference Group found no reports of injecting drug use for Antigua and Barbuda, Barbados, Belize, Dominica, Grenada, St Kitts and Nevis,  
 St Lucia or St Vincent and the Grenadines. However, civil society consulted for this report noted that this information is no longer up to date.
b	 All	operational	needle	and	syringe	exchange	programme	(NSP)	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach 
 workers.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d Estimate from 2002. Civil society consulted for this report believed the number of people using opiates to have doubled to approximately 60,000.
e Estimate based on sub-national data, relating to the area of San Juan only.
f Each of the six NSPs has multiple sites; for example, one syringe programme has 15 sites.
77 GLOBAL STATE OF HARM REDUCTION 2016
Both NSP and OST available
OST only
NSP only
Neither available
Not known
Map 2.4.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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Harm reduction in the Caribbean
Overview
The Global State of Harm Reduction 2014 reported a 
UNAIDS finding that HIV prevalence in the Caribbean 
had decreased greatly since 2001.(7) According to a 2016 
UNAIDS report, however, the Caribbean witnessed a 
9% rise in new HIV infections among adults between 
2010 and 2015, with the annual number of new HIV 
infections ranging between 7,500 and 11,000.(8) UNAIDS 
also reports that 75% of people living with HIV in Latin 
America and the Caribbean are aware of their HIV status, 
yet survey data among key populations in the Caribbean 
indicate that periodic HIV testing and knowledge of HIV 
status are particularly low.(8)
Epidemiological data on HIV, viral hepatitis and drug 
use in the Caribbean region continue to be sparse. 
UNAIDS reports that the number of people who inject 
drugs in Latin America and the Caribbean is 721,000, 
but the wide-ranging interval of 312,000–1,375,000 
illustrates the lack of robust data for both regions.(9) 
Most of the information comes from Puerto Rico and, 
to a lesser extent, the Dominican Republic. Due to the 
paucity of data, however, the Global State can only report 
population size estimates from these two countries/
territories (see Table 2.4.1), both of which civil society 
believes to be vast underestimates.(6, 10) A unique issue 
in terms of data collection for Puerto Rico specifically is 
that it is often omitted from reports on the Caribbean 
because it is a territory of the United States, but also it is 
excluded from some US reporting.(11)
HIV prevalence rates among people who inject drugs 
are available only for Puerto Rico and the Dominican 
Republic, where poor access to sterile injecting 
equipment has been identified as a significant 
contributor to HIV epidemics. Between 1981 and 2013, 
51% of people in Puerto Rico who died whilst living with 
HIV/AIDS acquired the infection via unsafe injecting 
practices.(6) In the same time period, people who inject 
drugs represented the highest percentage of those living 
with HIV/AIDS who did not have access to medical care 
for their condition.(6) The distinct lack of adequate harm 
reduction services in the country means that this key 
population faces a higher risk of both HIV and hepatitis 
C infection,(11) with over 20% of new HIV infections 
attributed to this demographic.(12)
Drug treatment services for people who use drugs 
in much of the Caribbean region primarily focus 
on abstinence. St Lucia, for example, has only one 
drug treatment service, which exists in the form 
of a rehabilitation centre.(13) Similarly, Trinidad has 
a government-supported drop-in centre offering 
assessment, referral and rehabilitation for homeless 
people who use drugs.(14) Abstinence-oriented 
interventions have been found to be effective for only 
a minority of people who inject drugs; harm reduction 
services such as opioid substitution therapy (OST) are 
widely acknowledged as the first line of treatment.(15) Yet 
Puerto Rico and the Dominican Republic remain the only 
countries in the region offering harm reduction services.
Although there are a number of harm reduction 
programmes providing needle and syringe programmes 
(NSPs) and OST in Puerto Rico, a reduction in state 
funding in recent years due to the financial crisis has 
seen many of these essential services decline or close 
down completely. As such, the various faith-based drug 
treatment services in the country now represent the 
sole treatment option for many people who inject or 
use drugs in Puerto Rico. The Mental Health Law of 
2000, which labelled ‘addiction’ as a spiritual and social 
issue rather than as a health issue, served to cement 
faith-based services as central to the national drug 
treatment response.(16) The implementation of this law 
exempted faith-based treatment from State regulation. 
In 2008, however, the Mental Health Law was amended 
to recognise the role of physicians alongside spiritual 
advisors, as opposed to just the latter. Many of the 
residential drug treatment programmes are run by one 
chain – Comunidad de Re-Educación de Adictos (CREA), 
which reportedly approaches people who use drugs and 
their families via the drug courts.(17) CREA centres, which 
are faith-based, receive little government supervision 
and some of their practices have been criticised on 
human rights grounds.(17, 18) It is also reported that 
many people who use drugs in Puerto Rico have been 
forcefully relocated to drug rehabilitation centres in the 
United States, where their identification documents 
are confiscated upon arrival and treatment is denied, 
culminating in people being left homeless and unable 
to return home.(19, 20) Even these controversial and 
restricted services are insufficient for the number of 
people who use drugs in the country.(18) With high rates 
of HIV, and hepatitis C prevalence rates of 89% among 
people who inject drugs, it is clear that Puerto Rico 
urgently needs to increase its harm reduction response.
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In the Dominican Republic, unsafe injecting drug use 
is reported to account for 1% of HIV transmission,(21) 
although civil society queries the accuracy of this figure. 
The country opened its first NSP in 2012, and in 2016 is 
reported to be planning the implementation of a small 
OST site providing buprenorphine-assisted treatment 
for people who use heroin.(6)
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
Even though the effectiveness of NSPs in reducing 
viral transmission of both HIV and hepatitis has been 
documented numerous times,(22) the annual budget 
designated to NSPs in Puerto Rico ($80,000) is five times 
less than that of NSP services in the Northwest region of 
the United States ($400,000).(11) Intercambios Puerto Rico, 
the island’s primary harm reduction organisation, has 
managed to expand its NSP provision to include two new 
municipalities in the eastern region of the island and, 
between 2014 and 2015, distributed 165,000 syringes to 
people who inject drugs.(6) However,  several state-funded 
NSPs were forced to reduce their syringe provision 
services, or temporarily close, due to a government delay 
in allocating funds.(6) The impact of this on people who 
inject drugs has not yet been documented. Meanwhile, 
as the Puerto Rican bankruptcy and budget crisis 
worsens, it is almost certain that government funding to 
assist harm reduction and HIV responses in the country 
will diminish further.(6)
Although there has been an expansion of NSP services 
to the east in Puerto Rico, there is still a largely unmet 
need in semi-urban and rural areas, with the present 
facilities operating at full capacity. There is an urgent 
need to expand services to neighbouring municipalities 
and communities. This cannot be done without 
increased financial support from government.(6)
The Dominican Republic opened its first NSP in 2012, 
supported by Centro de Orientación e Investigación 
Integral (COIN).(23) Since its inception, more than 1,000 
people have accessed its Open Doors programme. 
Between June and December 2012, 4,000 syringes were 
distributed, 20% of them to women who inject drugs.(24) 
In 2015 this service distributed a total of 14,398 needles/
syringes to people who inject drugs in the Dominican 
Republic.(6)
In 2016 St Croix began implementing a new pilot NSP 
in the US Virgin Islands, run by Frederiksted Health 
Care Incorporated with technical assistance from 
Intercambios Puerto Rico and the Migrant Health 
Centre.(6) Although there is a much greater need for NSP 
service provision within the region, the introduction of 
such new services is an important step forward.
Opioid substitution therapy (OST)
Puerto Rico remains the only territory in the Caribbean 
to provide OST. Plans have been made for the 
implementation of buprenorphine-assisted therapy for 
people who use heroin in the Dominican Republic, with 
support from consultants from the School of Public 
Health of Puerto Rico, but the programme is yet to be 
established.(6)
OST in Puerto Rico in the form of methadone or 
buprenorphine is provided at six fixed sites, two mobile 
units and through one prison-based programme. 
Although there has been an increase in the availability of 
buprenorphine, the number of sites has not been scaled 
up since 2014. People who use drugs still face huge 
barriers to accessing quality OST services, with many 
reporting stigma, poor treatment, arbitrary decision 
making by medical providers, punitive measures and 
providers withholding care.(6) The only providers of 
methadone are government-run clinics, which have 
scaled back provision since 2014.(6) While the availability 
of buprenorphine has increased at community level, 
many people who inject drugs report a very high 
threshold requirement for new admissions, making 
access extremely restrictive.(6) People who use drugs 
who are homeless or estranged from their family face 
additional barriers as the OST programme requires an 
accompanying adult who will vouch responsibility for the 
appropriate use of the prescribed medication.(6) Anyone 
based in a rural setting is also at a disadvantage because 
services are only located in the large metropolitan areas 
of Ponce and San Juan.(6) Women who use drugs are 
especially affected by the lack of access to OST as many 
treatment centres on the island refuse to accommodate 
them.(6)
Harm reduction for people who use crack cocaine
Crack and similar cocaine derivatives are the main 
stimulant used in the Caribbean, and in the Americas.
(25, 26) Despite the number of people who use crack in 
the region, and the health implications of sharing pipes 
(in terms of hepatitis infections via sores) being widely 
documented,(27, 28) there are only a small number of 
drop-in centres in the Dominican Republic, Trinidad, 
Jamaica and St Lucia that provide any form of service for 
this group.(29)
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The Castries facility in St Lucia offers shelter and other 
services for people who use crack cocaine who are 
homeless and living with HIV, providing adherence 
support for residents receiving antiretroviral therapy 
(ART). Although it does not distribute cannabis, the 
centre advocates the use of the drug for residents as a 
method of combating crack cocaine dependence and 
the nausea that is often a side-effect of ART.(29) Small-
scale studies on the experimentation of cannabis as 
a form of substitution therapy for crack have yielded 
positive results.(30, 31) There is a need for further research 
and exploration into harm reduction responses to crack 
use in the region and worldwide.
In Jamaica, Tek it to Dem 2 provides outreach to 
homeless people who use crack and who are reluctant to 
access zero tolerance or total abstinence programmes. 
The initiative provides peer education on HIV and 
sexually transmitted infection prevention, alongside hot 
food, companionship and transportation.(32)
In Puerto Rico, Intercambios is working to establish harm 
reduction services for people who use crack, which will 
begin in 2017.(6)
Viral hepatitis
Since Global State 2014, there has been very little new 
information on hepatitis C (HCV) among people who 
inject drugs in the Caribbean region. As illustrated in 
Table 2.4.1, HCV prevalence rates are markedly higher 
than HIV prevalence rates among people who inject drugs 
in Puerto Rico. A 2016 study attributed this high rate of 
HCV not to the sharing of needles and syringes, but to the 
sharing of injection ‘works’ (i.e. cookers, cotton and water), 
with this occurring more than twice as often as needle 
sharing.(34) Despite this, the Puerto Rico Department of 
Health does not routinely monitor HCV infection rates.(6)
Hepatitis C testing and treatment is rarely offered to 
people who use drugs in the Caribbean,(6) with treatment 
available only from private healthcare providers, whose 
prohibitive costs restrict access for the vast majority of 
people who use drugs.
Tuberculosis (TB)
There has been a consistent dearth of information on 
the extent of tuberculosis infection rates among people 
who inject drugs in the Caribbean. The World Health 
Organization (WHO), however, asks countries to report 
on TB case notifications among the general population 
and from this we can see that the highest number of 
reported cases of TB in the Caribbean in 2014 were in 
Haiti (15,806) and the Dominican Republic (4,405).(34)
A 1999 study in Puerto Rico found that TB incidence 
was highest among people living with HIV who inject 
drugs.(35) Between 1981 and 2013 a total of 1,302 
people in Puerto Rico received diagnoses of HIV 
and TB co-infection, with 61.6% of cases occurring 
among people who inject drugs(36) – again highlighting 
a disproportionate vulnerability to TB. Whether in 
response to this data, or for reasons of best practice, 
all drug treatment centres in Puerto Rico now require 
TB testing prior to admission, with TB treatment then 
available at health centres.(6)
Antiretroviral therapy (ART)
Approximately 75% of people living with HIV in the 
Caribbean know their HIV status.(37) Between 2010 and 
2015 this region saw a 9% rise in new infections among 
the general population.(8) Although ART coverage in the 
Caribbean rose from 20% in 2010 to 50% in 2015,(8) 
key populations continue to struggle to gain adequate 
access to HIV testing and treatment. For example, 
considering the high prevalence of HIV among people 
who inject drugs in Puerto Rico, HIV care for this group 
is often grossly inadequate.(11) There is a distinct lack of 
funding to support rapid HIV testing for hard-to-reach 
populations such as people who use drugs.(6) Within 
Puerto Rico, it is reported that over 43% of people living 
with HIV/AIDS acquired the infection via unsafe injecting 
drug use.(6, 38)
Between 1981 and 2013 over half (51%) of the people in 
Puerto Rico who died while living with HIV/AIDS acquired 
the infection via injecting drug use.(39) Moreover, in 
2013 people who inject drugs represented the highest 
percentage of the population living with HIV/AIDS who 
did not have access to medical care for their condition 
(between 41% and 53%) even though they had the 
highest retention rate once they initiated treatment.(39)
People who use drugs are heavily criminalised in Puerto 
Rico. They rarely seek medical treatment due to fear of 
incarceration. When they do seek ART, many are denied 
this service until they can demonstrate abstinence from 
drug use, with drug treatment and detoxification centres 
denying services to people who have visible ulcers.(6)
HIV prevention is inadequately funded across the 
Caribbean.(8) Only four islands have healthcare facilities 
providing integrated HIV and TB treatment services 
(Antigua and Barbuda, Dominican Republic, Haiti and St 
Lucia).(7) Overall, there is very little information covering 
testing and ART for people who inject drugs in the 
region, even though a regional synthesis of UNAIDS 
progress reports from 2008 emphasised the need 
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for the Caribbean to quickly increase the meaningful 
involvement of its most vulnerable populations in its HIV 
response.(40) 
Harm reduction in prisons
The Caribbean region’s median prison population 
rate stands at 347 per 100,000.(41) Thanks to the 
implementation of extremely punitive drug laws across 
the region, driven by the US ‘war on drugs’, people who 
use drugs make up a large proportion of this prison 
population. In 2012, for example, the Puerto Rican 
Department of Corrections and Rehabilitation reported 
that 87.71% of prisoners had been sentenced in cases 
relating to drug use, of which nearly 50% were first-time 
offenders and approximately 75% were people who use 
drugs.(18)
The prevalence estimate of HIV among incarcerated 
populations in most Caribbean countries and territories 
is double the national prevalence estimate.(42) Data 
relating to HIV and HCV prevention, treatment, care and 
support in the region’s prisons, however, are scarce due 
to a continued lack of systematic monitoring. One study 
in 2014 unsurprisingly found that Puerto Rican prisons 
represented the main point of access to HIV screening 
and treatment for the people who circulate through the 
country’s prison system.(43)
In addition to unsafe injecting drug use, the risk of HIV 
and HCV transmission in Caribbean prisons is intensified 
by the criminalisation of sex between men, the lack of 
condom provision and the denial of key harm reduction 
services.(23) According to civil society, OST is available 
in only some prisons in Puerto Rico, and this service 
remains limited to small numbers. There are no prison 
NSPs operating in the Caribbean. Given the rise in 
new HIV infections and the large proportion of people 
who use drugs in detention, there is an urgent need to 
introduce or expand harm reduction services in prisons 
across the region.(6)
Overdose
The Caribbean continues to have an extremely limited 
overdose response, with no naloxone peer distribution 
and no overdose programmes operating in the region.
Fatal overdose is reported to be high in Puerto Rico 
among the population of people who inject drugs (37% 
in Puerto Rico compared with 13% in New York).(11)  A 
cross-sectional survey in Puerto Rican prisons found that 
almost half of the incarcerated population had witnessed 
an overdose in prison, and one-third knew someone to 
have died of an overdose while incarcerated.(44) Of those 
reporting injecting drug use prior to incarceration, over 
60% had witnessed an overdose incident and just under 
half knew of an overdose death.(44) There is no overdose 
surveillance programme operating at the Department 
of Health, yet there is a clear and urgent need for 
monitoring and for an effective overdose response in 
the country.
In 2015 legislation was introduced in Puerto Rico to 
permit naloxone distribution programmes, however, it is 
yet to be voted in by the House of Representatives and 
there appears to be a lack of political will to pass this 
legislation.(6)
Policy developments for harm 
reduction
Since Global State 2014, there have been few 
developments in harm reduction policy at national or at 
regional level in the Caribbean.
As mentioned above, in Puerto Rico, a Good Samaritan 
Bill to allow overdose prevention education and 
naloxone distribution was passed by the Senate and is 
pending a vote by the House of Representatives (P.S. 
1445).(6) In relation to wider drug policy developments, 
the potential decriminalisation of cannabis represents 
an important change in Puerto Rican legislation. A bill 
to eliminate criminal penalties for possession of small 
amounts of marijuana for personal use (P.S. 517) has 
been passed by the Senate and is pending a vote by the 
House of Representatives; a bill to legalise marijuana for 
medical purposes is also pending a vote by the House of 
Representatives (P.C. 1362); and a house bill to call for a 
referendum on the issues of marijuana decriminalisation 
has been submitted to a judiciary committee, but has 
not yet been voted on (P.C. 2172).(6)
In Jamaica, the House of Representatives passed a 
law decriminalising possession of up to two ounces 
of marijuana, and allowing for the cultivation and 
distribution of cannabis for medical and religious 
purposes.(45)
Harm reduction is mentioned as a key component of 
the national response to drugs in the 2014 version 
of the National Drug Policy of Trinidad and Tobago.(46) 
According to data gathered for this Global State report, 
this policy appears to be the region’s sole national policy 
relating to HIV and/or drugs to include harm reduction.
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Civil society and advocacy 
developments for harm reduction
Although policy changes are extremely slow, civil society 
action for harm reduction in the region continues to be 
at the forefront, advocating for change.
Intercambios Puerto Rico, in particular, has been a 
dedicated influential advocate of harm reduction in the 
region. In April 2013 it launched a campaign for the 
decriminalisation of people who use drugs, which was 
featured locally in over 30 radio shows, 16 television 
interviews, 8 newspapers and more than 56 online 
publications. In November 2014 the UNAIDS Programme 
Coordinating Board Thematic Statement for the meeting 
‘Halving HIV Transmission among People Who Inject 
Drugs’ held this campaign up as a successful example 
of pairing harm reduction services and advocacy 
to decriminalise drug use, and one that should be 
replicated.(6) This campaign has been central to the 
strengthening of drug policy discourse in the region, as 
well as serving to put public pressure on legislators to 
reduce or overturn the sentences of people imprisoned 
for possession of marijuana.(6)
In 2013 the Coalicion Puertorriqueña de Reduccion 
de Daños (CoPuReDa - Puerto Rican Coalition of 
Harm Reduction) began unifying four of the six NSPs 
providing services in Puerto Rico: Amore Que Sana, 
Casa Joven del Caribe, Intercambios Puerto Rico and 
Migrant Health.(6) The coalition advocates for better 
harm reduction policies and increased state funding for 
essential harm reduction interventions.
In April 2015 Intercambios Puerto Rico partnered with 
the Transnational Institute (TNI) and the Washington 
Office on Latin America (WOLA) to organise and host the 
first ‘Caribbean Drug Policy Dialogue’ in San Juan, Puerto 
Rico. The meeting focused on drug decriminalisation 
in the Caribbean and on the upcoming United Nations 
Special Session (UNGASS) on the drugs. Intercambios 
Puerto Rico was invited to speak at UNGASS as a 
civil society representative for Puerto Rico and the 
Caribbean, enabling it to raise awareness of the need for 
drug policy reform and improved harm reduction in the 
region at an important international forum. Increased 
involvement of Caribbean civil society in global drug 
policy discussions is an important step forward for the 
region, which can often be neglected in drug policy 
forums.(6)
In September 2015 Caribbean representatives from 
Intercambios Puerto Rico and COIN (Dominican 
Republic) joined LANPUD (Latin American Network of 
People Who Use Drugs) in a meeting held in Taganga, 
Colombia to raise awareness of the needs of people 
who use drugs within the region.
In October 2016 the Fifth Latin American and First 
Caribbean Drug Policy Conference was held in Santo 
Domingo, Dominican Republic, with local partner COIN, 
helping to ensure a focus on drug policies and harm 
reduction within the Caribbean. It was the first time this 
biannual conference had been held in the region.(6)
Funding developments for harm 
reduction
Harm reduction within the Caribbean has been largely 
funded by international donors. Although the Global 
Fund Round 9 signified an important advance for harm 
reduction funding in the region, much of this support 
ceased in 2014.(47) Within Puerto Rico, AIDS United 
provided financial support to three NSPs. However, this 
funding has been diminishing and the future of this 
support is uncertain. The other NSPs, supported by the 
Government of Puerto Rico, have already seen their 
funding suspended due to the country’s budgetary 
crisis.(6) Open Society Foundations (OSF) provided 
funding for advocacy against rights violations in drug 
dependence treatment and for harm reduction services, 
which will continue until 2017.(48) Intercambios Puerto 
Rico and CoPuReDa have been, and continue to be, 
involved in advocacy efforts with the Department of 
Health to increase funding for harm reduction services. 
However, the funds allocated to these vital services 
remain the same, with below US$750,000 being spent 
annually on HIV prevention, only US$135,000 of which 
is directed towards the three NSP programmes and 
HIV testing for people accessing NSP services.(6) It is 
interesting to note the vast difference between funds 
spent on reducing harms associated with drug use 
and those spent on punitive drug control measures. 
For example, the Puerto Rico Police received an 
annual budget of US$749,373,000 in 2014, but just 
US$2,500,000 of this was allocated to anti-drug 
operations and related costs.
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Table 2.5.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Latin America. 
Country/
territory with 
reported       
injecting drug 
use
People who 
inject drugs
HIV 
prevalence 
among people 
who inject 
drugs (%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among people 
who inject 
drugs (%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among people 
who inject 
drugs (%)
Harm reduction responsea
NSP OST
Argentina 65,829 (64,500 - 67,158)(2)b 3.5
(3) 4.8(4) 1.6(4) 3(5)c 7
Bolivia nk nk nk nk 7 7
Brazil 540,000(2) 5.92(6) 63.9d 2.3 3e 7
Chile 21,783(7)f nk nk nk 7 7
Colombia nk 2.7(8) nk nk 3(9) 7(5)g
Costa Rica nk nk nk nk 7 7
Ecuador nk nk nk nk 7 7
El Salvador nk nk nk nk 7 7
Guatemala nk nk nk nk 7 7
Honduras nk nk nk nk 7 7
Mexico 164,000(10) 2.5(10) 96 nk 3(5) 18(5)h  (M, B)
Nicaragua nk nk nk nk 7 7
Panama nk nk nk nk 7 7
Paraguay nk 9.35 (3.7-15)(11) 9.8 nk 3(7) 7
Peru nk 1(12) nk nk 7 7
Uruguay nk 0.2(13) 21.5(14) 19.5(14) 3(5) 7
Venezuela nk nk nk nk 7 7
 
nk = not known
a Unless otherwise stated, data has been sourced from Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment and care 
services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet. 2010;375(9719):1014-28.
b	 This	estimate	was	taken	from	1999	and	injecting	drug	use	is	thought	to	have	reduced	significantly	since	this	date.	However,	no	new	estimates	of	either	drug	use	or	injecting	
drug use have been undertaken in the country.
c The number of NSP sites has declined since the Global State last reported (n=25) with civil society reporting a decline in the number of people who inject drugs in Argentina
d Figure is taken from 2000/2001 and no recent estimate is available.
e The number of NSP sites are believed to have diminished from the 150-450 Global State estimate in 2012. No new estimate of NSP service provision is currently available
f	 Civil	society	organisations	believe	this	figure	to	be	an	overestimate.
g In Columbia, OST is being developed in Armenia, Bogota, Bucaramanga, Cali, Cucuta, Medellin and Pereira, but exact numbers of sites are unknown.
h Of the 18 OST sites, 17 are private clinics and 1 is government run.
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Map 2.5.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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Harm reduction in Latin America
Overview
There are an estimated 721,000 people who inject 
drugs in Latin America.(10) Prevalence of injecting drug 
use remains low although unsafe injecting has been 
associated with HIV and viral hepatitis transmission, 
particularly in northern Mexico, and in Colombia.(15, 16) 
Cocaine is more commonly injected than heroin in the 
region,(16) and non-injecting drug use primarily centres 
on cocaine and its derivatives (particularly the smoking 
of crack cocaine and pasta basei) which remain the most 
predominant drugs used in the region. In certain areas, 
such as Tijuana and Cd. Juarez in northern Mexico, 
injecting drug use has seen an increase, with an escalating 
HIV epidemic among people who inject drugs.(17)  
In Argentina, however, the estimated proportion of 
new HIV infections among people who inject drugs has 
reduced, going from 7.6% to 0.4% in 2013, indicating a 
decrease in people who inject drugs in the country.(10) 
It is important to note that due to the lack of data, the 
figures included in Table 2.5.1 may not reflect overall 
prevalence of injecting drug use across the region,(5, 18) 
as they are based primarily on data from the Reference 
Group to the United Nations on HIV and Injecting 
Drugs Use collected in 2008.(2) There is a clear need for 
updated research on the numbers of people who inject/
use drugs in this region.
According to a recent report by UNAIDS, HIV among 
people who inject drugs averages 2%,(19) with a 0.3% 
incidence of new HIV infections among this population 
each year.(10) However, these rates can vary greatly 
between countries and reliable figures on incidences of 
HIV, viral hepatitis and tuberculosis (TB) among people 
who inject/use drugs are extremely limited. The latest 
figures from Brazil report HIV prevalence among people 
who inject drugs at 5.9%, yet this reflects data published 
in 2009. 
The Brazilian Ministry of Health reports there has been 
a statistically significant decreasing trend of HIV among 
people who inject drugs between 2004-2013.(6)  The use 
of crack and other coca derivatives (e.g, coca paste), is 
growing. Brazil is reported to have one of the world’s 
largest crack markets, which may comprise of up to 1 
million people,(20) with research finding levels of HIV at 
approximately 23% among people who smoke crack 
cocaine.(21, 22) In the previous edition of the Global State, 
it was reported that the non-governmental organisation 
É de Lei of São Paulo had been distributing new crack 
pipes as a harm reduction response.(23) However, civil 
society organisations report crack pipe distribution 
as part of this project has now been halted.(18) Other 
initiatives, such as the “Braços Abertos” (Open Arms) 
programme which aims to reduce the significant health, 
social and security problems in Cracôlandia, a huge open 
crack scene in Sao Paulo, Brazil, which was launched by 
the Sao Paolo City Council in 2014. This project offered 
people living in the “favela” (slum) housing in one of the 
motels contracted by the government, without requiring 
abstinence from crack use as a precondition of housing. 
Program participants are given access to health care, 
receive three meals a day and the opportunity to work 
cleaning parks and other public places. Information is 
provided about existing treatment programs and other 
services, but there’s no obligation to use them. Thus far 
the programme has made a significant impact on health 
outcomes,(24) and the Brazilian government announced 
plans to support reproduction of the program in other 
Brazilian cities in 2015. In Sao Paolo, however, a newly 
elected Mayor declared shortly after winning that he 
would close Bracos Abertos.(25)
Injecting drug use does occur in Mexico, and has 
increased since the Global State last reported,(26) yet the 
harm reduction response in terms of needle and syringe 
programmes (NSP) or opioid substitution treatment 
(OST) has decreased following cessation of Global Fund 
support to the country.(18, 27) An increase in polydrug use 
has been observed, particularly in the Northern border 
cities such as Tijuana,(28) with methamphetamine use 
continuing to expand.(29, 30) 
Harm reduction services at raves and festivals are being 
increasingly practiced via civil society organisations, with 
substance analysis taking place to ensure drugs are safe, 
general information regarding drug use is offered, and 
psychological support is given for people experiencing 
psychological difficulties.(31) Since 2012, Échele cabeza 
cuando se de en la cabeza (or, Use your head before it 
goes to your head), a project of Acción Técnica Social 
(ATS) has been implementing harm reduction services 
and substance analysis in festivals and raves. They have 
analyzed more than 2,000 samples and have witnessed 
a decrease in the adulteration of MDMA/ecstasy pills by 
25%. During this time, ATS has also emitted 17 health 
alerts to bring attention to the adulteration of cocaine, 
fake LSD and 2CB.  These alerts were shared more than 
45,000 times on social media and taken up by both print 
and television media.(32)
i Also known as paco and basuco, pasta base is a paste that is produced in the intermediate stages of cocaine preparation, and is marketed as a cheaper alternative to pure 
     cocaine in a number of Latin American countries.
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Harm reduction services such as these demonstrate 
Mexico and Colombia’s policy shift away from 
punitive responses to drug use and further towards 
decriminalisation. However, reports suggest that these 
changes to laws have not translated into reduced arrests 
or incarceration in many instances, and services are 
primarily being undertaken without the support of the 
government.(32, 33) There is still some way to go until harm 
reduction services are scaled-up to meet needs.
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
NSP services for people who inject drugs in Latin 
America continue to be extremely limited, and since 
the previous edition of the Global State, coverage 
has reportedly diminished.(18) It is important to note, 
however, that the majority of substance use in the 
region relates to the use of cocaine and its derivatives, 
which are often smoked. In some cases coverage of NSP 
services are believed to have declined due the reduction 
in the number of people who inject drugs, for example, 
in Argentina,(10) Brazil and Uruguay.(5, 34) However, up 
to date estimates on the number of people who inject 
drugs in much of Latin America is unavailable. Of the 12 
countries in the region that report injecting drug use, 
only six operate NSPs (see Table 2.5.1).
Colombia began implementing a mobile health service 
through the Medical Care Centre for Drug Addicts 
(CAMAD), which targeted people who inject drugs. 
However, this service has since closed.(8) Support from 
Open Society Foundations helped establish a syringe 
programme in Pereira and Dos Quebradas in 2014,(8) 
with 818 people who inject drugs registered in the 
programme.(5) Further NSPs have since been developed 
by NGOs with support from the Ministries of Justice and 
have begun operating in Bogotá and Cali(5) However, the 
services available for people who inject drugs remain 
limited, and are often unavailable outside of city centres. 
A study undertaken in Colombia in 2016 observed a 
high rate of new injector initiation and the sharing of 
products used to clean syringes, noting HIV prevalence 
rates among this population of 2.7% in Medellin and 
Pereira.(8) Due to a lack of knowledge regarding safe 
injecting practices, and limited harm reduction service 
provision, these figures are expected to rapidly increase.
(8) In light of this, is it essential that NSP continue to be 
implemented in the country.
In Mexico, the sale of needles is legal and does not 
require a prescription. However pharmacists often resist 
sales to people who inject drugs.(16) UNAIDS reports that 
the number of needles and syringes has increased in 
Mexico, going from 3.9 per person who injects drugs 
per year in 2014,(35) to 7.2,(10) a figure which is still low in 
terms of provision.(36) However, NGOs in Tijuana and Cd. 
Juarez report that distribution of needles and syringes 
per person who injects drugs fell by between 60 to 90% 
following cessation of Global Fund support. Funding 
cuts also meant that outreach was reduced, requiring 
people who inject drugs to come to NGO offices, rather 
than receiving sterile injecting equipment where they 
are.  Even the limited level of existing harm reduction 
services has relied partly on commodities donated by 
organisations ceasing operations after the withdrawal of 
the Global Fund.    
Redumex, a network of organisations working to reduce 
HIV among people who inject drugs, report a reduction 
in the amount of needles distributed, with women 
experiencing more pronounced inaccessibility to NSPs 
due to greater stigma.(34) 
In the countries where NSP provision is available, many 
people who inject drugs are deterred from accessing 
services due to restricted opening hours, long waiting 
times, insufficient resources, criminalisation of drug use 
and inadequately trained service providers.(18, 34) Further 
research, advocacy and service provision is necessary 
in the region to ensure people who inject drugs have 
appropriate access to safe injecting equipment.
Opioid substitution therapy (OST)
Of the 17 countries where injecting opioid use has 
been reported, civil society organisations note that 
only Mexico, Colombia, Argentina and Brazil provide 
OST to people who inject drugs and/or use opiates, 
primarily in the private sector.(5) Of these, only Colombia 
and Mexico provide OST outside of the private sector, 
with Mexico having one government facility providing 
methadone for people who use opiates compared to 
17 private OST sites. In Colombia, publicly available 
OST sites operate across seven cities: Bogotá, Medellin, 
Cali, Pereira, Armenia, Cúcuta and Bucaramanga.(37) 
However, the number of sites available is unknown. 
As a controlled medicine, several countries in Latin 
America, such as Mexico, Guatemala, Bolivia, El Salvador, 
Honduras and Colombia have requirements that impede 
access to opiates as a form of OST in hospital-based 
services, often requiring four doctors to sign an opiate 
prescription.(38)
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In Argentina, opiate use is reportedly rare, but OST can 
be made available at some public hospitals based on 
results from toxicology services,(39) and a methadone 
programme was initiated in 2015.(40) Given that opiate 
use, although not common, is apparent in the region, a 
scale-up of OST provision continues to be necessary.(34) 
In Brazil, there are no public methadone programmes 
integrated within the healthcare system, but methadone 
can be obtained through private clinics.(5)  
 
Human rights, ‘treatment’ and 
harm reduction in Latin America 
 
Abstinence-oriented drug treatment services for 
people who use opiates continue to remain the norm 
in the region. Such interventions have been found to 
be effective for only a small minority of people who 
inject opiates, with harm reduction services, such as 
OST, widely acknowledged as the preferred first line of 
treatment.(36, 41) 
Mexico has approximately 2,000 registered residential 
abstinence-focused treatment centres and a reported 
35,000 people who use drugs placed in centres that 
operate outside the law.(42) Many of the unregistered 
centres have no medical personnel, and no medications 
for withdrawal like opioid substitution therapy.(43) It 
has recently been reported that treatment can consist 
of inhumane acts such as forcing people to eat their 
own vomit, and to eat food from the container where 
they urinate or defecate.(43) Reports also suggest that a 
‘spiritual patrol’ operate, in which people who use drugs 
are often forced into church-run treatment centres.(44) 
Centres such as these are not unique to Mexico. In 
Guatemala many people who use drugs end up in 
private Pentecostal rehabilitation centres rather than 
prisons.(45) And the US and Caribbean also contain 
organisations operating unorthodox and zero tolerance 
faith-based rehabilitation centres, using methods not 
based on the scientific evidence of harm reduction 
or substitution therapy, but instead preferring 
‘confrontational therapy’ which sometimes involves 
sessions throughout the night over 12 hour periods 
with buckets of icy water thrown at the participant.(45) 
Both registered and unregistered centres in the region 
receive little government supervision, and often violate 
the rights of people who use drugs, such as the right to 
be free from cruel and inhuman or degrading treatment.
(45, 46) 
 
In 2016, the Community of Latin American and 
Caribbean States (CELAC), adopted the Quito 
Declaration. Drug policy officials highlighted the need to 
incorporate the principles of the Universal Declaration of 
Human Rights into drug conventions in a comprehensive 
way, concentrating on policies which centre on citizens 
well-being.(47) The implications of the Declaration could 
significantly improve drug treatment centres if actioned.
 
Viral hepatitis
Data on viral hepatitis among people who inject drugs in 
Latin America is sparse and often out of date.  Argentina 
is believed to have the lowest prevalence of hepatitis C 
among people who inject drugs in the region, at 4.8%(7) 
and Mexico the highest, at 96%.(1) In Brazil, prevalence 
rates for hepatitis C were recorded as 28.9% among 
people who inject drugs in 2011.(48) The figures cited are 
from data published in 2009 and 2005 respectively, and 
since the Global State last reported in 2014, there are no 
updated estimates available for Latin America. 
A 2002 study in Buenos Aires and Montevideo, 
highlighted the vulnerability to infection among people 
who use drugs but do not inject, through practices such 
as sharing straws, and emphasised the need for harm 
reduction services tailored to them in Latin America(49)  
In 2011, the Buenos Aires provincial ministry of health 
launched the Programme for Prevention and Detection 
of Viral Hepatitis to work in conjunction with the 
HIV/AIDS and Sexually Transmitted Infections (STIs) 
Programme. However, civil society organisations contest 
the levels of access to hepatitis C testing and treatment 
said to be available across the country.(50) Mexico is 
currently drafting a national viral hepatitis programme 
with REDUMEX as one of the consultants, it is expected 
that the plan will be complete by the end of 2016.(34) 
Tuberculosis (TB)
Previous evidence has suggested that tuberculosis (TB) 
rates in countries such as Brazil are extremely high, with 
44 cases per 100,000 people in the general population 
in 2014,(51) a marginal decline since the Global State 
last reported.(26) Although research on TB prevalence 
among people who use drugs in Latin America is lacking, 
there is evidence to suggest that they are experiencing 
elevated TB infection rates,(52) perhaps as a result of 
disproportionate rates of incarceration or detention in 
treatment facilities lacking TB control.
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Most Latin American countries offer HIV testing to 
anyone presenting with TB. However, as in other regions, 
prevalence figures do not detail what proportion of 
infections are among people who use drugs or who 
inject drugs. Moreover, whilst diagnosis services 
are available across the region, access to these is 
inconsistent for people who use drugs.(5)  
 
Antiretroviral therapy (ART)
In a recent report, UNAIDS noted that coverage of 
antiretroviral therapy (ART) for people living with 
HIV in Latin America was 55%,(19) a decrease of 8% in 
comparison to 2010.(15) Latin America has the highest 
total spend on ART among low- and middle-income 
countries, at just under US$800 million.(53) Argentina, 
Brazil, Chile, Cuba, Guyana, and Mexico all achieved 
universal access to treatment for HIV in 2012.(54) 
However, access for people who inject/use drugs 
remains unclear in many of the aforementioned 
countries.
Although Brazil has a well-documented treatment 
system with high coverage rates and free ART, a 2011 
study noted that many people who inject drugs had 
failed to initiate ART due to a lack of access to HIV 
testing and stigma surrounding injecting drug use.(55) The 
criminalisation of drug use continues to greatly restrict 
access to services and treatment adherence among 
people who inject drugs, although figures relating to 
rates of service provision among key populations are 
severely lacking. Further research on the availability 
of ART for people who use drugs in Latin America is 
urgently needed. 
 
Harm reduction in prisons
Despite the gradual trend towards decriminalising drug 
use and possession for personal use in the region, the 
cultivation and distribution of drugs - including for very 
small quantities - continue to be heavily criminalised. As 
a result, people who use drugs continue to be treated 
as criminals, and frequently end up being prosecuted as 
traffickers. Currently, approximately one in five prisoners 
are detained in the region’s grossly overcrowded 
criminal justice system for drug-related offences, many 
of them in pre-trial detention facilities where they can 
wait years before being sentenced.(56, 57) Drug-related 
incarceration rates have grown in most countries in 
the region in recent years.(56) In Mexico, for example, 
the number of people held for drug-related offences 
increased by 1,200% between 2006 and 2014,(56) while 
in Brazil it has gone up by 211% since 2005.(58) This 
punitive approach to drugs has been shown to have 
a particularly disproportionate impact on women in 
the region. Currently, more than 60% of the female 
prison population in Argentina, Brazil, and Costa Rica is 
incarcerated for drug-related offences, the majority of 
whom are single mothers.(59)
Despite the lack of data on the issue, injecting drug use 
in prison has recently been reported in some countries 
in the region, including in Mexico(60) and Brazil.(61) 
Similarly, despite the persistent scarcity of research on 
HIV, HCV and TB in Latin American prisons, prevalence 
rates are still reported to be much higher (up to 25% 
in some countries) in prisons than in the broader 
community.(62) A recent systematic review of the global 
burden of HIV, HCV and TB among prisoners found that 
prevalence rates among prison populations in Latin 
America are 2.3%, 4.7% and 1.9% respectively.(63) At the 
national level, a recent study in Mexico revealed that 
the prison population was six times more likely to be 
living with HCV, and that HIV prevalence was 0.7% higher 
among prisoners than the broader community.(60) In 
Argentina, HIV prevalence is reportedly more than seven 
times higher in prisons,(64) while in Brazil, HIV prevalence 
among prisoners is reported to be between three and 
16%,(65) and a recent systematic review found the mean 
prevalence of HCV to be 13.6% among prisoners.(66) 
Despite the clear need for comprehensive harm 
reduction service provision in prisons in Latin America, 
the regional response remains the weakest in the world. 
Available data (or lack thereof) suggest that NSPs, OST 
and harm reduction approaches to cocaine use continue 
to be entirely absent in Latin American prison settings, 
in violation of public health and human rights standards. 
Research on prison-based testing, treatment and care of 
HIV, HCV and TB is still scarce, but existing data suggest 
the availability and accessibility of these services vary 
between and within countries. A recent cross-sectional 
study of prisoners in Mexico City, for example, revealed 
that there is no routine testing for communicable 
diseases on entry to prison,(60) and that prisoners are 
only tested for HIV, for example, when prison healthcare 
staff suspect infection.(60) According to Mexican civil 
society organisations, HIV, HCV and TB treatment and 
care are only sometimes available within prisons and 
condom provision tends to be unreliable due to a lack 
of resources.(18) In Brazil, HIV testing and condom use 
are reported as being irregular, which may in part be 
due to the stigma associated with HIV status in prisons.
(61) Thanks to standardised treatment guidelines in that 
are used in both prison and community settings, access 
to HIV-related medical services in Argentinian prisons is 
considered widespread, and prisoners reportedly feel 
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confident they will continue to receive these services 
upon release.(64)  
Alongside the obvious and urgent need to scale 
up prison-based harm reduction in the region in 
accordance with international human rights and 
public health standards, more systematic research is 
desperately required to help ensure that prison-based 
harm reduction policies and programmes, when they 
are developed and implemented, are as effective as 
possible. 
 
Overdose
As mentioned in The Global State of Harm Reduction 
2014, there is no official support for overdose 
prevention programmes in the whole of Latin America. 
One of the central issues amongst people who use/inject 
drugs is the fear of arrest when seeking medical care or 
attention.(34) 
Naloxone, a highly effective opioid antagonist used to 
reverse the effect of overdose, is generally unavailable 
in Latin America except in hospitals. Naloxone is made 
available by the federal government in Mexico, but 
has been consistently undersupplied, with paramedics 
lacking it as part of their basic medical kit.(18) In Colombia, 
a study undertaken in 2012 noted that in both Pereira 
and Medellin, six out of ten people who use drugs 
revealed they would not access healthcare services if 
they had another overdose for fear of referral to law 
enforcement authorities.(67) During 2014-2015, civil 
society organisations began building capacity and 
training to increase the use of Naloxone in Colombia. 
Since then, 84 doses of Naloxone have been distributed 
and have been effectively used 49 times by people 
experiencing an overdose.(32) 
 
Policy development for harm 
reduction
Several Latin American countries are slowly seeing a 
policy shift away a punitive approach to drug use and 
towards a model that favours health and human rights. 
In August 2009, Mexico’s federal government partially 
decriminalised the possession of small quantities of 
drugs such as cannabis, cocaine, amphetamines and 
heroin, with people being diverted to treatment services 
or OST, rather than criminalised.(33) As previously noted, 
however, this has yet to reduce incarceration or arrest 
rates. In 2011, Bolivia denounced the 1961 Single 
Convention on Narcotic Drugs, reassessing it with a 
reservation allowing the traditional use of the coca leaf 
domestically, enabling indigenous communities to legally 
cultivate and use the leaves.(68) In 2013, the Government 
of Uruguay passed legislation to regulate state-
controlled sales of cannabis becoming the first country 
in the world to do so,(69) and the National Strategy on 
Drugs 2016-2020 advanced the development of an 
alternative model using risk and harm reduction as the 
basis for a new approach to the use of drugs. Colombia 
has also begun defining guidelines for a new approach 
to drug policy which promotes human rights and social 
inclusion.(70) However, the recent referendum on the 
peace process in Colombia is believed to have had a 
significant impact on advocacy as well as policy reform in 
the future.(71)
In April 2016, during the United Nations General 
Assembly Special Session (UNGASS) on drugs in  
New York, Brazil, Costa Rica, Colombia and Uruguay all 
made statements in explicit support of harm reduction.(72)  
The Research Consortium on Drugs and the Law 
(Colectivo de Estudios Drogas y Derecho – CEDD), 
incorporating researchers from nine Latin American 
countries (Argentina, Bolivia, Brazil, Colombia, Costa Rica, 
Ecuador, Mexico, Peru and Uruguay) was established 
in 2010. CEDD seek to foster debate in the region 
regarding the effectiveness of current drug policies and 
recommend more feasible policy alternatives given the 
increasing and unmanageable rate of incarceration for 
drug offenses in Latin America.(73) 
An important development emerged during the 55th 
Directing Council 68th Session of the Regional Committee 
of WHO (World Health Organisation) for the Americas, 
held in September 2016, which included non-injecting 
drug users as a key population group within the new 
Plan of Action for the Prevention and Control of HIV and 
Sexually Transmitted Infections 2016-2021.(74)
Civil society and advocacy 
developments for harm reduction 
 
One of the challenges increasingly recongised by civil 
society groups in Latin America is the integration of 
harm reduction into drug services as a cost-effective 
and human rights based approach.(75) In light of this, 
the Civil Society Task Force – established as the official 
NGO (Non-Governmental Organisation) engagement 
mechanism in the run up to the United Nations General 
Assembly Special Session (UNGASS) on the drugs – 
surveyed a number of NGOs actively engaging with 
people who use drugs to urge governments to respond 
to the different forms of drug consumption in the region 
using a harm reduction approach.(75) This sentiment 
was echoed by the Latin American Network of People 
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Who Use Drugs in their contribution to the UNGASS, 
together with Caravan for Peace, Life and Justice, a large 
organisation of networks and activists highlighting the 
growing discontent with the effects of the drug war.(76, 
77) In 2015, in Sao Paulo, a Regional Dialogue on HIV and 
Drug Policy, organised by the United Nations Office on 
Drugs and Crime (UNODC) and involving civil society 
took place, with the objective of offering technical 
assistance to participants contributing to the ongoing 
regional, national and international level discussions in 
the approach to the UNGASS. 
In Argentina, to develop a harm reduction perspective 
and facilitate access to health services, training 
workshops on the accessibility of drug users to health 
services was undertaken with support from the UNODC, 
and co-organised by the National Direction of AIDS and 
STD and local government. Intercambios developed 
the workshops in seven Argentine provinces and the 
deferral penitentiary system in order to improve health 
providers’ practices, aiming to build capacity among 
health and social teams and enabling better access for 
people who use drugs.(78) In August 2016, the Argentinian 
civil society organisation Associación Pensamiento Penal 
(APP) introduced a Declaration endorsed by more than 
550 Argentine magistrates, judges and lawyers calling 
on the government to redraw its policy on narcotics 
and end the ‘War on Drugs’.(79) It is estimated that 
approximately 70% of cases pending before the Federal 
Courts relate to possession of drugs for personal use(79) 
Mexico, too, is resuming its leadership between the 
federal government, civil society organisations, and local 
governments to carry out a more coordinated approach 
to harm reduction.(34) 
In October 2012, the Latin American Network of People 
who Use Drugs (LANPUD) was formed.(26) Since then, 
the regional Harm Reduction Network of the Americas 
(which include Colombia, Brazil, Canada, United States, 
Mexico) has been formed, and country level groups are 
in development such as the Mexican Harm Reduction 
Coalition.(18) The ‘Support Don’t Punish’ campaign, a 
global advocacy campaign which occurs every year 
on 26 June and calls for drug policies to be based on 
health and human rights, has been growing throughout 
Latin America. It is receiving greater support and 
raising awareness of harm reduction and the need to 
end repressive policies against people who use drugs, 
subsistence farmers and vulnerable groups.(18) 
Harm reduction as a concept is expanding within Latin 
America, with organisations questioning the impact not 
only of drug use, but also the negative impacts of the 
current policies. As a means of addressing these policies, 
including violence, corruption and widespread human 
rights violations, organisations are diversifying their 
partners to include victims and ensure that their voices 
are heard within the drug policy debate. In addition to 
seeking new ways of addressing the increasing levels 
of stimulant consumption, the increase in the use of 
substance analysis services in nightlife spaces provide 
an innovative opportunity to reach young people and 
people who use drugs. There is a clear recognition by 
civil society organisations that most people who use 
psychoactive substances do so without generating any 
problematic use and therefore must be provided with 
information, harm reduction services and improved 
quality of access. Responsible consumption as a concept 
is gaining force amongst a new generation that seeks 
direct information and political and social mechanisms 
through which they can contribute.(32, 71) 
 
Funding developments for harm 
reduction
As previously reported, much of Latin America has 
received limited international donor support for their 
harm reduction initiatives.(26) The Global Fund, one of 
the primary donors in the region, has allocated funding 
in Colombia and Paraguay.(5) Open Society Foundations 
have also provided harm reduction funding in the 
region, and the Levi Strauss Foundation have supported 
similar initiatives in Argentina.(5) However, the Global 
Fund is no longer providing funds for harm reduction, 
and other international organisations have continued to 
reduce resources.(18) 
Civil society organisations report that one of the main 
issues regarding HIV funding is the focus on injecting 
drug use rather than stimulant-oriented non-injecting 
and poly-use consumption patterns which occur to 
a greater extent in the region.(28) This has left many 
innovative harm reduction approaches, for example 
cannabis as a substitute for crack use, overlooked and 
lacking financial support.(18) Donors are increasingly 
restricting resources for middle-income countries, and 
the sustainability of many harm reduction projects in 
Latin America is therefore at risk.(5) With an estimated 
2% of HIV prevention investment directed towards 
key populations in the region,(80) it is imperative that 
government support increases, as it has been in 
Colombia and Uruguay, where the governments have 
increasingly begun to advocate for harm reduction, and 
now provide state funding to support operational and 
administrative aspects of various projects.(18)
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Table 2.6.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in North America
a	 There	are	no	identified	reports	of	injecting	drug	use	in	Greenland.
b	 	The	number	in	brackets	represents	the	number	of	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	
outreach workers.
c The number in brackets represents the number of operational OST sites, including publicly and privately funded clinics and pharmacy dispensing programmes. (M) = 
methadone,	(B)	=	buprenorphine,	(BN)	=	buprenorphine–naloxone	combination,	(O)	=	any	other	form	(including	morphine	and	codeine).
d DCR = drug consumption room, also referred to as a safer injecting facility (SIF).
e	 It	has	been	reported	that	over	2	million	people	who	inject	drugs	reside	in	North	America,	with	both	figures	for	Canada	and	the	United	States	believed	to	be	underestimates.
f Year of estimate: 1992.
g These services operate in 35 of the 50 states, which include Puerto Rico. Figure from 2016. 
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Map 2.6.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
Both NSP and OST available
OST only
NSP only
Neither available
Not known 
DCR available
CANADA
UNITED STATES
GREENLAND
1002.6 NORTH AMERICA
Harm reduction in North America
Overview
There are an estimated 2 million people who inject 
drugs in North America, of which 90% currently live in 
the United States.(4) Approximately 3.6% of people who 
inject drugs in the US are living with HIV, 80% of whom 
are also co-infected with hepatitis C (HCV).(4) In Canada, 
11% of the estimated 90,000 people who inject drugs 
are living with HIV.(3, 4) National estimates, however, 
suggest the number of people who inject drugs newly 
infected with HIV in Canada is declining.(2) While the 
total number of new HIV infections is declining in the US 
thanks to HIV testing remaining stable or increasing in 
recent years, progress has been uneven and diagnoses 
have increased among some key populations.(8) The 
most explosive HIV outbreak on record, for example, 
occurred in 2014/2015 and was associated with injecting 
drug use.
The election of a new federal government in Canada in 
October 2015 has ushered in the prospect of drug policy 
reform in the country, with harm reduction adopted as 
a pillar in its response to drugs. Although the US has not 
embraced harm reduction in quite the same way, it does 
appear to be adopting more of a public health approach 
than in previous years. 
Key harm reduction services, such as needle and 
syringe programmes (NSPs) and opioid substitution 
therapy (OST), are available to people who inject drugs 
in both countries, but barriers to access persist and 
service provision remains uneven. The region’s most 
marginalised and stigmatised populations, including 
prisoners, racialised and Indigenous communities, 
continue to be the most disproportionately affected by 
these disparities. 
The prevalence of opioid use in North America remains 
high (3.8%) in relation to the global average,(9) and the 
region continues to experience the world’s highest  
drug-related mortality rate in the world.(10) The 
magnitude of the epidemic has forced leaders in both 
countries to intensify their responses, resulting in a 
number of positive developments since 2014, including 
a dramatic increase in naloxone coverage on both 
sides of the border. Civil society continues to be very 
active and has played a key role in the numerous harm 
reduction victories achieved since the Global State last 
reported in 2014. 
Developments in harm reduction 
implementation 
 
Needle and syringe programmes (NSPs)
NSPs are available in both Canada and the US. Although 
the exact number of NSPs operating in Canada is not 
known, it is estimated that 94.5% of people who inject 
drugs used sterile injecting equipment at last injection.(4)  
In the US, 244 NSPs are now operating across the 
country,(11)h representing a 25% increase since the Global 
State last reported in 2014. In reality, however, with 
several NSPs operating clandestinely in those states 
where punitive environments prevail, these figures are 
likely to be higher. 
This increase in NSPs in the US has in large part been 
driven by a dramatic HIV outbreak in rural Indiana in 
2014/2015 associated with injecting drug use. In less than 
12 months, 181 cases of HIV infection were documented 
in a town with a population of 4,300 - one of the highest 
incidence rates ever recorded.(12) In the wake of this public 
health emergency, the federal government changed its 
legal position on NSPs, resulting in a partial repeal of the 
28-year ban on federal funding for NSPs. While the use of 
federal funds to purchase sterile needles or syringes to 
inject illegal drugs remains prohibited, the Consolidated 
Appropriations Act, 2016, passed by Congress in 
December 2015, enables federal funds to be allocated 
to other aspects of NSPs, including HIV and HCV testing, 
naloxone provision, human resources, rent, and other 
expenditures needed to keep them in operation.(13-15)
Despite these developments, NSP coverage in the US 
remains low. According to UNAIDS, 50 syringes are 
distributed per person who injects drugs per year, and 
only 35% of people who inject drugs are believed to 
have used sterile equipment in the past 12 months(4) 
According to civil society, people who inject drugs 
in both the US and Canada continue to come up 
against several barriers to accessing this service. Fear 
of stigma and discrimination, for example, impedes 
access, particularly in rural or remote communities 
where there is a heightened risk of being identified. In 
Canada, some municipal bylaws and other legal barriers 
reportedly continue to prevent NSPs from operating 
within particular communities which, again, tends to 
disproportionately affect people who inject drugs in 
rural and remote communities, as well as Indigenous 
(First Nations, Métis and Inuit) communities.(16) 
h Only in 35 states, the District of Columbia, Puerto Rico, and the Indian Nations. For more info, see North American Syringe Exchange Network. Directory of Syringe Exchange 
 Programs. Available at: https://nasen.org/directory.
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Meanwhile, in the US, drug law enforcement is often 
responsible for hindering access to NSPs, even where 
these are legally sanctioned. Five years ago, a national 
survey revealed that nearly 50% of NSPs reported 
that their clients experienced police harassment on 
at least a monthly basis.(17) A recent study on police 
encounters among NSP clients in Baltimore confirms 
that this harmful practice continues today. The study 
found that even under a favourable policy and legal 
regime, police continue to unlawfully confiscate injecting 
equipment and interfere with the functioning of NSPs, 
with non-white clients more likely to report confiscation 
of injecting equipment or arrest.(18) Adversely affecting 
both the behaviour and health of people who inject 
drugs, drug law enforcement is evidently an important 
determinant of health for this population, and 
particularly for marginalised groups within it. In order to 
ensure the full uptake and impact of NSPs, policing as 
a barrier to access should be urgently addressed in the 
country.  
 
Opioid substitution therapy (OST)
Like NSPs, OST is available in both Canada and the US. 
In Canada, methadone and suboxone are available to 
people who use opioids.(16, 19) In Ontario, Canada’s most 
populous province, the number of people receiving 
methadone was just under 50,000 in 2014, up from 
29,000 in 2010.(20) A comparable number of people are 
currently also receiving OST in the provinces of British 
Columbia, Saskatchewan and New Brunswick.(21) In light 
of a staggering number of opioid overdoses across 
the country in recent years, however, there have been 
calls to scale-up OST provision across the country.(16) 
Following a legal challenge, the federal government took 
an important step on 7 September 2016 by officially 
overturning the ban on heroin-assisted therapy (HAT).(22)  
Under the new regulations, physicians can prescribe 
pharmaceutical-grade heroin to individuals for whom 
it is clinically indicated, including those have tried other 
approaches, such as methadone and buprenorphine, 
without success.(23)
In the US, the 2015 National Drug Control Strategy 
affirms the government’s commitment to ensuring 
access to evidence-based treatment models, including 
OST(24) and methadone or buprenorphine is currently 
available in 48 states, as well as in Washington DC. 
Regrettably, the service remains completely unavailable 
in North Dakota and Wyoming.(15) According to the 
most recent data, 382,237 people are enrolled in OST 
in the country.(4) Unsurprisingly, the number of private, 
for-profit facilities providing methadone has been 
increasing, with 60% of people who received methadone 
in 2012 receiving it from this type of facility.(25) 
Despite these services being available, several barriers 
continue to limit their accessibility throughout the 
region. In the US, these are typically associated with 
unreasonable cost and lack of health care coverage.(26) 
In Canada, obstacles range from unaffordable user or 
clinic fees, long waiting lists, restrictive directly-observed 
therapy requirements, lack of access to take home 
doses, and municipal resistance to the operation of OST 
clinics materialising in zoning bylaws and other legal 
barriers.(16, 19) One other serious obstacle to accessing 
OST in Canada is the limited number of physicians 
able to prescribe OST, coupled with their geographical 
inaccessibility, which disproportionately affects 
Indigenous and other rural or remote communities. 
Recent advances in telemedicine-delivered OST in 
Ontario, whereby physicians prescribe OST through 
telecommunications technology, are encouraging, 
however, and experts believe this trend could be 
adopted by other provinces in the near future.(21)  
 
Drug Consumption Rooms (DCRs)
Drug consumption rooms, generally known as safe 
injection facilities or sites (SIFs/SISs) in North America, 
are professionally supervised healthcare facilities 
where people can consume drugs in a safe and non-
judgmental environment. Since the Global State last 
reported, one additional DCR – the Dr. Peter Centre 
– received a two-year stamp of approval from the 
Canadian government to operate legally in Vancouver, 
bringing the total of authorised DCRs in the region 
to two. With so many people injecting drugs in North 
America and so few sanctioned DCRs, coverage is 
currently virtually non-existent, particularly since both 
facilities are located in Vancouver. Several cities across 
Canada, however, now have firm plans to establish 
DCRs. Toronto, for example, is in the process of applying 
for legal exemption to open three facilities.(19) While 
Canada has become much more amenable to the idea 
of DCRs since 2015, having recently approved a 4-year 
extension for Insite to continue operating its DCR, the 
new federal government has defended the Respect for 
Communities Act, a law which requires a minimum of 
26 conditions to be met before the federal Minister 
of Health may even consider allowing an exemption 
for a DCR to legally operate. Regrettably, the current 
government has not taken firm steps to repeal or amend 
the law.(16, 19)
While there are still no DCRs in the US, some recent 
initiatives are worth mentioning. For example, in 
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September 2015, the Harm Reduction Coalition, with 
OSF and the American Foundation for AIDS Research, 
convened a consultation on alternatives to public 
injecting.(15) Experts from several countries shared their 
various DCR models, planning and policy development 
processes, implementation challenges and evaluation 
results, with participation from a broad range of 
stakeholders, including government representatives, 
advocates for people who use drugs, service providers 
and law enforcement.(27) Also in 2015, a community-
based NSP modified a bathroom to accommodate 
safer drug consumption and then shifted to opening a 
supervised injecting room.(15) Although service delivery 
was limited in a number of ways due to the illegal nature 
of the DCR, both models were evaluated to determine 
and compare the benefits and challenges in how each 
operated. The study has now officially come to an end 
and the results will soon be published. In terms of legal 
and policy developments, DCR bills have now been 
introduced in the states of Maryland and California, and 
there have been discussions around introducing one in 
Seattle, too.(15) Finally, New York City Council Preliminary 
Budget for 2017 includes a US$100,000 for an impact 
study on instituting DCRs in New York City.(28) 
Viral hepatitis
Viral hepatitis among people who inject drugs continues 
to be a major public health concern in North America. In 
the United States, there are between 2.7 to 4.7 million 
people living with chronic hepatitis C virus (HCV),(29) 
and an estimated 30,000 new cases are acquired each 
year,(30) making HCV the largest on-going infectious 
disease epidemic in the country. Injecting drug use 
remains the most common risk factor for acquiring HCV 
in the US, accounting for more than 50% of all American 
cases.(31) Nearly 75% of people living with HIV who inject 
drugs are also living with HCV, which more than triples 
their risk for liver disease, liver failure and liver-related 
death.(32) In recent years, an emerging HCV epidemic 
among young people who inject drugs has been 
reported in rural and suburban settings in the US(30, 33-35) 
Those most likely to be affected have been identified as 
being 25 years of age or younger, primarily white, both 
male and female, residing in non-urban areas, having 
used oral prescription opioids (e.g. oxycodone) before 
transitioning to injecting heroin, and highly mobile, 
often making them more difficult to locate.(30, 36) There 
is a growing concern that this emerging epidemic could 
begin to reverse the decline in overall HCV incidence 
and prevalence observed in the country over the past 
two decades.(36)
According to the latest modelling, approximately 
252,000 Canadians were chronically infected with 
HCV in 2013.(37) Similar to the US, sharing injecting 
equipment is considered the most significant mode of 
HCV transmission in the country,(38) accounting for over 
60% of newly acquired HCV infections each year.(39) A 
considerable proportion of people living with HCV are 
also living with HIV. Canadian studies conducted among 
people who inject drugs have reported HCV and HIV co-
seropositive infection at approximately 10%.(3)
Despite the lack of data on testing and treatment 
coverage in the region, the considerable barriers 
standing between people who use drugs and these 
services suggest that accessibility remains quite limited 
for this population. In the US, access to HCV testing is 
limited by the cost of testing kits,(15) and treatment is so 
prohibitively expensive (US$84,000 per HCV treatment 
course)(39) that Medicaid and private insurers have 
responded by restricting access. Despite the fact that 
treating people who inject drugs with curative HCV 
therapies could reduce HCV prevalence by 20-80%,(29) 
the overwhelming majority of states restrict access to 
HCV treatment for people who inject drugs and those 
receiving treatment for drug dependence, such as OST.(40) 
In 88% of state Medicaid committees, drug and 
alcohol use is included in the eligibility criteria, with 
half requiring a period of abstinence and two-thirds 
requiring drug screening.(40) With these discriminatory, 
unfounded and stigmatising restrictions in place, it is 
not surprising that lawsuits alleging discrimination are 
currently being prepared.(41) Furthermore, two-thirds 
of states have restrictions that limit the prescription 
of newly approved HCV medicines to HCV specialists, 
rather than allowing prescription by HIV or harm 
reduction service providers, who are in better contact 
with people who inject drugs.(42) The recent Action Plan 
for the Prevention, Care, and Treatment of Viral Hepatitis 
2014-2016 is somewhat encouraging, however, in that 
it recognises the importance of focusing a variety of 
resources on improving access to HCV services for 
people who inject drugs, and recommends that “(w)here 
state, local, or private resources are available, these 
comprehensive services should include access to sterile 
injection equipment”.(36)
Although Canada does not have a national policy on 
HCV, testing and treatment are theoretically available 
for people use drugs. Again, while coverage is difficult 
to assess due to a lack of data, civil society reports that 
access remains a challenge for many.(16) In a national 
sample of people who inject drugs, for example, over 
25% of those found to be living with HCV were unaware 
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of their positive status prior to being tested in the study.(43) 
In addition, only half of those who knew their status 
were consulting a physician for HCV care, while only 
10% of these individuals reported ever receiving HCV 
treatment.(43) One of the primary deterrents to seeking 
testing and treatment in the country remains fear of 
stigma and discrimination in health care settings. This 
was made vividly clear in a 2011 study among 528 HCV 
specialist physicians from across Canada, which found 
that only 19% were willing to provide HCV treatment to 
patients who were actively injecting drugs.(44)  
 
Tuberculosis (TB)
Data on tuberculosis (TB) prevalence, prevention, 
treatment and care among people who inject drugs 
in the region continue to be scarce, limiting the 
effectiveness of policies and programmes designed 
to address this issue and making it difficult to provide 
a useful overview of the situation in both countries. 
Despite this shortage of systematic research, a few 
general comments and recommendations can still be 
made. 
Like in all other regions of the world, people who use 
drugs in North America have increased rates of TB 
infection, particularly if they are living with HIV.(45) When 
TB treatment is integrated with HIV, HCV and OST, 
improved outcomes for each condition have been 
observed, as well as improved adherence and retention 
in TB treatment for those living with TB.(45) In accordance 
with international standards, services in both the US and 
Canada should ensure that they adopt a coordinated 
and integrated response to the needs of people who 
use drugs in order to provide universal access to 
prevention, treatment and care services at all entry 
points.(46) This requires collaborative planning between 
HIV and TB services, harm reduction services and the 
criminal justice system.(46)
Antiretroviral therapy (ART)
People who inject drugs continue to be at high risk of 
transmitting or acquiring HIV in the region for several 
reasons, including laws criminalising the possession and 
use of drugs, the resulting high rates of incarceration, 
and a lack of sterile syringes. In 2010, 7% (3,096) of 
the estimated 47,352 diagnoses of HIV infection in the 
United States were attributed to injecting drug use, of 
which 46% were among Black people.(47) In 2013, 10% 
of all AIDS diagnoses and more than one in four (26%) 
deaths among people with AIDS were attributed to 
injecting drug use.(47) More recently, an HIV outbreak in 
rural Indiana associated with injecting drug use resulted 
in 181 cases of HIV infection in a small village in less 
than 12 months, one of the highest incidence rates ever 
recorded.(12)
In Canada, incidence and prevalence rates are similarly 
high. According to national HIV estimates from 2014, 
people who inject drugs are 59 times more likely to get 
HIV than people who do not inject drugs, 19% of people 
living with HIV may have acquired their infection through 
injecting drug use, and HIV prevalence among people 
who inject drugs is approximately 11%.(1) The same 
study found disparities in HIV incidence among people 
who inject drugs, with 21% and 45% of the estimated 
new HIV infections in women and Aboriginal people 
attributable to injecting drug use, compared to an 
estimated 11% of new infections among all Canadians.(2)
Despite these figures, a large proportion of people who 
inject drugs often still have trouble accessing HIV testing, 
treatment and care. According to UNAIDS, between 50-
75% of people who inject drugs in the US, and around 
75% of people who inject drugs in Canada are accessing 
HIV testing.(48) Data collected as part of the Canadian HIV 
surveillance system showed that an estimated 20% of 
people who inject drugs and are living with HIV are not 
aware of their positive status.(49) Civil society reports that 
Indigenous people living with HIV are only half as likely 
to have access to ART as non-Aboriginal individuals.(19) In 
the US, access to treatment is often restricted by socio-
economic factors, with almost two-thirds of people who 
inject drugs living with HIV reporting being homeless, 
61% reporting being incarcerated, and 44% reporting 
having no health insurance in the last 12 months.(47) 
Barriers to initiating ART in Canada are often linked to 
many of the same issues. They may also relate to health 
professionals’ stigma and discrimination against people 
who inject drugs and/or a requirement to initiate drug 
treatment as a condition of access to ART.(50) 
 
Harm reduction in prisons
The United States has the world’s second highest rate 
of incarceration at 698 per 100,000.(51) A new Human 
Rights Watch report on the human toll of criminalising 
drug use in the US reveals that state law enforcement 
agencies made more than 1.25 million arrests for drug 
possession in 2015, which translates into an arrest for 
drug possession every 25 seconds of each day.(52) The 
majority of these arrests result in incarceration. Indeed, 
50% of males and 59% of females in federal prison were 
serving time for drug offences in September 2014,(53) and 
every year, nearly 200,000 people who are dependent 
on opioids enter the American criminal justice system.(54)  
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The US’s so-called “war on drugs” has had vastly 
unequal outcomes across racial groups, with Black and 
Latinxi communities experiencing much higher arrest 
and incarceration rates.(52) For example, Black adults 
accounted for only 14% of people who used drugs in 
the country in 2014, but made up 37% of those arrested 
for drug possession, effectively making them nearly six 
times more likely to be arrested for drug possession 
than white adults.(52, 55) 
Although the incarceration rate is much lower in 
Canada, systemic discrimination and inequality have 
similarly resulted in Aboriginal and Black people being 
overrepresented in the country’s prisons. Although 
they only make up 3.8% of the Canadian population, 
Indigenous people currently represent approximately 
23% of the federal prison population(56) and are among 
those most targeted in the country’s drug enforcement 
measures.(57) Similarly, Black people represent 
approximately 9.5% of the federal prison population 
while representing just 2.9% of the Canadian population 
as a whole, and Black women are most likely to be 
incarcerated for a drug-related offence, often committed 
as an attempt to address situations of poverty.(58) 
Similar to all other regions of the world, injecting 
drug use occurs in North American prisons. A recent 
study undertaken in Baltimore on the links between 
incarceration and injecting drug use found that not only 
did incarceration not curtail injecting drug use, but also 
that longer periods of incarceration were associated 
with increases in injecting among former injectors.(59) 
In Canada, 80% of men entering the Canadian federal 
system are thought to use drugs.(58) In 2012, it was 
reported that 34% of drug offenders had ever injected 
drugs, while injecting during incarceration was reported 
by 11% of the prison population in Canada.(60) 
HIV prevalence among prisoners in the United States 
is reportedly three times greater than the broader 
population, and one in every seven people living with 
HIV will be incarcerated every year.(61) At the same time, 
4.2% and roughly 33% of prisoners are living with TB and 
HCV respectively.(62, 63) In Canada, the estimated HIV and 
HCV (17.2%) prevalence rate is respectively 10 and 30-40 
times greater in prisons than it is outside of prisons.(58, 64)  
These infections, like incarceration, are marked by 
significant racial and socio-economic disparities. In 
Canada, for example, incarcerated Indigenous people 
experience significantly higher rates of HIV and HCV 
than other prisoner groups.(65) 
Despite the clear necessity for harm reduction in 
prisons in the region, provision continues to be woefully 
inadequate, falling far short of meeting both the needs 
of prisoners and international human rights and public 
health standards. Most critically, needle and syringe 
programmes remain completely unavailable in the 
region’s prisons. Canadian civil society continues to 
apply pressure on federal and provincial governments 
to make this essential service immediately available 
to prisoners,j including through a lawsuit against the 
federal government to compel it to implement prison-
based needle and syringe programs.
With OST only available in a small number of American 
prisons (Riker’s Island in New York, and a selection of 
prisons in Baltimore, Philadelphia and Rhode Island),(15) 
coverage remains abysmally low. It is estimated that 
nearly 90% of those currently receiving OST outside of 
prisons would have their treatment cut off if they were 
incarcerated,(66) while the only people typically allowed to 
initiate OST in prison settings are pregnant women.(15)  
The situation in Canada, although far from perfect, is 
considerably better. In all 43 of the country’s federal 
prisons, where people serve a sentence of 2 years or 
more, OST initiation and maintenance are both available.(16) 
At the provincial and territorial level, however, there are 
major gaps in availability and accessibility. Civil society 
reports that only ten provinces (out of 13 provinces 
and territories) permit OST continuation, while even 
fewer allow OST initiation in prisons.(16) Prioritisation 
of candidates for prison-based OST is also reportedly 
problematic, with sentence length and release eligibility 
dates often arbitrarily used to determine who gains 
access first.(67) Prisoners in British Columbia launched 
a constitutional challenge in 2016, alleging that 
correctional policy prevented them from accessing OST 
if they were not in custody for at least three months. 
The policy has since been amended to ensure the 
provincial prison system follows the same guidelines 
for administering OST as the College of Physicians and 
Surgeons of BC, which does not require a waiting period 
in order to be eligible for OST.(16) Regrettably, and as is 
often the fate of prison-based harm reduction services, 
the annual budget for OST in Canadian prisons was cut 
by just over 10% in 2014/15,(67) a retrogressive measure 
that could amount to a violation of the prisoners’ right 
to health under international law.k Canada’s new federal 
government may revisit this decision as part of its drug 
policy reform, however. 
HIV treatment and care are generally available in 
American prisons.(15) A recent study found that although 
most detention facilities provide some degree of HIV 
testing, only 19% of prisons and 35% of jails provide 
routine opt-out testing consistent with national and 
i Latinx, pronounced ‘La-teen-ex’, is the gender-neutral alternative to Latino, Latina and even Latin@.
j See, for example, Canada Can’t Wait: The time for Prison-Based Needle and Syringe Programs is Now. Statement by nearly 250 organisations Canada-wide. 1 June 2016. 
k  Under international human rights law, there is a strong presumption that retrogressive measures taken in relation to the right to health contradict the principle of 
	 progressive	realisation	and	constitute	a	violation	unless	they	have	been	duly	justified	and	weighed	against	the	enjoyment	of	other	rights.	See,	Committee	on	Economic,	
 Social and Cultural Rights, General Comment No. 14: The right to the highest attainable standard of health. UN Doc. E/C.12/2000/4, 11 August 2000, paras. 32 and 48.
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international guidelines.l Routine mandatory HIV testing 
for all prisoners was reported by only 37% of prisons, 
in clear violation of prisoners’ human rights.(68) Despite 
the importance of retaining people living with HIV in 
treatment, the study also found that less than one-
quarter of prisons and jails provide comprehensive 
treatment services for prisoners living with HIV after 
their release.(68) A recent Human Rights Watch report 
identifies funding as a major barrier to implementing HIV 
interventions in American jails and prisons. According 
to the report, “(t)he federal government is the primary 
funding source for managing the HIV epidemic in all 
50 states. The unavailability of this federal funding for 
prisoners significantly impacts the response to HIV in 
local correctional settings.”(69) 
In Canada, HIV testing and treatment are available to 
individuals in federal, provincial and territorial prisons.(16)  
Although 93% of all individuals living with HIV in 
federal prisons were on antiretroviral treatment in 
2014-2015,(70) some harmful practices have still been 
reported, including treatment disruptions(16) and stigma 
and discrimination.(71) Earlier this year, a landmark 
outcome from a legal challenge concerning stigma and 
discrimination based on a prisoner’s HIV status secured 
a number of positive outcomes, including a requirement 
to train prison staff on issues relating to people living 
with HIV or AIDS in prison and display notices on the 
rights of people living with HIV in all Ontario provincial 
prisons.(71) 
While American prisons offer some HCV treatment, 
routine testing and treatment protocols are available in 
less than one-third of US prisons and jails.(72) A recent 
study evaluating the effects of HCV screening and testing 
in prisons found that implementing risk-based and opt-
out screening could diagnose up to 122,700 new HCV 
cases in the next 30 years. Compared with no screening, 
this could avert up to 12,700 new HCV infections and 
prevent up to 11,700 liver-related deaths.(73) In Canada, 
systematic screening for HCV is available to prisoners 
in federal facilities, but unfortunately not in most 
provincial and territorial facilities.(74) HCV treatment is 
available in federal prisons, but prisoners have reported 
difficulties in accessing treatment, with data recently 
released by Correctional Service Canada revealing a 
sharp decline in the number of prisoners receiving HCV 
treatment because of budget cuts, increasing prison 
populations and substantial HCV treatment costs.(75) In 
many provincial and territorial prisons, HCV treatment 
is only available to those who were already undergoing 
treatment in the community.(74) 
 
Condoms are only available in prisons and jails in three 
American states, Vermont (since 1992), Mississippi (since 
1992 and limited to married prisoners receiving conjugal 
visits) California (since 2014), as well as several cities.(76) 
In Canada, condoms are available in all federal prisons, 
but barriers to access have been reported, including as 
a result of inconsistent stocking or condom dispensers 
being located in areas visible to security staff.(16)
Finally, some positive developments in overdose 
prevention among prisoners have taken place in the 
region since the Global State last reported. Most recently, 
the naloxone programme for public health units in the 
Canadian province of Ontario was expanded to include 
prisoners returning to the broader community,(77) and 
the Canadian province of British Columbia has begun to 
provide overdose response training and naloxone kits to 
prisoners in provincial institutions upon discharge.(103)  
In the United States, the Harm Reduction Coalition has 
been involved in providing naloxone and overdose 
prevention training to prisoners and their family 
members in prisons and jails in San Francisco(78) and 
in the state of New York, including Rikers Island.(15) In 
early 2015, a pilot training programme began at the 
Queensboro Correctional Facility in New York City. To 
date, more than 1,000 prisoners have been trained in 
opioid overdose recognition and response, with these 
now part of the facility’s prisoner orientation. A refresher 
training is offered shortly before prisoners are released, 
along with the option to receive a naloxone kit free of 
charge upon release.(15) 
 
Overdose
Contributing an estimated 25% of the world’s drug-
related deaths, North America continues to have the 
highest drug-related mortality rate in the world.(10) In 
the United States, the rate of fatal drug overdose has 
increased by 137% since 2000, with more people dying 
from drug overdoses in 2014 than during any previous 
year on record, 61% of which were opioid-related.(10, 79)  
Across the border in Canada, drug overdose deaths have 
jumped 327% since 2008.(80) In British Columbia and 
Alberta, two of the hardest-hit provinces, fatal overdoses 
linked to fentanyl soared from 42 in 2012 to 418 in 
2015.(81) Following 200 opioid-related deaths in the first 
three months of 2016, the province of British Columbia 
declared its first ever public health emergency.(82)
This rise in fatal overdoses in the region is thought to 
be in large part driven by an explosion in prescription 
opioid dependence. North Americans are thought 
to consume about 80% of the world’s prescription 
opioids,(83) and nearly 80% of current opioid users report 
l	 Prisons	and	jails	are	different	institutions	in	the	United	States.	Prisons	are	operated	by	a	state	or	the	federal	government	and	typically	hold	people	with	sentences	of	
 more than one year. Jails detain people who are accused of crimes and awaiting trial, as well as those convicted of a crime, with the median length estimated to be 48 hours, 
 and generally not exceeding one year. Solomon L, Montague BT, Beckwith CG et al. (2014) ‘Survey Finds that Many Prisons and Jails Have Room to Improve HIV testing and 
 Coordination of Post Release Treatment.’ Health Affairs 33(3):434-42.
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that their first opioid was a prescription pain reliever.(84)  
Accessibility, cost, and high potency of heroin are 
reported to be driving the transition from prescription 
opioids to use of heroin.(85) This is taking place alongside 
the rise of illicitly produced fentanyl, a synthetic opioid 
50 times stronger than heroin and 100 times more 
powerful than morphine. The result is that people 
looking to buy drugs similar to what they were using 
before, are getting fentanyl (or fentanyl-laced drugs) 
instead, which are far stronger than what they are used 
to and leading to a huge increase in fentanyl-related 
overdoses.(86)
Several important developments have taken place in 
the region in response to this epidemic. In the US, 37 
states and the District of Columbia have now enacted 
some form of Good Samaritan laws to protect people 
from arrest or prosecution for drug possession when 
they call for help in the event of an overdose.(87) This 
represents an increase of 13 states since 2014. In 
2015, the United States Food and Drug Administration 
approved nasal spray naloxone, which is thought to 
be easier to administer,(88) and as of June 2016, all but 
three states (Kansas, Montana, Wyoming) had passed 
legislation designed to improve access to naloxone.(89) 
Largely as a result of these legal and regulatory changes, 
over 150,000 people had received training and naloxone 
kits by the end of 2014, which has reportedly resulted 
in the reversal of more than 26,000 overdoses.(90) 
Additionally, as of May 2016, naloxone programmes for 
law enforcement had begun in at least one municipality 
in 35 states and, while naloxone is still not available ‘over 
the counter’, civil society report that it is now available 
in the corporate pharmacy chains CVS and Walgreens 
without needing a prescription from a doctor in 23 
states.(15) 
In Canada, the federal government removed naloxone 
from the prescription drug list in March 2016 to allow 
its emergency use, without a prescription, outside 
of hospital settings.(16, 19) In a further move to make 
naloxone more accessible, the health Minister officially 
authorised naloxone nasal spray for non-prescription 
use in October 2016.(91) Until then, only injectable 
naloxone had been approved in in the country. Some 
provinces and territories (7 out of 13) have already 
implemented community-based take-home naloxone 
programmes, while others have undertaken regulatory 
changes to allow use by first responders.(16, 19) Despite 
these developments, access to naloxone still varies from 
province to province, with cost (particularly for the nasal 
spray) reported as one of the barriers.(92)  
 
In Ontario, however, all pharmacies are eligible to 
dispense naloxone emergency kits free-of-charge, 
significantly increasing their accessibility.(19) Additionally, 
earlier this year a Good Samaritan Act was introduced 
as a private members’ bill in Parliament.(93) An essential 
step in dealing with Canada’s overdose crisis, this bill has 
received widespread support across the country and, as 
of September 2016, had passed the first two readings 
and was in the ‘Report‘ stage.
Finally, both countries have been taking steps to 
respond to the increase of prescription opiate 
dependence. In the US, the Centers for Disease Control 
and Prevention (CDC) released guidelines for prescribing 
opioids for chronic pain in 2016, representing an 
important step for improving prescriber education and 
pain prescribing practices in the country.(85) In Canada, 
the College of Physicians and Surgeons in at least four 
provinces (British Columbia, Nova Scotia, New Brunswick, 
and Newfoundland) are proceeding with initiatives to 
rein in opioid prescribing, including incorporating some 
of the CDC’s 2016 guidelines.(94)  
 
Policy development for harm 
reduction
Although still refusing to mention the words ‘harm 
reduction’ in national policy and international forums, 
the US government is beginning to adopt more of 
a public health approach to drugs and continues to 
endorse harm reduction interventions.(15) At the UNGASS 
on drugs in April 2016, for example, it specifically urged 
Member States to scale-up their public health responses 
to drugs and adopt evidence-based interventions 
such as OST and NSPs.(95) At the national level, the 
2015 National Drug Control Strategy,(24) as well as the 
most recent HIV/AIDS(96) and viral hepatitis(36) strategies 
explicitly support the provision of OST and NSPs. 
The government has also demonstrated a renewed 
commitment to key populations, evidenced by the new 
US$100 million PEPFAR fund for key populations (see 
funding section) announced in June 2016.(97) 
One significant development in relation to NSPs has been 
the amendment to the longstanding federal funding ban on 
these programmes, signed by President Barack Obama on 
December 18, 2015. The Consolidated Appropriations Act, 
2016, as the provision is formally known, still prohibits the 
use of federal funds to purchase sterile needs or syringes 
to inject illegal drugs, but now allows federal funds to be 
used to support other facets of NSPs, such as HIV and HCV 
testing, naloxone training and provision, human resources, 
syringe disposal, human resources and syringe disposal.(13-15)
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The twin epidemics of opioid use and overdose have 
also been driving American public policy towards a 
public health and harm reduction approach. These 
issues were a key focus for the US at the 59th Session 
of the Commission on Narcotic Drugs, in March 2016, 
and again at the UNGASS on drugs the following month. 
Since the Global State last reported, 13 US states have 
enacted some sort of Good Samaritan laws to protect 
people from arrest or prosecution when calling in an 
overdose, bringing the total number up to 37 states.(87) 
As of June 2016, all but three states (Kansas, Montana, 
Wyoming) had passed legislation designed to improve 
access to naloxone,(89) which has already resulted in 
26,000 overdose reversals.(90) Finally, 24 states now 
have some form of medicinal cannabis legislation, and 
regulated markets for recreational cannabis use now 
exist in Alaska, Colorado, Oregon, Washington and the 
District of Columbia (Washington, DC).(15) 
Following years of ideological opposition to harm 
reduction, Canada’s new federal government has been 
vocal in its support of harm reduction in both national 
and international forums, including at the 59th Session 
of the Commission on Narcotic Drugs in March 2016. 
In a speech at this session, Canada described harm 
reduction as critical and announced its support not 
only of evidence-based harm reduction measures such 
NSPs, but also – in a complete policy shift from the 
previous regime – supervised injection sites, stating that 
it anticipated more would be operating in the future.(98) 
The following month, at the UNGASS on drugs in New 
York, Canada’s federal Health Minister publicly embraced 
harm reduction as a key pillar of the response to drugs, 
acknowledged the need to protect human rights and, 
making headlines worldwide, announced Canada’s plan 
to legalise cannabis in 2017.(99) 
Following years of legal challenges, the Canadian 
government officially overturned the ban on heroin-
assisted therapy (HAT) in September 2016.(22) Under 
the new regulations, physicians can prescribe 
pharmaceutical-grade heroin to patients for whom 
it is clinically indicated, including individuals who 
have tried other approaches, such as methadone 
and buprenorphine, without success. In response to 
the opioid overdose epidemic, the government also 
removed naloxone from the prescription drug list,(16, 19)  
which enables over-the-counter provision and 
dramatically increases accessibility, and authorised 
the provision of nasal-spray naloxone (see overdose 
section).(91) Alongside these developments, a Good 
Samaritan bill was introduced in Parliament and is 
currently before the House of Commons.(93) The bill 
would amend the Controlled Drugs and Substances Act 
to give immunity from prosecution for the offences of 
simple possession of a controlled substance to anyone 
who calls 911 to report an overdose.  
 
Civil society and advocacy 
developments for harm reduction
Civil society continues to be very active in the region, 
playing a strong role in advocating for harm reduction 
both regionally and internationally, and making 
significant accomplishments in the last two years. 
The 2016 UNGASS on drus held in New York in April 
provided an unprecedented opportunity for regional civil 
society organisations to mobilise on drug policy reform, 
both at the national and international levels.(15) In the US, 
the revival of the New York NGO Committee on drugs 
(NYNGOC) in preparation for the UNGASS was a major 
achievement for civil society engagement on drug policy 
issues and was instrumental in bringing a large number 
of geographically diverse organisations together.(15) 
In terms of important policy development, the Harm 
Reduction Coalition worked closely with Congress and 
the Obama Administration to revise the longstanding 
federal funding ban for NSPs in the country. 
In Canada, the new federal government’s explicit 
support for harm reduction at the national level and in 
international forums are due in part to the campaign 
and advocacy efforts of civil society, many of whom have 
had the opportunity to meet with the Health Minister 
and her office to advocate for harm reduction in Canada 
and globally.(16) In 2015, a national Working Group on 
Best Practice for Harm Reduction Programs in Canada, 
made up of people who use drugs, service providers, 
policy makers and researchers, produced the Best 
Practice Recommendations for Canadian Harm Reduction 
Programs that Provide Service to People Who Use Drugs 
and are at Risk for HIV, HCV, and Other Harms: Part 2, 
to help NSPs and other harm reduction programmes 
across the country improve service delivery to people 
who use drugs.(50) 
Given that harm reduction and drug policy advocacy and 
services were so under-resourced under the previous 
Canadian federal government, civil society has identified 
funding as a major advocacy priority in the coming  
years.(16, 19) At the same time, urging the federal 
government to explicitly refer to ‘harm reduction’ as one 
of the key pillars of a new national drug policy will be 
another principal advocacy objective.(16)
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Funding developments for harm 
reduction
One of the most important funding developments in 
the region since 2014 has been the modification to the 
federal funding ban on NSPs signed by the President 
on 18 December 2016. The revised policy still prohibits 
the use of federal funds to purchase sterile needles and 
syringes to inject illegal drugs, but makes allowances for 
these funds to be used to contribute to NSPs in other 
ways based on evidence of a demonstrated need by the 
state or local health department, and in consultation 
with the CDC.(13) The change in the funding ban has 
allowed for new federal funding options and small 
programmes are being pushed to collaborate or merge 
with larger organisations to deliver broader health care 
services.(15) 
Another noteworthy funding development in the United 
States was the PEPFAR announcement at the UN 
High Level Meeting on ending AIDS held in New York 
in June 2016, about the creation of a US$100 million 
Key Populations Investment Fund. The Fund, which 
demonstrates the country’s renewed commitment to key 
populations, will work to address the complex dynamics 
driving stigma and discrimination in order to expand 
access to evidence-based HIV prevention and treatment 
services for key populations.(97)
Canada’s National Anti-Drugs Strategy, a hangover 
from the previous federal government, was allocated 
CA$515.9 million for 2012-2017.(100) With harm 
reduction entirely absent from this Strategy, however, 
funds could not be allocated for this purpose, and the 
majority (between 40%(100) and 70%(101)) has been spent 
on enforcement. Thankfully, this Strategy expires in 
March 2017 and it is hoped that funding allocations 
will be revised going forward. Meanwhile, with health 
care being a provincial mandate, harm reduction 
services are typically funded by provincial and territorial 
governments.(16) For example, the Ontario Harm 
Reduction Distribution Program, which is funded by the 
province of Ontario’s Hepatitis C Secretariat, Ministry of 
Health and Long-term Care, provides harm reduction 
supplies and other resources to needle and syringe 
programs across Ontario.(102) But while provincial and 
territorial governments are responsible for health care 
in their respective jurisdictions, the federal government 
holds responsibility for ensuring the availability of health 
services for specific populations, including Indigenous 
people and people incarcerated in federal prisons.(70) 
Considering these two populations are currently both 
the most in need of harm reduction services and less 
likely to access them, the federal government should 
urgently devote more resources, including funding, to 
ensure that these key populations’ fundamental rights 
are being fulfilled. 
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Country/territory 
with reported 
injecting drug use
People who 
inject drugs
HIV 
prevalence 
among 
people who 
inject drugs 
(%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among 
people who 
inject drugs 
(%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among 
people who 
inject drugs 
(%)
Harm reduction response
NSPb OSTC DCRa
Australia 93,000 (67,800-118,200)(1)d 1.7%
(2) 54(2) 4(2) 33,000+ 32,589
(3) 
(B, M) 31
(4) 
Fiji nk nk nk nk 7 7 7
New Zealand 12,840(5) 0.2%(6) 50(7)e nk 3192+ 3 7
Papua New Guinea nk nk nk nk 7 7 7
Samoa nk nk nk nk 7 7 7
Timor Leste 53(8) nk nk nk 7 7 7
nk = not known
Oceania
Table 2.7.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Oceania
a DCR is a drug consumption room (please refer to chapter for details), also referred to as a safer injection facility. 
b	 This	includes	all	operational	NSP	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	workers.
c (M) = methadone, (B) = buprenorphine, (O) = any other form (including morphine and codeine). 
d	 Civil	society	believe	this	figure	to	be	an	underestimate	as	there	is	no	distinction	given	between	regular,	frequent	and	occasional	people	who	inject	drugs. 
e	 The	updated	figure	from	the	World	Drug	Report	notes	this	has	increased	to	57%,	however	due	to	the	sample	size	(n=700)	figures	have	been	taken	from	2014	report.
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Map 2.7.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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Harm reduction in Oceania
Overview
The regional prevalence of injecting drug use in Oceania 
is limited to data from Australia, New Zealand and Timor 
Leste (please see Table 2.7.1). Since the 2014 edition of 
the Global State, there has been little new research into 
drug use or drug related harms undertaken in the Pacific 
Island countries and territories (PICTs).f This remains a 
concern due to the reporting of injecting drug use, and 
the lack of harm reduction programmes in this region.(4) 
Injecting drug use is not thought to be common within 
the PICTs,(9) yet there appears to be a marked increase 
in the use of amphetamine-type stimulants (ATS).(9) The 
most recent UNAIDS report to emerge from Fiji states 
only one case of HIV infection occurred through injecting 
drug use in 2014.(10) 
Approximately 105,893 people inject drugs in Australia, 
New Zealand and Timor Leste combined. The use of 
heroin reportedly declined in Australia between 2010-
2013.(11) However, there has been a small increase in HIV 
prevalence among people who inject drugs from 1.2% 
in 2014,(12) to 1.7% in 2015.(13) Although harm reduction 
initiatives have been well-established in Australia, there 
are still reportedly significant disparities in service 
provision among Indigenous Australians.(2) Injecting 
drug use is less prevalent than other drug use among 
this population, yet there is a high incidence of unsafe 
injecting practices,(14) and higher rates of HIV infection 
associated with injecting drug use.(15) 
In both New Zealand and Australia severe side effects 
and low success rates of hepatitis C treatment had 
previously formed a significant barrier for people who 
inject and/or use drugs. Yet the availability of a free 
hepatitis C treatment using direct-acting antivirals in 
Australia since February/March 2016 has seen a rapid 
increase in the numbers of people seeking treatment.(16)  
In New Zealand, uptake of testing and treatment for 
hepatitis C among people who use drugs remains 
extremely low, and there is an urgent need to amend 
the way hepatitis C is diagnosed and treated in the 
country.(17)
 
 
 
 
 
 
 
The rise of stimulant use in 
Australia
Stimulant use, although increasing in Australia, is 
estimated to have remained relatively stable in New 
Zealand, with approximately 26,000 people reporting 
use of amphetamine-type stimulants (ATS) in the past 
year.(18) In Australia, however, findings from the Kirby 
Institute show a marked rise in methamphetamine 
use between 2010 and 2014, with methamphetamine 
reported as the last drug injected by one-third of 
respondents in the Australian Needle and Syringe 
Program Survey (ANSPS) in 2014.(13) More than 
200,000 people are reported to be using crystalline 
methamphetamine (commonly known as ‘ice’) in 
Australia, an increase of 100,000 since last reported in 
2007.(19) National data indicate that methamphetamine 
injection has increased significantly from 27% in 
2011, to 36% in 2014, overtaking heroin as the most 
commonly injected drug in the country.(20) In 2015, it 
continued to be the most commonly injected drug 
in the majority of jurisdictions, including New South 
Wales (32%), Queensland (34%), South Australia (53%), 
Tasmania (42%), and Western Australia (45%).(20) Crystal 
methamphetamine is also believed to be one of the 
most commonly injected drugs among gay and bisexual 
men living in Sydney.(21) 
Not only does there appear to be a rise in the use 
of ATS and, in particular, an increase in crystal 
methamphetamine injecting in Australia, but there is 
also a rise in polydrug use.(22) This calls for an adapted 
harm reduction approach, as opioid substitution 
therapy (OST) is only indicated as a treatment for 
opioid drug use.(23) In response to the growth of ATS 
use, the politically conservative Australian government 
commissioned a report on ‘ice’.(19) Although the report 
recommends a move away from law enforcement to 
local area focused health responses to ice use, it fails to 
mention harm reduction,(4) which came as a profound 
disappointed to some civil society groups.(4, 24) 
At present there is little solid evidence relating to 
pharmacological treatment for amphetamine use.(25)  
However, harm reduction for people who use 
amphetamines follows the same fundamental principles 
as harm reduction for people who use opioids.(25)
f The PICTS comprise 22 countries and territories subdivided into Micronesia, Polynesia and Melanesia. They are American Samoa, Cook islands, Federated States of  
 Micronesia, Fiji, French Polynesia, Guam, Kiribati, Marshall Islands, Nauru, New Caledonia, Niue, Northern Mariana Islands, Palau, Papua New Guinea, Pitcairn Islands,  
 Samoa, Solomon Islands, Tokelau, Tonga, Tuvalu, Vanuatu, and Wallis and Futuna. 
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Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
It is estimated that approximately 10,000 people make 
use of NSP services in New Zealand, with 3 million 
new needles distributed each year.(6) NSPs operate via 
21 primary sites and approximately 170 pharmacies 
providing needles and syringes. These high coverage 
rates make HIV rates among people who inject drugs 
remain consistently low. In Australia, NSPs have been 
in place for many years and there are over 3,000 NSP 
outlets in operation, including mobile outreach services 
and vending machines.(4) 
A scientific paper from Australia published in 2009 
argued that sterile injecting equipment was limited by 
supply rather than demand, and estimated that needle 
and syringe distribution needed to double in order 
to reduce the annual incidence of hepatitis C virus 
infections in particular.(26) In response to this paper, 
the New South Wales Ministry of Health removed limits 
to the amount of equipment supplied when visiting a 
service, and people who inject drugs in this state can 
now access as many syringes as they require. (27, 28)  
A further development in NSPs in Australia has been the 
ability of peers to legally provide injecting equipment in 
the Australian Capital Territory, Tasmania, the Northern 
Territory, and New South Wales.(4, 28) Although there 
have been improvements in policy relating to NSPs, the 
ANSPS found that the prevalence of people re-using 
needles and syringes (including reuse of one’s own 
syringes) in ranged from 21-25% between 2011 and 
2015,(20) indicating the need to undertake more focused 
efforts to reduce this practice.(28) 
As previously noted in past editions of the Global 
State, there is a disparity of service provision among 
indigenous communities and indigenous people who 
inject drugs continue to be underrepresented in NSP 
services.(4) Findings from the ANSPS show that the 
number of people from an Indigenous background 
accessing NSPs is increasing, from 5% in 1995, to 14% 
in 2014.(13) However, between 2010 and 2014, 16% of 
all HIV diagnoses among Aboriginal and Torres Strait 
Islander people is attributed to unsafe injecting drug 
use, highlighting the urgent need for targeted harm 
reduction responses for these populations.(2) 
While NSPs continue to operate across the country in 
many jurisdictions in Australia, some barriers to access 
remain, including limited after-hours service availability, 
geographic access and stigma and discrimination 
experienced by some people who inject drugs when 
accessing harm reduction services.(20)
Opioid substitution therapy (OST)
In 2015, there were 2,589 outlets providing OST in 
Australia covering 48,522 clients. OST provision has seen 
an increase of 564 sites in Australia since the Global 
State reported in 2014,(29) while the number of people 
receiving OST nationally has nearly doubled - from 1.3 
to 2.1 per 1,000 population - since 1998.(30) The vast 
majority (88%) of OST in Australia is dispensed from 
pharmacies.(29) The ratio of clients per OST prescriber, 
however, decreased from 23 in 2013,(31) to 19 in 2015.(29) 
Although there has been a scaling-up of OST provision 
in the country, the cost continues to be extremely 
prohibitive for people who use opioids, and has yet to be 
addressed. While the drug is provided free, dispensing 
fees are charged by participating pharmacies, meaning 
people who receive doses are charged between AU$7 
and AU$10 every day.(4) Similarly to NSP provision, 
Indigenous people continue to be underrepresented in 
OST services.(3)
In New Zealand, current levels of OST provision are 
unclear, but in 2009 it was estimated that approximately 
4,600 people were receiving OST, predominantly in 
the form of methadone.(32) One of the main barriers to 
OST uptake is the banning of OST for those who are 
found to be continuing to use illicit drugs. Urine analysis 
is commonplace, with people removed from OST 
treatment if their urine is found to contain illicit drugs.(33) 
There can also be up to a six-month wait in New Zealand 
to accessing OST services.(33) However, civil society report 
that OST is now available through NGO services.(17)
Viral hepatitis
Historically, Australia has one of the best examples of 
harm reduction globally, however, the prevalence of 
antibodies to hepatitis C virus among people who inject 
drugs only declined from 60% in 1995 to 53/54% in all 
years between 2010-2014.(13) This highlights the need for 
greater accessibility of hepatitis C treatment for people 
who use drugs, as well as better coverage of NSPs and 
other prevention services. High prevalences of lifetime 
hepatitis C diagnostic screening, ranging from 83% to 
88%, were illustrated in a recent study with just over half 
(54%) of respondents having had a hepatitis C test in the 
previous 12 months in 2015.(20) 
In March 2016, the Australian government made 
direct-acting antiviral treatments for hepatitis C available 
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free of charge without restriction relating to drug use or 
disease stage – only the second country in the world to 
do so.(34) The availability of these new treatments through 
the Pharmaceutical Benefits Scheme (PBS) is a significant 
positive step forwards, and is seen as a potential means 
to substantially reduce the growing burden of disease 
and interrupt ongoing transmission.(4)  
Findings from a report published in September 2016 
indicate that since the new treatments became available 
in March 2016, an estimated 26,360 people initiated 
treatment, compared with 7,296 in 2015.(16) However, it 
is not known what proportion of those accessing these 
treatments are current or former people who inject 
drugs. 
In New Zealand, the provision for hepatitis C testing 
and treatment for people who inject drugs remains 
extremely low. It is clear from the steady rate of hepatitis 
C among people who inject drugs in the country that an 
urgent change in treatment provision is necessary.
Tuberculosis (TB)
Tuberculosis (TB) continues to remain extremely low 
in both Australia and New Zealand, with six cases per 
100,000 people in Australia(35) and seven cases per 
100,000 people in New Zealand.(35) 
Although TB is covered to some extent in harm 
reduction policies in New Zealand, there is no evidence 
to suggest it is increasing among people who inject 
drugs.(33) This finding is echoed in Australia, although 
there is little information on rates of TB infection 
among people who inject drugs both in the country and 
surrounding PICTs. 
Antiretroviral therapy (ART)
The prevalence of HIV among people who inject drugs 
in Australia and New Zealand has remained consistently 
low (please see Table 2.7.1). However, the proportion 
of Aboriginal Australians who have acquired HIV 
through unsafe injecting drug use is 13% higher than 
among non-Aboriginal people exposed to HIV through 
injecting drug use.(2) Self-testing HIV screening kits are 
being increasingly used in Australia,(36) although more 
likely among men who have sex with men than among 
people who inject drugs. While access to HIV testing 
and treatment is available in the PICTs, it is unclear how 
many people who inject/use drugs receive treatment.
Harm reduction in prisons
Apart from Australia, data on harm reduction in prisons 
in the region continues to be scarce. In Australia, drug 
offences currently represent the second most common 
criminal offence, with a 17% increase in sentences for 
drug offences registered in 2015 alone.(37) As a result, 
people who inject drugs comprise a large proportion of 
the country’s prison population (approximately 50% in 
2011)(38) and injecting drug use continues to take place 
in prison settings. A recent study on the prison economy 
of needles and syringes in New South Wales found 
that out of 30 prisoners from 12 different prisons, six 
reported injecting at a frequency of less than monthly, 
three more frequently than monthly, three more than 
weekly, three daily and five more than daily.(39) The most 
commonly injected drug is amphetamine, with the most 
recent national prison entrants’ survey showing 59% of 
prisoners reporting it as the last drug injected.(40) 
The region of Australasiag has been identified as having 
the second highest prevalence of HCV in prisons in the 
world after Asia.(41) In Australian prisons, HCV prevalence 
has been found to be up to 38%(42) whereas HIV 
prevalence continues to be almost zero.(38) While there 
is very little data on the PICTs, a study undertaken in Fiji 
looking at a sample of prisoners post-release found that 
HIV prevalence was 1%, similar to that of the general 
population.(43) Although none of the participants involved 
in the study reported ever injecting drugs, one-third did 
not use condoms with casual sex partners, stating that 
this was due to a lack of availability.(43) Condom provision 
is also reportedly inadequate in prisons in Australia and 
New Zealand, with varying availability depending on the 
prison.(4, 33) 
OST, antiretroviral therapy, as well as diagnostics and 
treatment for HIV, HCV and TB, however, are reported to 
be available to prisoners in both countries.(4, 33)  
In Australia, OST can be initiated during incarceration 
if clinically directed, but measures are also in place 
to ensure continuity of OST for prisoners who were 
prescribed it prior to incarceration. While there is no 
data on coverage of OST in prisons at the national level, 
in the state of New South Wales, which houses one-third 
of the country’s prisoners, coverage has been estimated 
at 43%.(44) 
NSPs are still not available in prisons in New Zealand 
and Australia, despite high rates of HCV and unsafe 
injecting reported in the latter.(4) In Australia, a recent 
study found that prisoners were paying AU$100-AU$150 
on average, and up to AU$350, for one sterile needle/
syringe, demonstrating the inherent value of sterile 
injecting equipment in prisons.(39) The study also found 
that there were far more blood-borne virus risks related 
to the informal prison needle/syringe economy than 
there were opportunities to mitigate these risks, and 
g	 Australasia,	a	region	of	Oceania,	is	comprised	of	Australia,	New	Zealand,	the	Island	of	New,	Guinea	and	the	neighbouring	islands	in	the	Pacific	Ocean.
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concluded that provision of NSPs would greatly reduce 
the risk of disease transmission, as well as violence 
between inmates.(39) Although the ACT government has 
committed to an NSP trial at the Alexander Maconochie 
Centre (AMC) in Canberra, Australia, it continues to 
meet with fervent opposition from the Community and 
Public Sector Union (CPSU). Following years of deadlock 
on this issue, an NSP Working Group was appointed in 
2015 and tasked with developing a prison NSP model 
that could be safely and effectively implemented in 
the prison.(45) Unfortunately, the prisons officers union 
recently rejected the proposed model by majority 
vote,(45) and now a new model will be developed and 
voted on. 
Overdose
In Australia, deaths due to accidental overdose grew by 
61% between 2004 and 2014, with a 14% rise between 
2013 and 2014 alone.(46) Aboriginal people have been 
particularly affected by this epidemic, with accidental 
fatal drug overdoses per capita among this population 
increasing by 141% between 2004 and 2014 (from 3.9 to 
9.4 per 100,000) in the five jurisdictions with Aboriginal 
data.(46) In the same time period, an increase of 45% was 
recorded among non-Aboriginal people.(46) 
In 2014, the Global State reported the implementation 
of pilot naloxone programmes for people who use 
drugs in four states (Australian Capital Territory, 
Western Australia, Victoria, and New South Wales), 
with evaluations showing a high degree of success.(47) 
Since these pilots, naloxone has been co-scheduled 
by the Therapeutic Goods Administration (TGA) as a 
Schedule 3 and 4 drug, meaning it can be accessed 
without a prescription from a pharmacist, and the 
introduction of take-home naloxone has occurred in 
numerous jurisdictions in the country.(4, 28) Many of the 
programmes introduced receive government support, 
however, they are very small scale and there has been 
little broader uptake by general practitioners and other 
medical professionals.(4) An on-going issue, despite the 
scheduling amendments to naloxone, is the necessity 
for a prescribing doctor or pharmacist to be involved, 
especially if clients on health care cards are to receive 
the drug at cost. Naloxone is available for purchase at a 
pharmacy but may cost upwards of AU$40 for a single 
dose, although for those on a health care card and with 
a doctor’s prescription, the cost is approximately AU$6.(4)
Australia has a medically supervised injecting centre 
(also known as a DCR – please see Table 2.7.1), which 
provides sterile injecting equipment alongside a range 
of additional services for people who inject drugs. This 
service has been found to significantly reduce calls to 
ambulance-attended opioid-related overdoses in the 
small area of Sydney where it is located.(48) However, 
demands for additional supervised injecting facilities and 
the introduction of inhalation as an additional route of 
administration within DCRs have been met with limited 
to little or no support from the government.(4)
In New Zealand, no overdose prevention programmes 
exist in the form of naloxone distribution among peers. 
However, civil society report that this is being discussed 
as an initiative.(17) At present, overdose is handled 
through drug helplines and emergency services.(33)  
In the PICTs, information on overdose and prevention is 
unknown. 
 
Policy development for harm 
reduction 
 
Harm reduction has been a key pillar of successive 
Australian National Drug Strategies for over 20 years. 
Harm reduction is mentioned within various national 
policies and strategies including: the Seventh National 
HIV Strategy 2014-2017;(49) the Fourth National Hepatitis 
C Strategy 2014-2017;(50) the Second National Hepatitis 
B Strategy 2014-2017;(51) the Fourth National Aboriginal 
and Torres Strait Islander Blood-Borne Viruses and 
Sexually Transmissible Infections Strategy 2014-
2017;(52) and the National Drug Strategy 2010-2015.(53) 
However, it has been observed that Australia’s political 
commitment to harm reduction is waning.(4, 54)  
Australia made no reference to harm reduction in 
their statements at both the United Nations General 
Assembly Special Session (UNGASS) on drugs or the 
Commission on Narcotic Drugs (CND) meetings held in 
April 2016 and March 2016 respectively. New Zealand, 
however, did endorse harm reduction during their 
UNGASS statement. Despite previously being a world 
leader in harm reduction, civil society groups now 
lament the lack of progress and regression in Australian 
drug policy.(4) 
Civil society and advocacy 
developments for harm reduction
In Australia, civil society organisations continue to play 
a key role in the harm reduction response for people 
who inject and use drugs. In September 2014 the 
Alcohol and Other Drugs (AOD) Peaks Network was 
formed, providing a conduit for access to services in 
all jurisdictions of Australia, including harm reduction 
services.(55) Unharm was established in New South 
1182.7 OCEANIA
Wales in 2014 to promote safe environments at parties 
where drugs may be used, and to promote realistic 
and positive alternatives to the stigmatisation of illicit 
drug use.(56) Drug Policy Australia was also established 
in 2014, to promote new approaches to minimise the 
health risks and other harms associated with both licit 
and illicit drugs in the country.(57) 
Harm Reduction Australia was set up in late 2015 to 
represent the concerns of people working in the drug 
sector or concerned about drug policy in Australia. 
Harm Reduction Australia focuses solely on advocacy 
and is self-funded by members.(4) A National Naloxone 
Reference Group was established to provide structure 
and mode of delivery to existing naloxone programmes, 
map successes in implementation, look into the 
issues and challenges in implementation, evaluate the 
programmes, explore opportunities for expansion and 
engage professionals and community members.(58)
The work of peer-based organisations continues in 
most jurisdictions, yet too often their funding is under 
pressure from government budgets that struggle to 
meet the demand of the sector.(4) The Australian Injecting 
and Illicit Drug Users League (AIVL), has played an 
integral role in ensuring that harm reduction and policy 
reform issues are heard through their involvement on 
government committees.(47) In 2015, AIVL successfully 
retained its funding after funding threats and continues 
to conduct research and programming on stigma and 
discrimination towards people who use drugs.(59) 
In 2005, the Pacific Drug and Alcohol Research Network 
was established and met regularly since its inception, 
but ceased to operate in 2011.(9,4) Further research is 
needed for the development and provision of harm 
reduction services in the PICTs as the evidence base 
for these services has not yet been established. 
Currently many countries in the PICTs send people to 
New Zealand or Australia for drug and alcohol harm 
reduction interventions,(9) which is an infeasible long-
term option that highlights the necessity for further work 
to be undertaken in this part of the region. 
In New Zealand, civil society organisations provide the 
majority of advocacy activities for people who inject 
drugs.(33) Two primary organisations in the country are 
the New Zealand Needle Exchange Program, and the 
New Zealand Drug Foundation.(17) In the PICTs, although 
there is a Pacific Drugs and Alcohol Research Network 
(PDARN), the last meeting was held in August 2011. 
There has been a small increase in research in these 
territories, but further data gathering and advocacy 
should be undertaken regarding harm reduction 
approaches to drug use, particularly with the increase in 
ATS.
Funding developments for harm 
reduction 
 
Financial support for harm reduction in Australia has 
predominantly been provided by the government. 
However, funding for harm reduction remains at low 
levels, estimated to be as low as 2%, when compared 
to law enforcement, and treatment and prevention of 
drug budgets.(4) Funding for harm reduction has not 
increased over the years, despite the rise in injecting 
drug use among people who use ATS, and it is likely to 
be proportionally lower in the future.(4)  
In New Zealand, harm reduction activities are 
government funded, yet similarly to Australia, funding is 
limited and more is required to scale-up services.(17)
Policy domain AU$ million Percentage
Prevention 156.8 9.2%
Treatment 361.8 21.3%
Harm Reduction 36.1 2.1%
Law Enforcement 1123.3 66%
Other 23.1 1.4%
TOTAL 1,701.1 100%
Australian government spend on drugs(60)
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Middle East and North Africa
Table 2.8.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in the Middle 
East and North Africa
Country/
territory with 
reported       
injecting drug 
use
People who 
inject drugs
HIV 
prevalence 
among people 
who inject 
drugs (%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among people 
who inject 
drugs (%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among people 
who inject 
drugs (%)
Harm reduction response
NSPa OSTb
Algeria nk nk nk nk 7 7
Bahrain nk 55.8(1)c nk nk 7 7(M)d
Egypt 31,000(2)e 6.5–6.8(3) 49.4 (35.8–63)(4) 13.5 (10.9–16)(4) 39(5) 7
Iran 200,000(6) 13.8(6, 7) 50.2 (34.5–65.9)(4) 17.3 (3.7–30.9)(4) 3580(6)f 375,983 (M, B, O)(6)
Iraq 34,673(8)g nk nk nk 7(P) 7
Israel nk nk 67.6(4) 2.8(4) 35(9)h 3(B, M)
Jordan nk 6(10) nk nk 32(5)i 7
Kuwait nk 0(11) 54(11)j nk 7 7
Lebanon 3,114(12) 1(13) 52.8(14) nk 32(5)k 31
Libya 7,206(8)m 87(15)n 94(15) 5(15) 7 7
Morocco 18,500(16) 11.4(17) 57(18) nk 34(19) 36(19)
Oman nk 3.8(20)o nk nk 7 7
Palestine nk 0(3) nk nk 1(21) 7
Qatar nk nk nk nk 7 7
Saudi Arabia 10,000(22) 3.5(23)p 49.8 (14.1–85.4)(4) 49.8 (14.1–85.4)(4) 7 7
Syria 10,000(22) nk 60.5(4) 60.5(4) 7 7
Tunisia 9,000(17) 3(17) nk nk 33(24) 7
United Arab 
Emirates (UAE) nk nk nk nk
7 7(25)q 
Yemen nk nk nk nk 7 7
 
nk = not known
a	 All	operational	needle	and	syringe	exchange	programme	(NSP)	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	
workers. (P) = pharmacy availability.
b Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
c People who inject drugs are reached only through post-rehabilitation or prison programmes (n=244), which may not be representative of the total number of people who
      inject drugs.
d Although methadone is available for people who inject drugs in Bahrain, it is for detox purposes only.
e Sub-national data based on greater Cairo (30,000) and Menia (1,000). At the time of reporting there was no national estimate for Egypt.
f 580 refers to free state welfare organisation NSP provision and does not include needles and syringes that can be purchased at pharmacies.
g Figure based on a literature review between 1998 and 2005.
h Figure relates to the number of cities that operate NSPs in Israel, rather than the number of sites.
i Figure relates to the two known organisations providing NSPs in Jordan, rather than the number of sites.
j Figure based on a sub-sample of 98 people who inject drugs in a treatment centre.
k Figure relates to the two known organisations providing NSPs in Lebanon, rather than the number of sites.
l OST available only in the private sector.
n Figure based on a literature review between 1998 and 2005.
m Figure based on sub-national data from Tripoli and Benghazi.
o Figure based on facility-based mandatory testing and not on representative bio-behavioural surveys.
p	 2013	data	from	three	detoxification	centres	in	Riyadh,	Jeddah	and	Daman,	which	may	not	be	representative	of	the	total	number	of	people	who	inject	drugs.
q Although OST is available for people who inject drugs in UAE, it is for detox purposes only and only available at the National Rehabilitation Centre in Abu Dhabi.
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Map 2.8.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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Harm reduction in Middle East and 
North Africa
Overview
People who inject drugs, men who have sex with men, 
and female sex workers remain the most affected 
groups in terms of HIV, hepatitis C and hepatitis B in the 
Middle East and North Africa (MENA) region.(17) Newly 
identified HIV infections have increased in MENA by 31% 
since 2001.(26) From an estimated 240,000 (150,000–
320,000) people living with HIV, 57% of all new adult 
infections are among people who inject drugs.(27)
Within MENA, the number of people who inject drugs 
ranges between 299,000 and 1,128,000,(28) the wide 
range highlighting the uncertainty around current 
estimates of population size. In most countries, 
population size estimates are infrequently updated 
and there is a lack of bio-behavioural data. Instead, 
there is an over-reliance on HIV case reporting and 
detoxification-facility-based surveillance on HIV, viral 
hepatitis and tuberculosis (TB) among this group.(29)
New data on injecting drug use have emerged in some 
countries. The UNODC conducted a population size 
estimate of key populations in Egypt in 2014,(30) and 
the Middle East and North Africa Harm Reduction 
Association (MENAHRA) collaborated with the National 
AIDS Program in Lebanon to undertake a size 
estimation, risk behaviour assessment and disease 
prevalence study among people who inject drugs.(12)
Iran remains the only country in the region to have 
consistently scaled up harm reduction services. 
However, coverage levels of NSP provision are still 
considered low by UN standards. Morocco, the second 
country in the region to implement a nationwide harm 
reduction strategy after Iran,(31) has seen a steady 
increase in the number of people who use drugs in the 
north of the country over the last two decades.(19) Harm 
reduction services have not yet been sufficiently scaled 
up to meet the increasing need.(5)
In Saudi Arabia, although harm reduction services 
are not yet in existence, the National AIDS Program is 
working on implementing a project to improve access 
to services for people who use drugs.(32) However, it is 
unclear whether any of these services will include NSP 
or OST. At present, services for people who use drugs 
consist only of rehabilitation centres, an approach not 
recommended as a first line of treatment for people 
who use/inject opioids.(33)
There have been some indications of harm reduction 
implementation progress in the region since Global 
State 2014. The United Nations Office on Drugs and 
Crime (UNODC) has convened a National Opioid 
Substitution Therapy Taskforce in Egypt, commissioning 
a feasibility study to select, approve and procure the 
most appropriate controlled substances for piloting 
OST. At the time of reporting, the pilot programme was 
pending government approval.(34) Three organisations 
in Egypt have also been provided with funds through 
MENAHRA to implement NSP outreach.(35) Jordan had 
planned to scale up NSP outreach. However, harm 
reduction activities in Jordan during 2015 slowed down 
considerably due to governmental restrictions on 
external funding to NGOs, with money released only in 
the summer of 2016.(5)
The most common response to drug use in the region 
is detoxification and rehabilitation, requiring the 
involvement of psychiatrists and physicians. Drug-related 
services in over half of the MENA countries are all 
abstinence-based, with no availability of evidence-based 
harm reduction initiatives such as the implementation 
of NSP and OST.(36) Punitive responses to drug use are 
among the most extreme seen globally. Of the 549 
reported executions for drug offences carried out 
around the world in 2013, the majority were in Iran 
and Saudi Arabia.(37) Iran executed 367 people for drug-
related offences in 2014; however, this number is likely 
to be an underestimate.(37)
While there is no evidence to suggest that the death 
penalty for drugs serves as a deterrent to drug offences, 
the extremely punitive environment certainly hampers 
the extent to which harm reduction services can be 
delivered. Civil society reports that many people are 
often frightened to approach harm reduction services 
as they have experienced high levels of stigma, including 
frequent episodes of verbal and physical abuse by wider 
society and law enforcement figures, and a refusal of 
housing and employment as a result of being identified 
as someone who uses drugs.(5)
Few harm reduction services are tailored for women,(38) 
and further attention is required to ensure an 
appropriate response in the region to the health and 
social needs of women who inject drugs.(39) A regional 
capacity-building workshop on gender equality in harm 
reduction services was held in September 2015 by the 
Harm Reduction Consortium, comprising seven of the 
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leading international and regional harm reduction, drug 
policy and drug user networks. A number of civil society 
organisations from the MENA region participated in 
discussions on how to incorporate gendered services 
in harm reduction, and a manual entitled Integrating 
Gender-Specific Services to Harm Reduction Programs in 
the MENA Region has been developed and is awaiting 
publication. The manual includes a compilation of 
recommendations on how to address the gaps in 
providing harm reduction services to women, such 
as advocating for laws that specify access to services 
for females, and the recruitment of female outreach 
workers.(35)
Ongoing conflicts in MENA countries have led to large 
numbers of internally displaced, refugee and migrant 
populations in the region, and there is a need to explore 
the extent to which injecting drug use occurs among 
these groups and to establish the required harm 
reduction response.(39) More than half of the world’s 
refugees are located in Pakistan, Iran, Jordan and 
Lebanon,(36) which are also countries that sit along key 
drug-trafficking routes. These factors are a challenge 
to the fostering, implementation and scale up of harm 
reduction in the region.(36)
Developments in harm reduction 
implementation
Needle and syringe programmes (NSPs)
Within the MENA region, NSPs are available only in 
Israel, Egypt, Jordan, Iran, Lebanon, Morocco, Palestine 
and Tunisia. However, even where available, these 
services continue to fall short of need. Only in Iran, 
where unsafe injecting drug use continues to be the 
greatest contributor to HIV incidence, is NSP provision 
substantial, with 580 sites across the country.(6) NSP 
provision has steadily increased over the last five 
years, with coverage going from 26 to 35 syringes per 
person who injects drugs per year in 2012,(24) to 44 to 
60 syringes in 2015. However, this is still considered to 
be low coverage by UN standards.(6)r In 2015, 81.5% of 
people who inject drugs reported using sterile injecting 
equipment,(6, 7) with specific NSP sites, together with 
pharmacy provision, believed to contribute to relatively 
low unsafe injecting in the country.(6) In total, 10,136,060 
free sterile needles and syringes were provided to 
people who inject drugs in 2015 via the state welfare 
organisation.(6)
Since 2014, MENAHRA has financially supported 
organisations involved in NSP provision in Egypt, Jordan 
and Lebanon via the Global Fund regional grant. In 
Egypt, MENAHRA worked with two organisations, Friends 
of HIV+ and the Friends Association, to provide 21,235 
and 19,972 sterile needles and syringes respectively 
between July and December 2015.(5) UNODC also 
assisted with increased coverage of NSP provision in the 
Luxor and Alexandria governorates, distributing 4,000 
syringes between April and June 2015.(40) In Lebanon, 
Soins Infirmiers et Développement Communautaire 
(SIDC) reached a total of 176 people who inject drugs 
with NSP services in 2015, distributing a total of 89,523 
needles and syringes.(5) Skoun, a smaller NGO in 
Lebanon, also provided NSP outreach, distributing a 
total of 480 needles and syringes in the same year.(5) 
In Jordan, both Forearms of Change Center to Enable 
Community (FOCCEC) and Friends of Development 
and Investment Society (FDIS) delivered NSP through 
outreach and fixed sites in 2015, delivering 63,396 and 
80,368 sterile needles and syringes respectively.(5)
UNODC, in close partnership with civil society 
organisations, continues to provide comprehensive 
HIV services for people who inject drugs through drop-
in centres and outreach programmes in Palestine 
(specifically the West Bank and Gaza). In 2015, 456 
people who inject drugs benefited from harm reduction 
services, with 22,790 needles distributed and 1,396 
information, education and communication materials 
given to beneficiaries.(40) In Morocco, 238,946 syringes 
were provided to people who inject drugs (80 per 
person who injects drugs per year) during 2014, 
considered low coverage by UN standards.(19) In Israel, 
where NSPs operate in five cities, a total of 214,777 
sterile needles and syringes were distributed in 2015.(9)
Although the primary mode of HIV transmission in 
Bahrain is unsafe injecting drug use, there is still no 
NSP provision in the country and people are often 
arrested for possession of syringes.(1) In Jordan, FDIS and 
FOCCEC organised a stakeholders’ meeting in Amman 
to raise awareness of the benefits of NSP as a vital 
harm reduction service, and to disseminate the positive 
impact of the NSPs running in Jordan across the wider 
regional community.
There continues to be a complex interplay between 
political, legal and social commitments to harm 
reduction initiatives for people who inject drugs in the 
MENA region. Many countries, such as Bahrain, Kuwait, 
Qatar, Algeria, Saudi Arabia, UAE, Yemen and Iraq, 
continue to offer only abstinence-based detoxification 
services for people who use drugs, ignoring the 
individual and public health benefits a harm reduction 
approach could bring.
r According to the 2012 revised WHO, UNODC and UNAIDS target-setting guide, less than 100 syringes distributed per person who injects drugs per year is considered low   
     coverage (100 to 200 is medium coverage and more than 200 is high coverage).
1262.8 MIDDLE EAST AND NORTH AFRICA
Opioid substitution therapy (OST)
Five countries in the region provide OST: Iran, Israel, 
Lebanon, Morocco and Palestine. However, many of the 
OST services fall short of need.
Iran presently runs the largest OST service in the region, 
but even its coverage levels are only just considered 
high by UN standards, with 41.2% of people who had 
injected drugs in 2014 in receipt of OST.(7)s Iran has since 
continued expansion of its OST programme, going from 
4,275 sites in 2014 to 5,983 sites in 2016.(6) According 
to UNAIDS, Morocco has also expanded its OST 
provision, enrolling 628 people who inject drugs onto 
its methadone programme during 2014.(19) Despite this 
increase in provision, OST continues to have long waiting 
lists in both Morocco and Iran, with additional barriers 
in Morocco such as limited geographical coverage, 
restrictive prescription and delivery regulations for 
methadone (limited to a psychiatrist or physician 
specialising in drug use) as well as a lack of high-dosage 
buprenorphine.(36)
Global State 2014 reported no OST in Egypt. Since 
then, however, UNODC convened a National Opioid 
Substitution Therapy Taskforce, commissioning a 
feasibility study to select, approve and procure the most 
appropriate controlled substances for piloting OST.(34) A 
pilot OST programme is now pending approval in Egypt.(35)
Following the first pilot of methadone maintenance 
treatment (MMT) in Ramallah, Palestine, which was 
initiated in May 2014, the Ministry of Health opened 
its first permanent OST site in Ramallah.(40) Prior to 
its inception, the UNODC conducted a one-week 
specialised training course on OST for 15 healthcare 
service providers in the Ministry of Health. The training 
covered all aspects of a diversified, accessible and 
quality drug dependence treatment service, including 
opioids and other drugs, maintenance treatment (the 
medicines, the evidence, effective practices – such as 
evaluation, initial dose and management of dose – 
and tapering procedures), clinical care detoxification, 
dual diagnosis and relapse prevention. By the end of 
September 2015, 65 people had benefited from this new 
harm reduction service.(40)
Viral hepatitis
There continues to be little data on the prevalence 
of viral hepatitis among people who inject drugs in 
countries within the MENA region. However, since 
Global State 2014, the hepatitis response in the region 
has entered a nascent stage, with some countries 
beginning to offer rapid screening for the hepatitis B 
and C viruses, alongside HIV screening.(5) In Jordan, 
for example, rapid screening as part of outreach 
programmes for people who inject drugs became 
available in August 2014. In Lebanon, rapid hepatitis C 
testing is available at voluntary counselling and testing 
centres and via outreach programmes for people who 
use drugs.(35)
The World Health Assembly adopted the Global Health 
Sector Strategy on Viral Hepatitis 2016–2021 in May 
2016. This strategy includes the term ‘key populations’ 
and highlights the need for a tailored response to 
tackling hepatitis among these groups.(41) Within this 
framework, there is an action plan for WHO’s Eastern 
Mediterranean Regional Office to focus its support 
on establishing national leadership and coordination 
in hepatitis control, and on collecting and analysing 
strategic information to guide the response, including 
the revision of policies. This work will also seek to 
strengthen services for the prevention and treatment of 
hepatitis by setting prevention, diagnosis and treatment 
targets for people who inject drugs; to collect and 
disseminate data; to promote policy dialogue to address 
barriers to harm reduction; to increase access to 
affordable medicines; and to monitor and evaluate the 
response for people who inject drugs.(41)
In light of the increasing hepatitis C epidemic, Egypt 
launched the first domestically funded national free 
treatment programme for hepatitis C in the region in 
2015.(42) This treatment is for people who are co-infected 
with HIV, but it is unclear how accessible the service is 
for people who inject drugs.(5)
At the end of 2014 the Lebanese Ministry of Health 
invited MENAHRA to collaborate in the roll out of a 
national hepatitis B vaccination programme for people 
who inject drugs. In April 2015 they held a training day 
for NGOs who were interested in participating. The aim 
of the training was to present the hepatitis B vaccination 
project elements to the participants and to review the 
developed documentation and evaluation tools. In 
August 2015, the project protocol was sent to the NGOs 
involved in order to begin implementing the project. 
Later that year 840 hepatitis B tests and 500 hepatitis C 
tests were distributed to the organisations.(35)
Although many countries in the region report hepatitis 
diagnostics and treatment availability to people who 
inject drugs (Bahrain, Egypt, Oman, Iraq, Iran, Kuwait, 
Qatar), it is clear that the lack of testing for people who 
inject drugs, problematic structures regarding referrals, 
stigma and inaccessibility of services, plus limited 
government support for this population, continue to 
s The 2012 revised WHO, UNAIDS and UNODC target-setting guide categorises OST coverage levels as follows: low coverage is less than 20%, medium coverage is between 
     20% and 40% and high coverage is more than 40% of opioid-dependent people who inject drugs on OST.
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pose great barriers to eliminating the hepatitis C virus 
among people who inject drugs.
Amphetamine-type stimulants (ATS)
Use of amphetamine-type stimulants appears to be 
increasing in certain countries in the region, with 
injecting becoming more prevalent. For example, among 
those who had injected within the last month in Iran, 
20.7% had mostly used methamphetamine, with 21.1% 
injecting.(6, 7) Captagon, an ATS, has seen an increase in 
use in many countries in the Middle East, in particular 
Lebanon, Saudi Arabia and Syria.(43)
Although an increase in ATS use is reported, only Iran 
has prepared a guideline, yet to be published, for the 
integration of ATS harm reduction strategies into current 
harm reduction initiatives in the country, which is in 
the piloting phase.(5) In Bahrain, training has been put 
in place for a national drug information expert team 
to update the previously conducted drug situation 
assessment in order to provide a more accurate picture 
of the recent emergence of ATS in the country.(40)
Tuberculosis (TB)
There is very little data on TB among people who inject 
drugs in countries in the MENA region. Although the 
WHO recommends diagnosis and treatment of TB as 
an integral component of the harm reduction package, 
targeted TB services for people who inject drugs are 
rarely in place. Within the region, only Morocco,(18) 
Oman(20) and Iran (by referral only)(6) document the 
availability of TB diagnosis and treatment for people who 
inject drugs.(42) However, TB screening targeting people 
who inject drugs is not evidenced.
Antiretroviral therapy (ART)
According to a report from UNAIDS, there are very low 
rates of HIV testing among people who inject drugs in 
the MENA region.(44) Many countries in the region are yet 
to offer harm reduction services, and where HIV testing 
and treatment for people who inject drugs is integrated 
or linked with harm reduction programmes, a lack of 
proper coordination between services reduces the 
effectiveness of such initiatives.(5)
There are some examples of good practice, however. In 
Iran, 68 facilities out of 269 offering ART also have OST 
services in place, with a further 142 sites linking clients 
with OST services if requested.(6) Capturing the number 
of people who inject drugs who have received HIV 
testing and treatment is often complex, and data are not 
disaggregated by population. However, Iran reported 
that 2,404 people who inject drugs were on ART in 
2013.(6) In 2015 SIDC in Lebanon provided testing for 
HIV, HCV and HBV to 217 people who inject drugs and 
FOCCEC in Jordan reached 146 people with the same 
tests.(5) UNODC, in close partnership with civil society 
organisations, also continued to provide comprehensive 
HIV services for people who inject drugs in drop-in 
centres and outreach programmes in Palestine.(40)
Although ART provision is available to all in the MENA 
region, civil society reports that people who use drugs 
have been marginalised and stigmatised within HIV 
treatment settings, which discourages service access 
and utilisation. Further reported barriers include weak 
referral systems to clinics providing care and treatment 
after HIV diagnosis and the geographical distance 
people are required to travel to get to ART sites. Many 
people who inject drugs in the region are deemed 
ineligible for ART due to a requirement for detoxification 
prior to initiating treatment.(5)
Harm reduction in prisons
There are approximately 625,413 prisoners in the 
MENA region,(45)t one-third of whom are reported to be 
incarcerated on drug-related charges.(46) Considering 
that conviction and punishment of people who use 
drugs is the primary approach for combating illicit drug 
use in the region,(46) with countries like Bahrain even 
arresting people for simply possessing syringes,(47) these 
figures are not very surprising. Injecting drug use in 
prison has been documented in several MENA countries, 
including Iran, Lebanon, Morocco, Oman, Palestine and 
Syria.(48, 49) A recent study on HIV and HCV prevalence 
and incarceration-related risks in three Palestinian 
governorates, for example, found that 83.6% of a sample 
of 288 people who inject drugs had spent time in prison, 
with nearly half reporting that they had injected while in 
prison.(49)
Unsafe injecting drug use is considered the main mode 
of HIV and HCV transmission among prisoners in the 
MENA region.(48, 49) A recent review synthesising all 
available data on HIV and HCV in MENA prisons found a 
median HIV prevalence among incarcerated populations 
of 0.01% in Egypt, 2.5% in Iran, 0% in Iraq, 0.1% in 
Jordan, 0.05% in Kuwait, 0.7% in Lebanon, 18.0% in 
Libya, 0.7% in Morocco, 0.3% in Oman, 0% in Palestine, 
1.2% in Saudi Arabia, 0.04% in Syria, 0.05% in Tunisia 
and 3.5% in Yemen. Although very few countries in the 
region had data on HCV in prisons, a median prevalence 
of 23.6% was found in Egypt, 28.1% in Lebanon, 37.8% in 
Iran, 1.5% in Syria and 23.7% in Libya.(48)
t This number does not include Palestine, where there are still no prisoner estimates available.
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While these findings highlight the need to implement 
comprehensive harm reduction services in MENA 
prisons, the regional response continues to be weak. 
Since Global State 2014, Iran has reportedly ceased to 
provide NSPs in prisons, regrettably signifying the end of 
prison-based NSP provision in the region. OST continues 
to be available in more than 50% of Iranian prisons,(50) 
although with around 43,500 prisoners accessing OST 
in 2014, coverage still remains inadequate.(6) Dwindling 
focus on, and support for, harm reduction, both in 
prisons and in the broader community, has been 
identified as an emerging concern in Iran, with the 
expansion of harm reduction services currently under 
serious threat due to severe financial constraints.(6)
More encouragingly, OST has reportedly been initiated 
in Nador and Al Hoceima prisons in Morocco,(18) and 
OST pilots (accessible only to prisoners who were 
prescribed OST prior to their arrest) were launched in 
some Lebanese prisons.(5, 51) OST is also reported to be 
available in some Israeli prisons.(52)
Testing for HIV, which is often mandatory, and ART 
are reported to be provided to prisoners in just over 
one-third of the region’s countries, including Egypt,(42) 
Iran,(6) Israel,(9) Lebanon(13) Libya,(53) Morocco(5) and Saudi 
Arabia(32). The provision of HCV diagnosis and treatment, 
however, is much more infrequent, reportedly only 
available to prisoners in Egypt, Kuwait, Lebanon and 
Oman.(5, 11) TB diagnosis and treatment within prisons is 
also scarce throughout the region. Evidence of diagnosis 
and treatment of TB in prisons could be found only in 
Egypt (limited), Iran, Kuwait (limited), Morocco, Lebanon 
and Oman. It is not known whether these services are 
available in other countries. Condoms are available 
to prisoners in Egypt, Iran (limited to conjugal visits), 
Lebanon and Morocco only.(5)
Overdose
Data on fatal and non-fatal overdose remain extremely 
limited in the region. The availability of naloxone (a 
highly effective opioid antagonist that reverses the 
effect of overdose) is restricted to hospitals in most 
MENA countries, and so remains unavailable for peer 
distribution.(5)
In Lebanon, civil society organisations have taken action 
to end hospital reporting of overdose cases to the police 
– a practice that is known to deter people witnessing an 
overdose from calling emergency services. Skoun and 
MENAHRA conducted a nationwide campaign to change 
hospital policies that prevent people from seeking 
help when in need.(5) Following these advocacy efforts, 
the Ministry of Health in Lebanon issued an official 
statement to all hospitals requesting that they refrain 
from reporting any overdose case to the police.(54)
Policy developments for harm 
reduction
As noted in Global State 2014, very few countries in the 
region make explicit mention of harm reduction in their 
national strategies. Only Egypt,(55) Iran,(6) Morocco,(18) 
Syria(56)u and Tunisia(3) specifically mention harm 
reduction for people who inject drugs. Iran’s national 
guideline promotes the inclusion of people who inject 
drugs in all aspects of a comprehensive package of HIV 
services.(6) Lebanon’s updated national strategic plan 
notes a focus on most-at-risk populations, including 
people who use/inject drugs.(35) Algeria,(57) Jordan(10) and 
Saudi Arabia(32) all mention high risk or key populations, 
but without specific reference to harm reduction for 
these groups. The national HIV strategy for Libya is 
currently being redrafted.(53)
In 2014 Oman took steps towards updating its national 
AIDS strategy, but the new document, finalised in June 
2016, will include no explicit mention of key populations 
or harm reduction.(20) However, Oman’s national 
strategies for drug use control and prevention for 
2016 to 2020 and for HIV/AIDS control and prevention 
specifically mention harm reduction.(20) In addition, 
the national narcotic law in Oman has been updated 
and guidelines to deal with psychoactive substances 
in health institutions and pharmacies have recently 
been established.(5) In November 2015, the WHO also 
developed a harm reduction protocol with a focus on 
MMT in the country.(5) Thanks to the national strategies 
for drug use control and prevention and for HIV/AIDS 
control and prevention, there has also been an increase 
in voluntary testing and counseling in the Muscat region 
of Oman.(5)
In 2015 UNODC, in collaboration with the WHO, 
translated two key guidelines into Arabic: the 
guidelines for countries to set targets for universal 
access to HIV prevention, treatment and care for 
people who inject drugs,(58) and the guidelines for the 
psychosocially assisted pharmacological treatment 
of opioid dependence.(59) Both will help to fill existing 
technical gaps and open new windows of opportunity 
for evidence-based harm reduction and drug treatment 
services.(5) In Iran, based on identified barriers during a 
recent assessment on HIV testing and treatment, policy 
changes have been made to enable the integration of 
HIV treatment and care within OST sites.(60)
u	 Based	on	the	national	AIDS	strategy	for	the	Syrian	Arab	Republic	developed	in	2011.	Given	the	ongoing	state	of	conflict	in	the	country,	this	information	has	not	been						
     updated.
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Civil society and advocacy 
developments for harm reduction
Civil society networks and organisations in the region 
continue to play a consistent and vital role in advocating 
and implementing harm reduction approaches. 
MENAHRA has played a long-standing role as the 
regional harm reduction network, and its advocacy, 
capacity building, development of publications and other 
tools and support for harm reduction service delivery 
across 20 countries has continued since Global State 
2014.
MENAHRA led the civil society engagement in the recent 
high-level processes of the United Nations General 
Assembly Special Session (UNGASS) on the drugs in 
April 2016 and at the UN High-Level Meeting on HIV 
in June 2016. In October 2015 MENAHRA participated 
in the Regional Dialogue on Drug Policy and HIV, 
contributing to ongoing national and regional discussion 
in advance of UNGASS.(61) In an effort to highlight the 
rights of drug users to policy makers in the region, 
MENAHRA also developed and disseminated four 
position statements to coincide with different occasions 
in 2015: The International Day Against Drug Abuse and 
Illicit Trafficking on 26 June,(62) World Hepatitis Day on 28 
July,(63) International Drug Users Day on 1 November(64) 
and World AIDS Day on 1 December(65). Unfortunately, 
political commitment and support for harm reduction 
by country representatives within the region during the 
UNGASS process was absent.
MENAHRA works closely with civil society partners 
throughout the region, as well as other regional bodies 
that cover harm reduction in their remit. Between 8 
and 10 December 2015 in Beirut, Lebanon, MENAHRA 
and the Regional Arab Network Against AIDS (RANAA) 
convened a regional dialogue meeting to consult 
stakeholders on current regional and national harm 
reduction needs and priorities.(35)
MENAHRA also coordinated the ‘Support Don’t Punish’ 
campaign action within the region (please see report 
overview for further information on the campaign). 
Thirteen countries in the region took part: Bahrain, 
Egypt, Iran, Jordan, Kuwait, Lebanon, Morocco, Pakistan, 
Palestine, Saudi Arabia, Syria, Tunisia and UAE. Activities 
included theatre acts, video messages from key harm 
reduction decision makers and activists, seminars and 
position statements.(5)
In Egypt, 15 civil society organisations are part of the 
Network of Associations for Harm Reduction, established 
in 2010 to strengthen collaborations among harm 
reduction service providers and to reduce the stigma 
and discrimination faced by key populations.(42) The 
Middle East and North Africa Network of People who 
Use Drugs (MENAPUD), a regional network of people 
who currently use or formerly used drugs, was initiated, 
with support from MENAHRA, in 2011. In 2014, funds 
were secured via the MENAHRA Global Fund grant 
to appoint a coordinator and MENAPUD is currently 
working to facilitate its registration as an NGO.(35)
Religious leaders have significant influence on the 
acceptance of harm reduction practices in many 
countries within the MENA region. A regional advocacy 
meeting on harm reduction was held for religious 
leaders in December 2012. It issued a declaration on the 
rights to health and harm reduction for people who use 
drugs. The regional religious leaders group contributed 
to the development of guidelines for religious leaders on 
harm reduction during 2014 and 2015.(35)
Funding developments for harm 
reduction
The Global Fund continues to be one of the most 
significant financial contributors to harm reduction 
in MENA. MENAHRA, principal recipient of the 
regional harm reduction grant in the MENA region, is 
approaching the end of its round 10 Global Fund grant, 
which aimed to strengthen civil society to advocate 
for a more conducive environment for implementing 
harm reduction in 13 countries in the region.(5) Thus far, 
this grant has assisted harm reduction programming 
and advocacy in Egypt, Iran, Jordan, Lebanon, Libya, 
Morocco, Palestine, Syria and Tunisia.(5) In 2016, within 
the context of the Global Fund’s new funding model, 
MENAHRA and RANAA submitted a joint concept note 
for further funding, bringing together the two regional 
organisations in an effort to provide complementary 
advocacy, research and services in the region for people 
who inject drugs, men who have sex with men, sex 
workers and people living with HIV.(35) If successful, the 
regional grant will fund harm reduction initiatives for 
these key populations from 2017 to 2019.
In Iran, with the highest population of people who inject 
drugs in the region, the Global Fund grant covers the 
majority of the harm reduction programmes in the 
country, currently delivered via outsourcing to private 
or non-government sectors.(6) This grant will end in 
2018. While Iran is one of the few countries in the region 
where the national government invests in harm reduction, 
the extent of current investment is unclear.(6)  
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Given the high numbers of people who inject drugs in 
the country, the imperative for Global Fund financial 
support to be extended via the new funding model is 
clear.
National government funds also go towards harm 
reduction in Oman and Morocco.(18) Although the 
Global Fund has consistently funded harm reduction 
in Morocco, the head of state, King Mohammed VI, 
recently funded a harm reduction building through the 
Mohammed V Foundation.(36)
Investment by national governments in harm reduction 
is negligible in most MENA countries, with the vast 
majority of harm reduction funds coming from 
international donors.(5) In Egypt, for example, the Global 
Fund (through a national grant and via MENAHRA), the 
Drosos Foundation, FHI 360 and UNODC have assisted 
harm reduction services and advocacy efforts.(42)
Although it is widely acknowledged that harm reduction 
funding in the region falls far short of need, evidencing 
the amount spent is challenging and requires dedicated 
research. In light of this, MENAHRA, with funding from 
UNODC, is piloting an investment tracking tool for 
harm reduction in two countries (Morocco and Egypt) 
between 2015 and 2016. This tool, developed by Harm 
Reduction International, has been used in other regions 
and will serve to illustrate spend versus need, increasing 
evidence-based advocacy for continued funding for vital 
harm reduction programmes. There are presently plans 
to expand the investment tracking tool project into three 
other countries (yet to be identified) in the region during 
2017 with funding from the Robert Carr Foundation.(35)
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Country/territory 
with reported       
injecting drug usea
People who inject 
drugs
HIV prevalence 
among people 
who inject 
drugs (%) 
Hepatitis C 
(anti-HCV) 
prevalence 
among people 
who inject 
drugs (%)
Hepatitis B 
(anti-HBsAg) 
prevalence 
among people 
who inject 
drugs (%)
Harm reduction 
response
NSPb OSTC
Burkina Fasod nk nk nk nk 7 7
Côte d’Ivoire nk(1)e nk(1)f nk nk 7 7
Ghana 6,314(2)g nk nk 3.1(1) 7 7
Kenya 18,327(3) 18.3(3) 51.4 (42.2–60.6)(4) 6.4(4) 313(5) 35(5)
Liberia nk 3.9(6) nk nk nk nk
Malawi nk nk nk nk 7 7
Mauritius 11,677(7) 44.3(7) 96.5(8) 6.7(8) 349(7) 318(7)
Mozambique 2,204(9)h 50.3–73.1(10) 61.7–77.3(9) 32.1–36.4(9) 7 7
Nigeria 19,000(11) 3.4(11) nk nk 7 7
Senegal 1,324(12)i 9.1(13) 38.85(12) nk 3 3(1)(14)
Seychelles 346(15) 5.8(15) 53.5(15) 0.1(15) 7 3(1)(15)
South Africa 75,000(16)j 14(16) nk nk 33(16) 3(M,B)(K)
Tanzania 30,000(17,18) 35(18) 28(19) nk 35(20) I,m 33(M,O)(20)
Uganda nk nk(21) nk nk 7 7
Zanzibar nk 11.3(22) nk nk 7 7
nk = not known
Sub-Saharan Africa
Table 2.9.1: Epidemiology of HIV and viral hepatitis, and harm reduction responses in Sub-Saharan 
Africa
a The countries included in this table are those with reported injecting drug use according to the 2008 United Nations Reference Group systematic review and/or with opera-
tional NSPs or OST at the time of data collection. HRI also found data on injecting drug use in Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Djibouti, Ethiopia, Gabon, 
Gambia,	Guinea,	Malawi,	Mali,	Niger,	Rwanda,	Sierra	Leone,	Somalia,	Togo,	Zambia	and	Zimbabwe,	but	did	not	find	verified	data	to	include	on	these	countries.
b	 All	operational	needle	and	syringe	exchange	programme	(NSP)	sites,	including	fixed	sites,	vending	machines	and	mobile	NSPs	operating	from	a	vehicle	or	through	outreach	
workers.
c Opioid substitution therapy (OST), including methadone (M), buprenorphine (B) and any other form (O) such as morphine and codeine.
d Global State of Harm Reduction 2014 reported that Burkina Faso had one OST site in operation. This information was incorrect and has therefore been omitted from this 
2016 report.
e Estimates based on sub-national data from Abidjan, there are believed to be 3,521 drug users who had used heroin and/or cocaine (both injecting and non-injecting) in the 
past year (see Overview below).
f Estimates based on sub-national data from Abidjan, the HIV prevalence rate among people who inject drugs is 5.2%, but this is based on a sample size of 57 (see Overview 
below).
g Estimates based on sub-national data in four areas: Accra, Tema, Cape Coast and Sekondi-Takoradi.
h	 Estimates	based	on	median	Integrated	Biological	and	Behavioral	Surveillance	(IBSS)	findings	conducted	in	Maputo	and	Nampula,	which	looked	at	lifetime	injecting.
i Estimates based on sub-national data from the Dakar region referring to people who use injectable drugs inclusive of heroin and cocaine.
j In late 2015 a stakeholder meeting hosted by the South African National AIDS Council to review the estimates on people who inject drugs, based on expert consultation and 
the available data, revised the previous estimate of 67,000 to 75,000.
k	 It	is	not	possible	to	put	a	figure	on	the	exact	number	of	OST	sites	in	operation	within	South	Africa	as	OST	is	also	available	in	private	clinics	and	government	hospitals	(the	
latter	use	it	for	detoxification	only).
l	 Médecins	du	Monde	and	its	partner	NGO	Mukikute	are	the	only	two	NGOs	implementing	NSPs	in	Dar	es	Salaam	through	five	fixed	sites	and	56	outreach	sites	with	the	
support of external donors.
m	 NSPs	operate	in	five	fixed	sites	in	three	districts	(Temeke,	Llala	and	Kinondoni).	Outreach	workers	also	provide	NSP	in	107	hotspots	within	the	three	districts.
n Based on a study conducted in Kampala in 2012, HIV prevalence among people who inject drugs was 16.7%, but this is based on a sample size of 54 (see Overview below),
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Both NSP and OST available
OST only
NSP only
Neither available
Not known
Map 2.9.1:  Availability of needle and syringe programmes (NSP) and opioid substitution therapy 
(OST)
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Harm reduction in Sub-Saharan Africa
Overview
An estimated 25.6 million people are living with HIV 
in the region of sub-Saharan Africa. UNAIDS reports 
substantial gains against HIV in the region since 2010, 
including a decline in the number of new HIV infections. 
This decline is most marked in eastern and southern 
Africa, where HIV incidence was 4% lower in 2015 than 
it had been in 2010, with 40,000 fewer people becoming 
HIV-positive. Similarly, coverage of antiretroviral 
treatment (ART) doubled in the region between 2010 
and 2015, meaning that over half of those in need now 
receive HIV treatment.(23)
The proportion of new HIV infections attributed to 
unsafe injecting drug use is relatively small compared 
with that in other regions: 0.4% of new HIV infections 
in western and central Africa, and 2% in eastern and 
southern Africa.(23)O In real terms, however, these 
proportions, which are based on a dearth of data 
and believed to be underestimates, add up to tens 
of thousands of people whose acquisition of HIV via 
unsafe injecting could have been prevented through 
the provision of harm reduction services. Indeed, new 
research on drug injecting from several countries in the 
region illustrates the potential for rapid expansion of the 
HIV epidemic through unsafe injecting and clearly shows 
the urgent need for harm reduction implementation 
and scale-up. For example, research has shown that 
between half and three-quarters of the people who 
inject drugs in Mozambique are living with HIV,(10) and 
over three-quarters are living with the hepatitis C virus 
(HCV).(9)
Since the Global State of Harm Reduction 2014, there 
has been an increase in international donor support 
for harm reduction activities in several countries in 
the region. This support covers essential academic 
research, advocacy and civil society strengthening 
as well as the establishment and implementation of 
programmes. Sub-Saharan Africa is likely to be the only 
region experiencing an increase in harm reduction 
funding, as the wider context is one of donor retreat 
from investment in middle-income countries in favour 
of directing support towards low-income countries. It 
is vital to note, however, that although harm reduction 
funding may be increasing, it is still supporting advocacy 
and programming in only a handful of the 54 countries 
that make up the African Union.
More research on injecting drug use has begun to 
emerge from the region, some of which was featured in 
a special issue of the International Journal of Drug Policy 
on sub-Saharan Africa in 2016.P A handful of countries 
do operate harm reduction services, although some of 
these are still in their infancy and operate on a small 
scale. After a long period of political rejection of harm 
reduction services, Kenya now has both NSP and OST 
facilities, with its NSP service being steadily scaled up 
over the last decade to 13 NSP sites in operation. Since 
the Global State 2014, five OST sites are now in operation 
where previously there were none.(5) According to the 
National AIDS and STI Control Programme data from 
2014 to 2016, 20 needles and syringes are distributed 
per person who injects drugs per year in Kenya. This 
provision is still significantly below internationally 
recommended standards, but it is a step forward in 
Kenya’s harm reduction response.
For the first time since the inception of the Global 
State of Harm Reduction report in 2008, information 
has become available on injecting drug use in Côte 
d’Ivoire, where, thanks to international donor support, 
the NGO Médecins du Monde (MdM) is working with 
local partners to develop harm reduction strategies 
for people who use drugs. As the primary form of 
heroin and cocaine consumption is smoking, MdM, 
alongside local partners, distributes information on 
safer pipe smoking to ensure people do not have to 
share equipment. They also provide medical care and 
support, including HIV testing.(24) In a study involving 450 
people who use drugs in Abidjan, Côte d’Ivoire, almost all 
respondents (98.2%) reported consuming heroin, with 
12.7% reporting injecting. Only one respondent noted 
that he had shared a syringe.(1) Civil society reports that 
syringes are available from pharmacies at low cost and 
without a medical prescription, but states the need for a 
harm reduction strategy to be put in place.(24)
In Kampala, Uganda, a study conducted in 2012 found 
that 16.7% of people who inject drugs tested positive 
for HIV.(21) In Ghana, a study estimated that 6,000 
people were injecting drugs, and highlighted the sharing 
of needles as well as the use of discarded injecting 
equipment found in hospital waste.(2, 25, 26) In Nigeria, a 
study undertaken in 2010 found that HIV prevalence 
rates among people who inject drugs ranged from 3% 
to 9.3%,(27) with 72% of respondents residing in the 
Federal Capital Territory reporting sharing needles.(27) 
Despite these findings, and the clear and urgent need 
o	 In	terms	of	HIV	prevalence	among	people	who	inject	drugs,	many	of	the	figures	cited	in	Table	2.9.1	often	stem	from	sub-national	data	and	should	therefore	be	viewed	with	
caution.
p The International Journal of Drug Policy’s special issue on sub-Saharan Africa (published in April 2016) is available from: www.ijdp.org/issue/S0955-3959(16)X0004-7.
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they illustrate, harm reduction interventions have yet 
to be implemented in the Côte d’Ivoire, Nigeria, Ghana, 
Mozambique or Uganda.
Although there has been progress in expanding the 
harm reduction response in some countries, there 
remains a predominantly punitive response to drug 
use in the region, with incarceration of people who use 
drugs on the rise.(28) Through continued civil society 
advocacy, academic research and international donor 
support, knowledge and awareness of harm reduction 
is increasing in several countries and pushes against the 
tide of negative and stigmatising attitudes and policies 
towards drug use. As in other regions, political and 
financial support for harm reduction is often precarious.
Changes in the political landscape can have a direct 
impact on the provision of harm reduction services. For 
example, a change in government in Mauritius in late 
2014 resulted in a severe scaling down of the national 
harm reduction response. Global State 2014 reported 
on Mauritius’s unique place in the region as a leader in 
harm reduction, with political and financial support from 
the national government for the provision of both NSPs 
and OST. Since then, the new government has moved 
OST distribution away from the health service to police 
stations with daily fixed times for people who use drugs 
to attend, and the number of needles and syringes that 
NGOs are able to provide has been greatly restricted(29) 
Tanzania’s 2015 change in government has also led to 
a stagnation of the harm reduction services available, 
with OST programmes in the country accepting no new 
clients.(5, 16)
Policies that greatly restrict the implementation of harm 
reduction remain in place in many countries in this 
region, despite a regional call by the African Union for 
harm reduction scale-up.(30) In Nigeria, for example, there 
continues to be no harm reduction policy or programme 
that is nationally approved,(31) even though the national 
policy for the control of viral hepatitis called for these 
essential services to be implemented.(32) In Uganda, the 
government is reluctant to amend certain sections of 
the Anti-Narcotics Act, which provides for long custodial 
sentences for non-violent drug-related offences.(33)
Since Global State 2014, there have been some 
significant developments in South Africa in relation to 
harm reduction research, policy and practice. Although 
the scale-up of harm reduction services remains 
slow, these programmes are now recognised by the 
Departments of Health and Social Development and 
by the Central Drug Authority as essential.(16, 34) The 
implementation of new NSP sites in different parts of 
the country is evidence of this positive step forward.(16,34) 
Political acceptance for harm reduction approaches is a 
welcome and an important progression, particularly in 
light of reports of high levels of the sharing of injecting 
equipment among people who inject drugs in South 
Africa.(35)
Although harm reduction services are improving in 
some countries in sub-Saharan Africa, it is clear that 
there is still discordance between the levels of HIV and 
HCV among people who inject drugs and the adequacy 
of service provision. Significant structural barriers in 
the form of drug policy, criminal laws, law enforcement 
and political priorities remain firmly in place for harm 
reduction in much of the region. Even where NSP and 
OST services are operating, people who use drugs often 
feel stigmatised and discriminated against when seeking 
out HIV testing and treatment, with a lack of integrated 
service provision for this key population group.(16, 29, 34, 36, 37) 
In addition, as in other regions, HCV treatment remains 
beyond the grasp of the vast majority of people (both 
people who use drugs and those who do not) due to its 
exorbitant costs. Many of the newer HCV direct-acting 
antivirals are not widely registered in the region, causing 
additional barriers.(16, 38)
Civil society organisations and drug user networks are 
attempting to overcome many of the structural hurdles 
in place and are steadily gaining a stronger voice 
within the political landscape of drug policy and harm 
reduction. In Senegal, the first association of people who 
use drugs, Health Life Hope (SEV), has begun advocating 
for a risk reduction rather than a punitive approach to 
drug policy in the country.(14) In South Africa, advocacy 
efforts preceded the launch of three NSP sites,(16) and 
two drug user networks were formed in Cape Town and 
Pretoria in 2015.(34)
With planned further research on injecting drug use 
in certain countries in the region emerging (from 
government departments, civil society groups and 
academics), continued funding from multilaterals such 
as the Global Fund, a growing civil society movement, 
the inclusion of drug user networks in the discourse, 
and umbrella advocacy groups (such as the West African 
Harm Reduction Network and the East Africa Harm 
Reduction Network) forming across territories, it is 
hoped that harm reduction will continue to gain strength 
in sub-Saharan Africa. However, it must be noted that in 
the majority of countries in the region there continues 
to be a rejection of harm reduction approaches, and 
further work on advocacy and awareness is essential.
1382.9 SUB-SAHARAN AFRICA
Developments in harm reduction 
implementation 
 
Needle and syringe programmes (NSPs)
As illustrated in Table 2.9.1, only five countries (of the 54 
countries that make up the African Union) provide NSP 
services for people who inject drugs: Kenya, Mauritius, 
Senegal, South Africa and Tanzania.
Kenya estimated HIV prevalence rates for people who 
inject drugs, between May and December 2012,  as 
14.5% in Nairobi and 20.5% in the coastal regions, with a 
reported 23% of people in Nairobi sharing needles.(39)  
In 2012 the Kenyan government announced the 
initiation of NSPs in the country, resulting in ten newly 
operational sites by 2014 reaching 4,500 people who 
inject drugs(40) The model used combined fixed-site 
NSPs alongside NSP outreach.(41) Prior to the inception 
of this service, UNAIDS estimated that 51.6% of people 
reported using sterile injecting equipment.(3) In 2016 the 
Community Action on Harm Reduction (CAHR) project 
found that 88.8% of people reported using sterile 
needles,(42) which is suggestive of the NSPs’ success. 
Given these figures, the Global State can now report 
Kenya’s consistent scaling up of NSP site provision, 
with civil society reporting up to 12,000 people who 
inject drugs accessing these services.(5) This rise in harm 
reduction service provision is thanks to both national 
and international advocacy efforts in the country, 
alongside increased international donor funding and 
government support (both political and financial).(5)
Global State 2014 reported on a planned harm reduction 
demonstration project in South Africa, due to begin in 
Cape Town, Durban and Pretoria.(43) This project, an 
initiative of the US Centers for Disease Control and 
Prevention, was established in 2014 by civil society 
organisations (TB/HIV Care Association and OUT LGBT 
Wellbeing) and provided over 400,000 needles and 
syringes within its first year of operation, alongside HIV 
testing and links to care for key populations in these 
areas. Thanks to this project there are now three NSPs 
operating in South Africa and, for the first time, a sub-
district of the Department of Health in the Western 
Cape provided a consignment of needles. The only NSP 
that operated previously (for men who have sex with 
men (MSM) and funded by Aids Fonds) came to an end 
in 2014. The beneficiaries of this service have been 
referred to the new NSPs in operation.(16)
Although injecting is not reported to be the main form 
of heroin use in Tanzania, with many people smoking 
cocktail (cannabis, tobacco and heroin), unsafe needle 
sharing is commonplace among those who do inject,(44) 
and HIV and HCV prevalence rates among people who 
inject drugs are estimated to be 51.1% and 75.6% 
respectively.(45) Smoking is also more commonplace 
than injecting in Senegal. However, amongst people 
who inject drugs in Senegal, HIV and HCV prevalence 
rates are lower, at 9.4% and 38.85% respectively.(12) In 
Tanzania, Médecins du Monde and its partner NGO 
Mukikute are the only two NGOs implementing an 
NSP service in Dar es Salaam, with five fixed sites and 
107 mobile outreach units.(20) Senegal’s NSP services 
began in 2011 in the Dakar region and are provided 
through the NGO Centre de Prise en Charge Intégrée 
des Addictions de Dakar (CEPIAD).(37) Given the rise in 
drug use in Tanzania, and the clear need of people who 
inject drugs in both Tanzania and Senegal, there is a 
definite requirement for further implementation of harm 
reduction services in these countries.(12, 14, 44) It seems 
that there has not been a major expansion of services 
in either Tanzania or Senegal since 2014.(14, 20) Civil 
society in Senegal reports that NSP implementation and 
scale have been hampered by the lack of aregulatory 
framework for the sustainability and safety of both NSP 
workers and those in receipt of the service.(14)
Despite the increasing number of NSP sites in sub-
Saharan Africa, coverage remains extremely low, with 
many countries where injecting is known to occur not 
providing this essential service.q The government of 
Nigeria does not politically support the provision of 
NSPs as a service for people who inject drugs. However, 
NGOs working in the field do try to provide sterile 
syringes.(31) Needles are reported to be widely available 
at pharmacies and medicine stores,(46) but it is unclear 
how accessible pharmacy provisions are to people who 
inject drugs. In the Seychelles, it has been found that 
high percentages of people who inject drugs practice 
unsafe injecting behaviour,(15) but an NSP service is yet to 
be established.
In those countries where NSP sites do exist, there is 
often intense social stigma around injecting drug use 
and the use of the programmes. For example, people 
accessing NSPs in South Africa may be subjected to 
multiple rights infringements, including harassment, 
arrest without cause and the confiscation of and 
breaking of injecting equipment by police.(16)
NSP sites in Mauritius, although still operational and 
financially supported by both the government and the 
Global Fund, are restricted by a fixed quota of 30,000 
needles per month.(29) This restriction has emerged since 
a new government came to power in December 2014, 
q Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Côte d’Ivoire, Djibouti, Ethiopia, Gabon, Gambia, Ghana, Guinea, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria,      
					Rwanda,	Seychelles,	Sierra	Leone,	Somalia,	Togo,	Uganda,	Zambia,	Zanzibar,	Zimbabwe.
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even though the number of people who inject drugs in 
the country is increasing.(29) Previously the provision of 
injecting equipment was responsive to need. However, 
due to the lack of materials provided by the Ministry of 
Health, provision has now been restricted to a quota of 
five syringes per person per visit, falling vastly short of 
the requirement for this population.(29)
 
Women, health and harm 
reduction
Women who inject drugs often experience 
disproportionately higher levels of negative health 
outcomes(19, 47) and face a greater risk of HIV than their 
male counterparts. This disparity has been documented 
in various countries:
• In Senegal, HIV prevalence among female drug users 
was found to be over four times that of male drug 
users (13.0% and 3.0% respectively).(12)
• In Tanzania, HIV prevalence rates reach 71% among 
women who inject drugs,(48) over four times higher 
than the national HIV prevalence estimate for all 
people who inject drugs (15.5%).(17)
• In Nigeria, women who inject drugs were found to 
have higher HIV prevalence rates than men in all 
four states surveyed, aside from the Federal Capital 
Territory.(27)
In South Africa, NSPs are still experiencing challenges in 
reaching women who inject drugs with their services(16) 
To ensure that services are well-equipped to reach 
women who inject drugs, service providers, including 
medical institutions providing HIV testing and treatment, 
must gain the trust of women who inject drugs. This 
trust can be established via the medium of women peer 
workers, multiple encounters and making personal 
connections with women who inject/use drugs.(48)
In Kenya, NSP services are using community-based 
outreach enabling access to equipment for women who 
do not wish to be seen seeking services.(5, 40, 49) Women 
who inject drugs have played a significant role in the 
development and implementation of harm reduction 
services in the CAHR project.(42) 
It has also been suggested that interventions directed 
towards sexual risk reduction in combination with harm 
reduction should be used for women who inject drugs.
(50) This approach recognises the link that may exist in  
 
 
some settings between heroin use, HIV and low condom 
use during sex work, serving to further increase the risk 
for women.(27)
 
Opioid substitution therapy (OST)
As with NSP, the majority of countries in sub-Saharan 
Africa with reported drug use have not yet introduced 
OST programmes (see Table 2.9.1 and Map 2.9.1). OST 
remains largely unavailable, with only six countries in the 
region implementing this as a public service.
In Kenya, OST was introduced outside of private 
providers in December 2014.(51) Although the scale of 
this service is small at present, three fixed sites have 
been initiated within two years in hospitals in Nairobi, 
Malindi and Mombasa, and two further independent 
sites were launched in 2016.(5) Mathematical modelling 
has shown that approximately 10% coverage of OST 
over a five-year period could reduce the HIV incidence 
among people who previously injected drugs by 
between 5% and 10%, and if coverage attains 40% the 
reduction could reach 20%.(51) Since the inception of the 
OST programme in 2014, 1,100 people have enrolled in 
this service.(32) However, in-depth interviews with people 
who inject drugs in Kenya show that while some are able 
to access the programmes successfully, others report 
hardship, stigma and the challenge of discrimination by 
clinic staff.(52)
In South Africa, the small pilot project in the Western 
Cape has been joined by a government-funded and NGO-
run OST site in Cape Town, providing buprenorphine-
naloxone to people who inject opiates(16, 53) The city of 
Tshwane in Gauteng has entered into an agreement for 
OST to be made available at selected primary healthcare 
centres, and an OST demonstration project is at the 
planning stage in Durban, with political support from the 
provincial Department of Health.(16) These are important 
developments within South Africa, where, until recently, 
OST provision was largely limited to the private sector.
Tanzania continues to have the largest government-run 
OST programme in sub-Saharan Africa. The first OST 
clinic offering methadone was launched in February 
2011 at the Muhumbili National Hospital in Dar es 
Salaam(54) and the programme continues to operate 
from three OST sites.(20) Since the change of government 
in 2015, however, no new clients have been accepted 
onto the OST programme.(5, 16)
In Senegal, OST has also been established in a medical 
centre in Dakar. There has also been a greater focus on 
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mapping injecting drug use in Senegal in recent years, 
with early findings showing that heroin is the most 
popular drug of choice, but it is often smoked rather 
than injected.(12) These findings illustrate the urgent need 
to scale up OST availability for people who use (including 
those who smoke) opiates.
In Mauritius, under the new government elected in 
2014, OST distribution has been moved from the health 
service to police stations, with daily fixed times (6.00 to 
8.00 am) for people who use drugs to attend.(29) OST 
from government-supported services is available only 
to people who had initiated treatment prior to the 
inception of new policies in January 2015, including 
those on maintenance therapy before that date.(29) 
Instead, Suboxone and Naltrexone are available, but 
selection criteria for this new treatment are uncertain(29) 
The retreat from a well-established and government-
supported harm reduction programme encompassing 
52 NSP sites and 16 OST sites is of international 
concern. Mauritius, which had been a harm reduction 
champion in the region, is now facing an increase in HIV 
and HCV infection among the estimated 10,000 people 
who inject drugs there.(55)
Viral hepatitis
Data on the extent to which people who inject drugs 
are affected by hepatitis C (HCV) in sub-Saharan 
Africa remain extremely limited. From the estimates 
available, it is clear that the prevalence of HCV is very 
high among people who use drugs when compared 
with national estimates. HCV prevalence among people 
who inject drugs in the Kinondoni municipality of Dar 
es Salaam, Tanzania is reported to be 75.6%,(45) over 
2.5 times higher than the national average of 28.0%.(19) 
The Integrated Biological and Behavioral Surveillance 
Survey (IBBS) in Mozambique, a study undertaken 
between October 2013 and March 2014 in the Maputo 
and Nampula districts, showed HCV screening results 
for a sample of people who inject drugs to be 77.3%(9) 
In preliminary studies in Dakar, Senegal in 2011, HCV 
prevalence in this population was 38.85%.(12)
The lack of availability of HCV testing and treatment is 
partly due to the prohibitive cost to both the service 
provider and the service user. In Tanzania, the cost 
of treatment for HCV is over €10,000 per patient,(56) 
rendering it beyond the reach of most people. In 
Mauritius, HCV testing is available for people who inject 
drugs. Although it is estimated that 97% are living with 
the HCV affordable treatment remains unavailable.(29) 
In South Africa, HCV testing is limited to less accessible 
facilities in the form of regional hospitals, and there is 
a dearth of data on the burden of viral hepatitis among 
people who inject drugs. To combat the lack of data, 
civil society organisations and academia are working 
together to conduct a cross-sectional survey in South 
Africa, recruiting 1,200 people who use drugs in Cape 
Town, Pretoria and Durban and using a range of HCV 
testing modalities to develop recommendations for local 
guidelines on HCV testing and treatment.(16) 
An initiative is under way to allow low- and middle-
income countries to avoid the exorbitant cost of 
HCV treatment. In sub-Saharan Africa and other 
regions, Gilead (the pharmaceutical company that 
has developed medicine suitable for treating HCV) is 
working with regional partners to introduce the low-
cost generic Sovaldi® (one of the new HCV treatment 
drugs recommended by the World Health Organization) 
for use in low- and middle-income countries.(57) Even 
with these initiatives, however, it is thought that the 
medicines will still be very expensive.
Tuberculosis (TB)
TB prevalence rates in sub-Saharan Africa are extremely 
high, with 28% of the world’s cases found in this 
region(58) Although TB testing and treatment are available 
to everyone in principle, they remain out of reach for 
much of the population in practice, and there is a great 
paucity of data regarding TB prevalence and treatment 
access among people who inject drugs.
Whilst the majority of those who have been diagnosed 
will not develop active TB, people who use, and 
particularly those who inject, drugs, together with 
prisoners, are more vulnerable to progressing to active 
TB due to increased HIV co-infection and the poor 
prison conditions in some countries.(59) A study from 
Côte d’Ivoire, for example, found that people living in 
the fumoirs (crowded spaces where heroin and cocaine 
are smoked, often located in urban slums) were nearly 
nine times more likely to have TB, with almost half of 
the participants also having been incarcerated at least 
once(1)
The criminalisation of drug use, which is inextricably 
linked with the intense social stigma and discrimination 
faced by people who use drugs in the region, often 
leads to poor health-seeking behaviours and deters 
individuals from accessing TB services.
Antiretroviral therapy (ART)
It is not clear to what extent people who inject drugs 
have benefited from the dramatic recent scale-up of ART 
access in sub-Saharan Africa. Data on the numbers of 
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people who inject drugs receiving ART within the sub-
Saharan Africa region are sparse. In the Seychelles, for 
example, it is reported that 63% of people who inject 
drugs have ever had a HIV test,(15) but it is unclear how 
many receive ART.
Enrolling people who inject drugs into ART programmes 
is imperative, and integrated services serve to enable 
access. However, a study conducted in Tanzania 
concluded that people receiving OST often had to wait 
weeks to receive their test results, and ART initiation 
was conducted off-site, creating an additional barrier 
to seeking essential HIV treatment.(60) Clients described 
the increased stigmatisation they felt at the HIV clinic 
due to their drug use, with women experiencing even 
greater levels of stigma due to assumptions of sex work 
with drug use and HIV.(60) Although integrated care is 
the recommended gold standard by the World Health 
Organization (WHO),(61) it is often not in place and poor 
linkages between harm reduction service providers 
and HIV testing and treatment services create further 
barriers for people who use drugs to access treatment.
Civil society reports from Mauritius, Nigeria and South 
Africa echo these challenges on ART access. While HIV 
testing and treatment are services that are available to 
all in principle, the criminalisation of drug use, coupled 
with experienced or perceived risk of stigma and 
discrimination in healthcare settings, act as deterrents 
to service access.(16, 29)
In Uganda, ART coverage is hoped to be increased to 
50% and eventually to 80% over time, and to include 
people who use drugs.(62) However, no tailored service 
for this key population is available, and civil society 
report that people who use drugs face violence and 
police harassment at clinics.(33)
Over the course of the CAHR project between 2011 
and 2015, the number of people who inject drugs in 
Kenya who registered for ART went from 6% at baseline 
to 54%.(42) This finding illustrates the positive impact 
of investing in an integrated harm reduction service 
provision approach for people who use drugs.
Harm reduction in prisons
Punitive drug policies and law enforcement contribute to a 
high proportion of people who inject drugs in sub-Saharan 
Africa being incarcerated. A study involving people who 
inject drugs in the Seychelles found that just over half had 
been arrested in the previous twelve months.(15) In a study 
of people who use drugs in Dakar, Senegal, a history of 
incarceration was reported by 61.9% (n=506), with 29.2% 
acknowledging that they consumed drugs whilst in prison.(12)
High-risk injecting practices in prisons in the region 
may be a significant contributor to accelerating HIV 
transmission.(63) Yet the only country to implement harm 
reduction services in prison is Mauritius. Methadone 
maintenance treatment (MMT) was available in prisons 
in Mauritius when the Global State last reported in 2014. 
However, since the change of government in 2014, this 
service has been limited to those who already received 
OST prior to incarceration. New prisoners seeking OST 
are now offered either buprenorphine or naloxone.
Kenya, Uganda, Tanzania, Seychelles, Mauritius 
and South Africa all provide HIV testing and ART 
for prisoners. Access to ART, TB diagnostics and 
treatment and condoms in South African correctional 
facilities has reportedly improved since Global State 
2014, following the prioritisation of these services by 
government in recent years.(16) However, HCV testing 
and treatment remains unavailable. In Mauritius, HIV 
testing is compulsory within the prison setting, with ART 
being provided to those who require it. TB testing and 
treatment are also provided. HCV testing is available, but 
there is currently no treatment for this, and condoms 
are not made available.(29) HIV and TB testing and 
treatment are also available in prisons in Tanzania, but 
HCV diagnostics and treatment are not.(20)
There is no HIV, HCV, TB testing or treatment available in 
Nigerian prisons, and condoms are not made available 
to prisoners.(31) Indeed, it appears that only South Africa 
and Lesotho distributes condoms in prisons.(71) It is 
clear from the few studies available that harm reduction 
services in prisons are greatly needed.
Overdose
There continues to be a dearth of data on the 
prevalence of and response to overdose in the  
sub-Saharan Africa region. The latest data from Kenya 
indicate that, in 2011, approximately 58% of people 
who injected drugs reported knowing at least one 
person who had experienced a fatal overdose, and the 
overdose cases were 83% to 90% higher in Nairobi than 
in the coastal areas.(64)
Naloxone, a highly effective opioid antagonist used to 
reverse the effects of opioid overdose, is reportedly 
available only in Kenya and Tanzania, via health clinics 
and outreach sites as part of the state health system. 
Peer distribution of naloxone has been discussed and 
advocated for in both Kenya and Tanzania, but has not 
yet been implemented.(5, 20)
Overdose prevention, in the form of training in 
behavioural change is available in South Africa as part of 
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NSP and HIV prevention services, but naloxone is yet to 
be established as a part of the response.(16)  
In Mauritius, there is a distinct lack of knowledge and 
training regarding overdose prevention and no naloxone 
provision, in spite of the established harm reduction 
programme.(29)
Policy developments for harm 
reduction
Although harm reduction implementation is increasing 
in some countries in the region of sub-Saharan Africa, it 
is clear that punitive drug policies and a lack of political 
will still form significant barriers to the implementation 
and success of a harm reduction approach to drugs.  
For example, in late 2014 Uganda’s parliament passed 
the Narcotics Law which when implemented, will result 
in much longer sentences for those convicted of  
drug-related offences in the country.(65)
Harm reduction was previously endorsed in the 
Tanzanian National Strategy for Noncommunicable 
Diseases, 2009–2015.(66) This policy is currently being 
revised with input by civil society organisations, 
although it is uncertain whether harm reduction will 
be mentioned in the new strategy.(20) In Nigeria, where 
there are no formal active harm reduction services, 
there remains a mention of harm reduction within the 
national hepatitis policy,(67) but not in the country’s HIV/
AIDS strategy or drug control master plan (2015–2019). 
Similarly, harm reduction has not been included in any 
of Uganda’s national policies, despite a significant need 
for these services.(33)
South Africa’s National Drug Master Plan 2013–2017(68) 
and National Strategic Plan on HIV, STIs and TB 2012–
2016(69) both make explicit reference to harm reduction, 
highlighting the gradual endorsement of these services 
for people who use drugs in South Africa.
Despite advances in some countries, policies in much 
of the region continue to focus on supply reduction 
and the criminalisation of people who use drugs, 
overshadowing any harm reduction response or even 
demand reduction response. However, the African 
Union, in its common position for the United Nations 
Special Session (UNGASS) on the drugs, committed 
to achieving a balanced and integrated approach 
among supply reduction, demand reduction and harm 
reduction.(30)
 
 
Civil society and advocacy 
developments for harm reduction
Civil society organisations have been increasingly active 
in sub-Saharan Africa, both in implementing harm 
reduction services and in working to increase awareness 
of the need for harm reduction. This mobilisation has 
led, in some countries, to increased levels of support for 
harm reduction interventions.
In South Africa, civil society organisations were 
supported by local government to host a Drug Policy 
Week in Cape Town in 2016, bringing together over 
80 representatives of national, provincial and local 
government, academia and civil society as well as 
participants from western and southern Africa and the 
Indian Ocean islands for three days of presentations 
and deliberations on drug policy reform. The initiative 
resulted in the creation of a website to share drug policy 
information among all participantsr  and increased levels 
of support for harm reduction interventions(16) Advocacy 
efforts also preceded the three NSP site launches in 
South Africa, and a series of discussions and workshops 
with law enforcement officials have since taken place 
covering issues relating to NSP provision.(16, 34) In April 
2016 the Central Drug Authority and the South African 
National AIDS Council met to discuss a joint strategy 
around HIV prevention and treatment for people who 
use drugs, where explicit support for NSP and OST 
services was highlighted. Although drug user networks 
do not exist in the country at present, the TB/HIV Care 
Association is supporting the establishment of two 
networks, in Pretoria and Cape Town, with input from 
both the International Network of People who Use Drugs 
(INPUD) and CoAct.(34)
South Africa also hosted the 21st International AIDS 
Conference in July 2016 in Durban. The extent to which 
this event could serve as a platform to raise awareness 
and promote harm reduction in the region and beyond 
was minimised by a distinct absence of harm reduction 
and drug-related presentations in the main programme. 
In the fringes of the conference, the drug user and 
harm reduction networking zone in the Global Villages  
ran around 40 sessions, which included presenters 
from Nigeria, Kenya and South Africa discussing harm 
reduction, drug policy and the situations faced by people 
who use drugs in these countries.t
The Tanzanian Network of People who Use Drugs 
(TaNPUD) is working to secure small but vital 
improvements in harm reduction provision, but is as 
r See www.sadrugpolicy.com.
s	 Convened	by	The	Urban	Futures	Centre	at	Durban	University	of	Technology,	in	partnership	with	TB/HIV	Care	Association	in	the	Global	Village	with	financial	support	from	the	
AIDS and Rights Alliance for Southern Africa (ARASA).
t The programme for the drug user and harm reduction networking zone is available at: www.sadrugpolicyweek.com/news/pwud-harm-reduction-zone-aids2016.
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yet not attached to any broader network such as the 
East African Harm Reduction Network.(20)
The Ugandan Harm Reduction Network (UHRN) is also 
continuing to advocate for the implementation of harm 
reduction programmes. It sits on the Key Populations 
Technical Working Committee, alongside the Ministry 
of Health, to advance the response to issues faced by 
people who use drugs.(33) UHRN also sits on the Most 
At Risk Populations (MARPS) Steering Committee at the 
Uganda AIDS Commission (UAC), which monitors HIV/
AIDS programming in the country. Although at present 
no harm reduction initiatives operate in Uganda, UHRN’s 
participation in these forums is a positive step forward.
Since Global State 2014, a Civil Society Coalition on Drugs 
has formed in Nigeria, and now advocates for national 
drug policy reform. YouthRISE has also been undertaking 
advocacy efforts involving young people who use drugs 
in Nigeria.(30)
In 2014 the Africa Key Population Experts Group was 
formed. At its third meeting in 2015, the group agreed 
on a strategic framework that noted the importance of 
the development of monitoring and evaluation tools for 
key populations in the region, and advocated for the 
meaningful inclusion of key populations.(70) With several 
national and regional Global Fund grants including harm 
reduction components, harm reduction for people who 
use drugs is now firmly on the agenda in Global Fund 
Country Coordinating Mechanisms. The East African 
Harm Reduction Network and the East and Southern 
Africa Regional Harm Reduction and Drug Policy Group 
also serve as regional platforms for harm reduction 
discussions and the sharing of policy and practice 
from across the differing countries. The West African 
Harm Reduction Network, consisting of 42 civil society 
organisations, issued a statement ahead of UNGASS 
calling for the acceptance of harm reduction.(37)
Funding developments for harm 
reduction
Multilateral agencies and international donors still 
provide the majority of harm reduction funding in 
sub-Saharan Africa, with the Global Fund being the 
largest contributor, as in other regions. In 2015 the 
East African Harm Reduction Network obtained a grant 
from the Global Fund to implement harm reduction 
interventions and improve advocacy efforts in Burundi, 
Ethiopia, Kenya, Mauritius, Seychelles, United Republic of 
Tanzania (mainland and Zanzibar) and Uganda.(29)
Nigeria was approved for a Global Fund grant for harm 
reduction advocacy and service implementation in 
2015 and received US$8 million. However, it is unclear 
how these funds have been disbursed in the country 
and the extent to which they have gone towards harm 
reduction programme planning and services. Prior to 
receiving the grant, the Nigerian Agency for the Control 
of AIDS requested that these funds be diverted to sexual 
transmitted infections (STI) prevention programmes as it 
was not in support of harm reduction. Such a diversion 
of funds runs contrary to harm reduction need and 
represents a tragic missed opportunity to increase harm 
reduction awareness and implement services.(31)
In South Africa, civil society will receive funding from 
the Global Fund through the South African National 
AIDS Council’s work to implement harm reduction for 
people who inject drugs in four metropolitan areas.(16) 
This funding will provide support until 2019. Funding 
has also been provided by Mainline, through Bridging 
the Gaps, which will also run until 2019. The Open 
Society Foundations and AmfAR (The Foundation for 
AIDS Research) have funded policy, human rights and 
advocacy work in the country. US government grants via 
PEPFAR (US President’s Emergency Plan for AIDS Relief)/
CDC (Centers for Disease Control and Prevention) have 
included people who inject drugs in their key population 
prevention programmes in South Africa, which will 
run from 2016/17 to 2021/22; the scope and specific 
funding allocations are yet to be announced.(34)
Through the Global Fund grant, and via the Kenya AIDS 
NGOs Consortium (KANCO), UHRN is implementing a 
three-year project on HIV and harm reduction in eastern 
Africa, which aims to build policy support and technical 
capacity for harm reduction interventions.
Although harm reduction is beginning to receive 
financial support from national governments in 
South Africa,(16) Senegal,(37) Tanzania and Mauritius, 
programmes are still largely dependent on international 
donor support. The Mauritian government, for example, 
provides only 25% of current funding for harm 
reduction, with the remaining 75% covered by the Global 
Fund.(29) In Tanzania, the Elton John AIDS Foundation 
(EJAF) funding that supported MdM’s harm reduction 
efforts in Dar es Salaam came to an end in May 2016. It 
is unclear how services in the country will be affected by 
this development, and whether other donors will provide 
money for much needed harm reduction services in the 
country.(20)
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